Chromosomes in the Clinic: The Visual Localization and Analysis of Genetic Disease in the Human Genome by Hogan, Andrew Joseph
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2013
Chromosomes in the Clinic: The Visual
Localization and Analysis of Genetic Disease in the
Human Genome
Andrew Joseph Hogan
University of Pennsylvania, ogdennash2@gmail.com
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the History of Science, Technology, and Medicine Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/873
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Hogan, Andrew Joseph, "Chromosomes in the Clinic: The Visual Localization and Analysis of Genetic Disease in the Human
Genome" (2013). Publicly Accessible Penn Dissertations. 873.
http://repository.upenn.edu/edissertations/873
Chromosomes in the Clinic: The Visual Localization and Analysis of
Genetic Disease in the Human Genome
Abstract
This dissertation examines the visual cultures of postwar biomedicine, with a particular focus on how various
techniques, conventions, and professional norms have shaped the `look', classification, diagnosis, and
understanding of genetic diseases. Many scholars have previously highlighted the `informational' approaches
of postwar genetics, which treat the human genome as an expansive data set comprised of three billion DNA
nucleotides. Since the 1950s however, clinicians and genetics researchers have largely interacted with the
human genome at the microscopically visible level of chromosomes. Mindful of this, my dissertation
examines the `observational' approaches of postwar genetics. This is accomplished through a series of case
studies, which examine the visual delineation, diagnosis, and genomic localization of a number of disorders.
My case studies explore various exemplary attempts to associate particular clinical disorders with specific
genetic mutations. This dissertation uses archival resources, oral histories, and the published biomedical
literature to examine the many successes of postwar biomedicine, and to highlight the contributions made by
a wide rage of biomedical professionals. I find that the visible, tangible human genome, as conceived and
depicted at the level of chromosomes, has become an important work object among a diverse array of
practitioners. Chromosomal ideograms, I argue, provide an important basis for communication and common
practices among this community. While genetic data is becoming increasingly significant to our
understanding of human disease, distinguishing the normal from the pathological remains a task that relies on
input from the laboratory and the clinic. Thus, the success of postwar genetic medicine must be seen in light of
the contributions of biomedical actors from many disciplines, who have agreed to see and communicate about
the human genome - their object of study - in standardized ways.
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ABSTRACT 
 
CHROMOSOMES IN THE CLINIC: THE VISUAL LOCALIZATION AND 
ANALYSIS OF GENETIC DISEASE IN THE HUMAN GENOME 
Andrew Joseph Hogan 
Supervisor: Susan Lindee 
This dissertation examines the visual cultures of postwar biomedicine, with a 
particular focus on how various techniques, conventions, and professional norms have 
shaped the ‘look’, classification, diagnosis, and understanding of genetic diseases.  Many 
scholars have previously highlighted the ‘informational’ approaches of postwar genetics, 
which treat the human genome as an expansive data set comprised of three billion DNA 
nucleotides.  Since the 1950s however, clinicians and genetics researchers have largely 
interacted with the human genome at the microscopically visible level of chromosomes.  
Mindful of this, my dissertation examines the ‘observational’ approaches of postwar 
genetics.  This is accomplished through a series of case studies, which examine the visual 
delineation, diagnosis, and genomic localization of a number of disorders.  My case 
studies explore various exemplary attempts to associate particular clinical disorders with 
specific genetic mutations.  This dissertation uses archival resources, oral histories, and 
the published biomedical literature to examine the many successes of postwar 
biomedicine, and to highlight the contributions made by a wide rage of biomedical 
professionals.  I find that the visible, tangible human genome, as conceived and depicted 
at the level of chromosomes, has become an important work object among a diverse array 
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of practitioners.  Chromosomal ideograms, I argue, provide an important basis for 
communication and common practices among this community.  While genetic data is 
becoming increasingly significant to our understanding of human disease, distinguishing 
the normal from the pathological remains a task that relies on input from the laboratory 
and the clinic.  Thus, the success of postwar genetic medicine must be seen in light of the 
contributions of biomedical actors from many disciplines, who have agreed to see and 
communicate about the human genome – their object of study – in standardized ways.      
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INTRODUCTION 
 
 
Informational and Observational Approaches to Human Genetics and Biomedicine 
 
This dissertation examines the visual cultures of postwar genetics and 
biomedicine.  I trace the changing ‘look’ of disease during an era in which an ever-
increasing number of disorders have come to be understood as having a ‘genomic’ basis.  
Since the 1960s, practitioners of biomedicine have sought to move past the variable and 
often confusing presentation of disorders in the clinic.  Instead, they have increasingly 
come to rely on the genomic markers of disease to aid in clinical delineation.  As part of 
this, a new nosological system was developed in biomedicine, which has sought to 
differentiate diseases by locating their causes within the human genome.  In this 
dissertation, I explore the many successes of this approach to disease classification, while 
also highlighting various complications that have arisen. 
Throughout the postwar period, clinicians and geneticists have looked to the 
genome, at the microscopically visible level of chromosomes, in the hope of improving 
the delineation, diagnosis, understanding, and treatment of disease.  I examine how 
human and medical geneticists have come to see and analyze the human genome – their 
object of study – in standardized ways.  Scholars have previously highlighted the 
‘informational’ approaches of postwar genetics, which treat the genome as an expansive 
digital data set.  Since the 1950s however, geneticists have largely interacted with the 
genome at the microscopically visible level of chromosomes.  Mindful of this, this 
dissertation explores the ‘observational’ approaches of postwar genetics.  Similar to the 
heart in cardiology, the human genome has been referred to as the ‘organ’ of medical 
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genetics.  Through historical case studies of disorders like Fragile X and Prader-Willi 
syndrome, I examine how clinicians and geneticists locate, assess, and develop 
confidence in correlations between visible chromosomal markers and likely clinical 
outcomes.  The human genome, I argue, has a tangible presence in postwar biomedicine 
as an anatomical entity and standardized scientific object that can be seen, analyzed, and 
dissected.  At the same time, the genome is also an important conceptual space in 
biomedicine, where the conventions, interests, and questions of basic genetics and 
applied clinical research intersect and intermingle.   
 
Examining ‘Mistakes of the Binder’ in Postwar Biomedicine 
In 1969, Yale University School of Medicine physician Herbert Lubs reported in 
the American Journal of Human Genetics on the identification of an unusual 
chromosomal abnormality in a boy affected by intellectual disability.  Chromosomal 
analysis had been performed, and a ‘secondary constriction’ was identified on one of the 
boy’s chromosomes (Figure 1).  The secondary constriction, which caused the 
appearance of large ‘satellites’ at the end of this chromosome, was also seen in the 
patient’s mother and similarly affected brother.  This suggested that the marker might be 
simply a benign genetic variant.  However, analysis of the boy’s extended family 
revealed that the secondary constriction was always associated with intellectual disability 
when seen in males, but seemed to have no clinical impact on females.  This inheritance 
 
 
3 
pattern suggested to Lubs that the chromosomal marker, and its physical effects, were X-
linked traits (Lubs, 1969).1  
 
 
 
 
 
Figure 1  Human chromosome karyotype showing the secondary constriction identified 
by Herbert Lubs.  This image was published in Lubs (1969), Copyright Elsevier (1969). 
Reprinted with permission. 
 
 
                                                 
1 X-linked traits are so named because they are inherited on the X chromosome.  
Normally, males possess one X chromosome, and females have two.  If such a trait is 
recessive, it is usually overridden by the other X chromosome in females, but is 
expressed in males, who have just one. 
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Perhaps the most clinically significant attribute of this new chromosomal marker 
was its heritability.  Chromosomal abnormalities – such as trisomy 21, the cause of Down 
syndrome – that had been identified over the past decade were most often the result of 
random reproductive events, meaning that they were not heritable and could not be traced 
through families.2  That this “marker X chromosome”, as Lubs called it (231), was passed 
down through a family, and predictive of intellectual disability, was potentially valuable 
clinically.  With this in mind, Lubs suggested at the beginning on his report that, 
“descriptive human cytogenetics [chromosomal analysis] is entering a new and important 
phase.”  Indeed, identifying smaller, heritable chromosomal anomalies, such as this one, 
was important because, “they may permit prevention of clinical disease by identifying 
high-risk marriages and allowing subsequent amniocentesis and abortion of abnormal 
fetuses if requested by the family” (Lubs, 1969, 231). 
Lubs’ chromosomal studies in this 1969 report are representative of a set of 
practices and conceptions that have not been adequately addressed among scholars of 
postwar genetics and biomedicine.  In 1963, human geneticist Lionel Penrose drew a 
distinction between gene-level mutations, “mistakes of an imaginary printer,” which are 
too small to be seen, and chromosomal aberrations, “mistakes of a binder,” that could be 
observed microscopically (Penrose, 1963, 136).  Much attention has been paid, in recent 
decades, to how researchers study these “mistakes of the printer,” using various 
‘informational’ approaches, relying on molecular level techniques.  Scholars, for 
instance, have highlighted the cracking of the DNA code, the importance of recombinant 
                                                 
2 Most often the abnormal event is non-disjunction, which generally leads to the loss or 
gain of one chromosome. 
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DNA technology, and the humbling impacts of the Human Genome Project (Lenoir, 
1999; Morange, 1998; Kay, 2000; Keller, 2000; de Chadarevian, 2002). 
These informational approaches to postwar genetics treat the human genome as an 
expansive, and abstract data set, comprised of over three billion DNA nucleotides.  
Scientists and scholars alike often describe the DNA code, which consists of four 
nucleotides abbreviated A, T, C, and G, as a ‘language’.  In its entirety, the human 
genome has often been referred to as ‘the book of life’, with obvious religious overtones.  
As Lily Kay has described, informational metaphors have driven genetics thinking and 
research throughout the postwar period.  Even before the demonstration of the double 
helical structure of DNA in 1953, information theory and cybernetics were already 
central to the practices of molecular biology (Kay, 2000; de Chadarevian, 2002).  While 
the 1960s marked a move away from explicit informational theory among geneticists, 
efforts at ‘cracking’ the DNA code, and learning to read, translate, and edit it, continued 
to drive research in the field.  Indeed, a shift from more formalistic mathematical 
approaches to deciphering the DNA code, to material biochemical techniques did not 
undercut the central role of informational metaphors in molecular biology in the 1960s 
(Kay, 2000).   
Informational approaches to postwar genetics were greatly enhanced during the 
1970s by the introduction and development of recombinant DNA technology, which 
allowed strands of DNA to be cut up, separated out, and recombined at the molecular 
level.  These techniques facilitated the large scale copying of specific segments of DNA 
through PCR and plasmid cloning, and provided a means for developing a molecular 
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level ‘physical map’ of the human genome (Rabinow, 1997; Gaudilliere and Rheinberger, 
2004).  Ultimately, these techniques, coupled with increasingly powerful computing, 
were harnessed and scaled up, leading to the proposal of the Human Genome Project 
during the mid-1980s.  By 2000, the first reference sequence of the entire human genome 
was finished and made publically available (Kevles and Hood, 1992; Cook-Deegan, 
1995; Rabinow and Dan-Cohen, 2005; Garcia-Sancho, 2012).   
While these molecular innovations have been central to the development and 
successes of postwar genetics and biomedicine, they were not the only tools that 
clinicians and geneticists used during this period to analyze the human genome.  In 
addition to these ‘informational’ methods, in recent years historians of science have 
begun to explore the ‘observational’ approaches of postwar human genetics: those that 
seek to identify and analyze various “mistakes of the binder”.  Rather than molecular 
techniques, observational approaches are largely based on the analysis of the 
microscopically visible human chromosome set.  During the postwar period, despite the 
great importance of DNA-level techniques, clinicians and geneticists have largely 
interacted with the genome at the visible level of chromosomes.  Mindful of this, a 
parallel history to that of molecular biology has recently began to be told by scholars 
(Martin, 2004; Lindee, 2005; de Chadarevian, 2010; Santesmases, 2010; Hogan 2013).   
 
Observational Analysis of the Human Chromosome Set 
Lorraine Daston has recently called for a “turn towards ontology” among 
historians and philosophers of science, in particular, “towards ontologies created and 
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sustained by scientific observation” (Daston, 2008, 97).  Observation is a collective 
practice and the building of visual ontologies is a gradual process, which takes place 
among a community that learns and agrees to see objects, both commonplace and 
obscure, in particular ways (Fleck, 1979; Daston, 2008).  Over the past several years, 
historians of science have begun to explore the observational practices of postwar 
genetics, in particular chromosomal analysis.  Unlike the theoretical, abstract, and sub-
microscopic underpinnings of DNA code cracking and analysis that has been previously 
highlighted by scholars, the study of chromosomes is highly visual, subjective, and 
fraught with ambiguous findings.  
 As Soraya de Chadarevian has noted however, chromosomal analysis was 
nonetheless of great value to human geneticists in the 1950s and 1960s because it 
“offered a glimpse of the complete genetic make up on an individual” (de Chadarevian, 
2010, 180).  This observational view of the human genome produced some extremely 
persuasive evidence for the genetic cause of disorders like Down syndrome, while at the 
same time demonstrating that visible genetic abnormalities are often complex, variable, 
and difficult to distinguish with absolute certainty.3  Despite various complications, the 
ability to physically ‘see’ the genome revolutionized the practices of postwar human and 
medical genetics.  The capabilities of chromosomal analysis were greatly improved 
during the early-1950s by the introduction of a number of new laboratory techniques.  
This included the use of colchicine, for arresting cells when chromosomes were visible, 
                                                 
3 For instance, in some cases of Down syndrome an extra copy of chromosome 21 was 
not visually obvious, because the cause was a translocation, involving chromosome 21 
(Cowan, 2008; Gaudilliere, 2001; Santesmases, 2010). 
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and the recognition that a hypotonic (low salt) medium helped to spread out the 46 
chromosomes present in each human cell, thus making them easier to see, distinguish, 
and count. Also significant were improvements in cell culture techniques, which allowed 
for human tissue samples to be derived from the skin or blood or patients, rather than, 
much more invasively and painfully, from their bone marrow (Kottler, 1974; Martin, 
2004; Lindee, 2005; Cowan, 2008).    
In large part due to these developments, the human chromosome set increasingly 
became an object of analysis in human genetics and biomedicine beginning in the mid-
1950s.  Also central to this progress were multiple international standardization meetings 
held during the 1960s, which helped to make chromosomes more scientifically and 
medically useful objects of study.  As scholars have previously noted, the biomedical 
value of chromosomes was even further revolutionized in the early-1970s, with the 
introduction of chromosomal banding (Lindee, 2005; de Chadarevian, 2010).  The impact 
of this new technique on how chromosomes were seen, standardized, and used in 
genomic research has yet to be fully explored by scholars, despite its central role in 
shaping how the human genome has been depicted and communicated about ever since.  
As I describe, since the 1970s, internationally standardized representations of the 
‘banded’ human chromosome set have been widely used to visually represent and analyze 
the organization of various genetic elements within the genome (Hogan, 2013).  
My focus in this dissertation is on how these observational approaches to postwar 
human genetics and biomedicine have shaped conceptions and depictions of the structure 
and function of the human genome since just before chromosome banding was introduced 
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around 1970.  In studying this, I am attempting to better understand the ongoing 
development of research, thinking, and practices in genetics and biomedicine, during the 
decades immediately before the Human Genome Project was completed in 2000.  Indeed, 
as clinicians and geneticists increasingly looked to the genome, at the microscopically 
visible level of chromosomes, they began to see various markers that were reproducibly 
associated with particular clinical disorders.  Identifying such markers required the 
development of standardized ways of seeing, reporting, and reproducing these 
chromosomal features.  As I show, in the years before large-scale DNA sequencing was 
possible, researchers achieved significant, and often overlooked successes, when using 
observational approaches to explore the human genome and its role in genetic disease. 
During postwar biomedicine, the visual genetic markers of disease have proven to 
be of both clinical and biological interest.  The association of chromosomal locations and 
abnormalities with particular clinical outcomes can be useful diagnostically, but it also 
may be seen as an important introductory step in determining biological mechanisms of 
causation.  Indeed, long before disease genes could be isolated and sequenced, 
observational analysis of the human chromosome set was used to locate disease etiologies 
in the genome and to explore the causative link between genetic aberrations and clinical 
expressions.  While “mistakes of the printer” largely could not yet be identified, the 
‘binding’ of the genome, as Penrose described it, proved to be more transparent than 
anticipated (Penrose, 1963, 136).  During the 1970s and 1980s, observational approaches 
to genetics and biomedicine increasingly began to reshape understandings of the genome, 
leading to the broader recognition of it as a physical entity, and a distinct part of the 
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human anatomy.  As I show, accounts of the human genome in the published biomedical 
literature around 1980 increasingly began discussing it, less as an informational 
abstraction, and instead more frequently as a discrete object, which was suitable for 
observational analysis. 
 
Classifying Disease in the Laboratory and the Clinic 
Scholars have consistently shown that the value and apparent sensibility of 
classification systems are always context dependent (Foucault 1970; Fleck 1979; Latour 
1987; Bowker and Star 1999).  In The Birth of the Clinic, Michel Foucault suggests that 
disease classification has long been influenced by a natural history tradition: since the 
18th century, physicians have sought to identify and classify clinical pathologies as 
Linnaeus did plants, “to see, to isolate features, to recognize those that are identical and 
those that are different, to regroup them, to classify them by species or families” 
(Foucault 1973, p. 89).  As those experienced in clinical practice recognize however, 
approaches to disease classification based on the identification of clinically visible signs, 
symptoms, and lesions often lead to uncertain or variant diagnoses.  Indeed, while some 
patients may present with the ‘classical’ bodily indicators of a particular disorder, the 
clinical spectrum of expression, and various “individual idiosyncrasies”, often complicate 
and inject uncertainty into the diagnostic process (Aronowitz, 1998, 7).   
Clinical practice is heavily influenced by an ‘ontological’ perspective on disease: 
one that treats diseases are real entities, which develop within, and impact, all individuals 
in a similar way.  As Charles Rosenberg has noted, this view of disease is part of a larger 
reductive trend in our society, which in this case gives individual diseases legitimate 
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identities (Rosenberg, 1992).  The ontological characterization of a disease becomes 
particularly persuasive when that disorder is deemed to be genetic.  In some cases, a 
disease may be considered to be genetic because it appears to be passed down through the 
generations of a family, while in others the disorder may became associated with a 
particular genomic mutation or visible aberration, as in the case of Down syndrome.  
While genetic factors may play a role in nearly all disease, to associate a disorder with a 
specific genetic etiology is to provide it with a unique ontological identity. 
One of the most influential and demonstrative examples of this ontological 
perspective on genetic disease in the postwar period can be found in Victor McKusick’s 
catalogs of disorders, Mendelian Inheritance in Man.  Beginning in the 1960s, McKusick, 
a leading figure in the burgeoning field of medical genetics, who had first-hand 
experience with the complexities of clinical diagnosis, promoted a new way of 
delineating clinically described genetic disorders.  This system, influenced in part by 
Linus Pauling’s demonstration that sickle cell anemia was caused by a specific, inherited 
protein anomaly (Pauling et al 1949; Stasser 1999; Interview with Kurt Hirschhorn, New 
York City, January 26, 2012), sought to link clinical disorders with specific genetic 
inheritance patterns (dominant, recessive, X-linked) and genomic mutations.  The success 
of this ontological system for genetic disease designation is made apparent by the 
growing size and scope of subsequent editions of Mendelian Inheritance in Man. 
Closely associated with McKusick’s approach to clinical classification is the 
‘gene-for’ concept of disease, which is related to the ‘one-gene-one-enzyme’ hypothesis 
developed by George Beadle and Edward Tatum in the early-1940s.  As scholars have 
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shown, genes are both real physical entities and powerful social concepts (Nelkin and 
Lindee; Kay, 2000; Moss, 2003).  Throughout the postwar period, clinicians and 
geneticists have suggested the presence of a gene-for X often long before one (or two, or 
none) was ever identified and sequenced.  As I trace in this dissertation, the gap between 
suggesting a gene-for-X syndrome and determining its DNA sequence or functionality 
was often quite wide in time and technique in the 1970s and 1980s.   
Nonetheless, the idea that there was a gene or mutation somewhere in the human 
genome that could be used to delineate a particular clinical disorder was, and continues to 
be, a significant driver of biomedical research.  Along the way, clinicians and geneticists 
have discovered however, both to their frustration and professional benefit, that in most 
cases the gene-for-X concept of disease is overly simplistic.  Indeed, as biomedical 
researchers looked to the genome, at the visible level of chromosomes, in order to find 
the gene-for-X during the 1970s and 1980s, they increasingly found that the functionality 
of the human genome was much more complex and multi-dimensional than many had 
previously anticipated. 
 
The ‘Syndrome’ Concept 
The case studies that I focus on in this dissertation are all inborn genetic 
syndromes.  Syndromes are characterized by an array of clinical symptoms, all occurring 
together, assumedly due to the same cause.  Each of the syndromes described here were 
eventually associated with a specific genomic mutation and etiological mechanism, 
though syndromes may also be caused by environmental or developmental exposure to 
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toxins.  The syndrome concept is generally attributed to 17th century English physician 
Thomas Sydenham, who sought to identify distinct disease entities as naturalists did 
species (Faber, 1923; Opitz, 1979; Opitz, 1994).  Unlike with Linnaean binomial 
nomenclature however, there is no standardized, top-down naming and classification 
system for syndromes.  During the postwar period, some medical geneticists, most 
notably McKusick and longtime American Journal of Medical Genetics editor John 
Opitz, played an intermediary role in disambiguating disease nomenclature.   
Syndromes may be named after those who first described them (Down syndrome, 
DiGeorge syndrome), certain clinical features (Kabuki syndrome, Velo-cardio-facial), or 
particular chromosomal markers (1p36 deletion syndrome, Fragile X syndrome), among 
other possibilities.  Many syndromes are known by multiple names, which may differ 
over time, by clinical subspecialty, or by city or country of diagnosis.  As this dissertation 
describes, the stabilization of a common or universal name for a syndrome generally 
happens over the course of years, and may be impacted by new genetic findings, the 
development of research and support institutes, or the acknowledgement that an existing 
name, though descriptive or useful, is offensive to those affected.  Indeed, while 
clinicians and geneticists may understand a particular syndrome to be a discrete 
ontological entity, this does not imply that they can easily agree on what to call the 
disorder, or what symptoms are components of its clinical spectrum. 
  McKusick sought to adjudicate the variable naming and understanding of genetic 
disorders in Mendelian Inheritance in Man (MIM) by associated specific syndromes, 
often known by multiple designations, with one particular MIM number and, when 
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possible, genetic inheritance pattern, mutation, or genomic location.  To this day MIM, 
now published exclusively online as OMIM, plays a key role in designating the 
ontological existence of disorders by providing them with an OMIM number and entry.  
Additional medical texts, such as David Smith’s Recognizable Patterns of Human 
Malformation similarly play a role in identifying and easing the diagnosis of genetic 
disorders.  As I describe in this dissertation, clinicians do not take lightly the application 
of the term ‘syndrome’ to a particular disorder.  Rather, the proper designation of 
syndromes in the clinic has been a hotly contested matter in some instances, for 
nosological, professional, and institutional reasons. 
 
Medical Technologies and New Types of People 
 As many scholars have previously described, the introduction of new technologies 
into the clinic alters how physician think about diseases, what they look like, and what 
groups of people may be impacted by them.  In the early part of the 20th century, new 
techniques of examining blood were central to the identification, diagnosis, and treatment 
of various disorders (Howell, 1995; Wailoo, 1997).  Similarly, the introduction of 
visualization technologies into the clinic, such as X-ray and ultrasound, as well as CT, 
MRI, and PET scans have greatly impacted the practices of healthcare and diagnosis in 
the 20th century (Kevles, 1997).  Indeed, new medical technologies, such as PET scans, 
have been used in the clinic, as well as the courtroom, to emphasize differences among 
people (Dumit, 2003).   
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 New technologies in the clinic, in addition to enhancing the ‘clinical gaze’, also 
have facilitated the development of the ‘molecular gaze’ (Foucault, 1973; Rose, 2007).  
In recent years, genetic markers have also been used widely to identify new categories of 
people, in some cases who could not be differentiated otherwise (Rabinow, 1992; 
Hacking, 20077; Parthasrarthy, 2007; Hogan, 2012).  A genetic categorization may 
designate a population with an increased risk of particular health consequences, such as 
breast cancer, Alzheimer’s disease, or cystic fibrosis.  Genomic abnormalities may also 
‘designate’ an individual as being part of a particular social group of affected persons 
(Navon 2011; Navon 2012).  The association of genetic markers with particular clinical 
risks and outcomes has led to what some scholars refer to as the ‘geneticization’ and 
‘biomedicalization’ of contemporary medical thinking and practice.  
 In 1991, Abby Lippman pointed to the geneticization of medicine, noting that 
human disease and difference was increasingly being reduced to molecular explanations 
(Lippman, 1991, 1992).  Just as Nelkin and Tancredi (1989) warned a few years earlier, 
the development of simple diagnostic tests for genetic conditions represented a 
potentially dangerous new form of social power.  Such tests carry scientific legitimacy, 
and their simplicity makes them broadly applicable, meaning that they be in wide use 
before their potential social harms are recognized.  In their 1995 book The DNA 
Mystique: The Gene as a Cultural Icon (1995) Nelkin and Lindee future demonstrated 
the social and scientific power of ‘gene talk’, tracing the prevalence of genetic 
essentialism in contemporary society, and its role in defining kinship, disease, and 
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responsibility.  The gene, they demonstrate, has been transformed into a source for social 
difference, with potentially destructive ends.  
  While Lippman (1991, 1992) originally intended for the term ‘geneticization’ to 
have a negative connotation, scholars, following the lead of Hedgecoe (1998, 2001), have 
more recently approached the process of geneticization from a more symmetrical 
perspective.  These studies of geneticization, conducted over the last 15 years, follow one 
of two general methodological approaches.  The first is ethnographic analysis, focusing 
on the day-to-day process of clinical diagnosis.  Ethnographers have questioned the 
extent to which genetic evidence has impacted clinical practice, arguing that the 
evaluation of patients’ bodies continues to provide key evidence for the diagnosis of 
disorders, while genetic data is often inconclusive (Shaw, 2003; Featherstone et al, 2005; 
Latimer et al, 2006).  These ethnographic studies have pushed back against existing 
accounts of the pervasiveness of genetic reductionism in medicine (Lippman, 1991; 
Keller, 2000; Hedgecoe, 2001).   
A more middle-of-the-road ethnographic study responds to the anti-reductionist 
perspective by suggesting that clinical diagnosis involves analytic “triangulation” among 
mutations, phenotypes, and disease categories (Rabeharisoa and Bourret, 2009, 701).  
Rabeharisoa and Bourret also explore the epistemological status of genetic data in the 
clinic, and conclude that a certain mutation is not automatically considered “objective 
proof” that a syndrome is present.  Rather, a mutation’s diagnostic value depends upon 
the pre-existing “interpretive model” for a particular disorder (704). 
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 Ethnographic studies provide valuable analysis of the heterogeneous evidence, 
social processes, and inevitable uncertainties associated with the process of clinical 
diagnosis.  However, while these studies have exposed scholars to the breadth of possible 
clinical interpretations and outcomes, they do not provide an in-depth look at the 
diagnosis of any one disorder in particular.  For instance, though the analysis of 
Rabharisoa and Bourret (2009) is broadly insightful, there is still a need to further unpack 
the historical development and impact of pre-existing interpretive models for disorders.  
For instance, how is a disorder initially associated with a genetic marker, and how is this 
correlation stabilized and made diagnostically useful?      
The second methodology used recently for studying the impact of geneticization 
involves a close analysis of the scientific literature on a particular disorder.  Certain 
studies have focused on the strategic attempts of researchers to ‘geneticize’ an existing 
disorder, such as diabetes and schizophrenia (Hedgecoe, 2001; Hedgecoe, 2002).  While, 
in other instances, scholars have focused on the impact of geneticization on the clinical 
diagnosis of a disease.  A few of these studies have looked at cystic fibrosis, and shown 
the ways in which the geneticization of a disorder, rather than providing simple and clear-
cut diagnostic markers, has instead further complicated clinical understandings of 
individual risks and likely symptomatic effects (Kerr 2000; Hedgecoe, 2003; Kerr, 2005).  
Throughout this dissertation, I examine various instances in which such complications 
arose that called into question the reliability of a seemingly straightforward genetic 
marker.  As I demonstrate, in the course of attempting to resolve these genetic 
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complications, clinicians and geneticists came to appreciate new levels of complexity in 
genomic function and disease causation. 
  
Perspectives on Biomedicine and ‘Biomedicalization’ 
This rise of ‘biomedicine’ has similarly been associated with the increasing 
centrality of molecular genetic conceptions of disease.  Nicholas Rose (2007) has argued 
that medical practice has shifted away from the “clinical gaze” that Foucault describes, 
towards a “molecular gaze”.  Understandings of disease at the molecular level, argues 
Rose (2007, p. 8), as well as Clarke et al. (2010), have led to new conceptions of “life 
itself”, and a novel “somatic ethics” of individualized biomedical knowledge, 
responsibility, and intervention.  Jean-Paul Gaudilliere (2002) has similarly pointed to the 
central role of molecular analysis in the rise of biomedicine, and has argued that the 
biological laboratory has replaced the pathology clinic as the primary location and focus 
of medical practice.  For Gaudilliere, and other scholars, this suggests that there is a 
largely unidirectional flow of knowledge in biomedicine from the basic biological 
laboratory to the clinic (Gaudilliere, 2002; Fujimura, 1992).   
 Other scholars however, have pushed back against this perspective on 
biomedicine in which knowledge in the laboratory supersedes and directs clinical 
diagnosis and understanding of disease.  Keating and Cambroiso (2000, 2003, 2004) have 
repeatedly argued that, in contemporary biomedicine, pathology has not been reduced to 
biology.  Rather, they suggest that biomedicine represents a realignment of the ‘normal’ 
and the ‘pathological’ (Canguilhem 1991), not a fusion of the two, or a reduction of one 
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into the other.  Biomedical practice, they argue, takes place in intellectually and 
institutionally collaborative spaces or ‘platforms’, which are, “benches upon which 
conventions concerning the biological or normal are connected with conventions 
concerning the medical or pathological” (Keating and Cambrosio 2000, p. 386).  
Still other scholars have expressed doubt about the transformative nature of 
biomedicine.  Based largely on ethnographic analysis of the practice of dysmorphology, 
the identification of genetic disorders through bodily characteristics, these researchers 
maintain genetic results are often quite uncertain, necessitating a return to the clinic.  
Indeed, as these scholars suggest, clinicians do not simply rely on genetic testing to slot 
patients into pre-existing and discrete categories.  Nor does genetic testing always make 
diagnosis a simple and immediate process.  Rather, the clinic has always been, and 
continues to be, central to medical knowledge production: genetic testing may 
supplement clinical judgment, but certainly has not supplanted it, as Rose (2007) 
suggested (Shaw, 2003; Latimer et al. 2006; Featherstone and Atkinson 2012).  In this 
dissertation, I explore how clinicians and geneticists locate, assess, and develop 
confidence in correlations between genomic markers and clinical outcomes.  The 
genome, I argue, has become an important conceptual space in biomedicine, where the 
questions, interests, and conventions of basic genetics and applied clinical research 
intersect and intermingle.   
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Outline for this Dissertation 
This dissertation draws on archival resources, informational interviews, and a 
thorough analysis of the published medical literature to examine the evolving look and 
‘genomic‘ understanding of a number of inborn genetic disorders.  Because of the 
contemporary focus on this research, available archival collections for this project are 
relatively limited.  As a result, I draw heavily on journal articles and medical textbooks 
relevant to my case study disorders, and medical genetics more broadly.  In line with 
Hannah Landecker’s Culturing Life (2007), this dissertation draws on the published 
biomedical literature to examine the broad impact of a specific concept: the genomic 
basis of disease.  I also rely on interviews with over 30 biomedical professionals.  These 
interviews helped to clarify the published literature, and often revealed what was thought 
and debated by clinicians and researchers, but not published in journals.  In some cases, 
these individuals also provided relevant materials that are not yet archived, including 
meeting minutes and correspondence concerning professional committees or joint 
publications.   
In chapter one of this dissertation, I explore the development of human 
cytogenetics in the postwar period.  Multiple scholars have thoroughly examined the 
early decades of human cytogenetics (Martin, 2004; Lindee, 2005; de Chadarevian, 2010; 
Santesmases, 2010), so my research primarily focuses on the 1970s and 1980s.  Over this 
period, I trace the parallel evolution of standardized chromosomal depictions and 
changing conceptions of the human genome.  I argue that, during this period, conceptions 
of the human genome shifted from abstract references to ‘all the human genes or genetic 
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material’ to more physical and bounded descriptions, physically embedded in the visual 
representations of the human chromosome set.   
I explore how the nomenclature system, initially developed to help standardize the 
laboratory and clinical analysis of banded chromosomes, was also adopted for gene and 
disease etiology mapping.  As part of this, I demonstrate how descriptions of the human 
genome became increasingly anatomical during this period.  Like heart in cardiology, the 
genome was described as the ‘organ’ of medical genetics, and the mapping of it as a 
‘neo-Vesalian’ revolution.  All of this together provided the basis for new ways of 
delineating, diagnosing, and understanding human disease.  Medical geneticists were now 
no longer dependent on clinical signs of disease alone: they could also rely on genomic 
locations to identify unique disorders. 
Chapter 2 offers a case study of the clinical and laboratory history of Fragile X 
syndrome.  I begin with a discussion of the debate over X-linked intellectual disability in 
the 20th century, and then address the first clinical description, in 1943, of what was later 
termed Martin-Bell syndrome, and eventually Fragile X syndrome.  From there, I discuss 
the identification of a cytogenetic marker, initial confusion over its laboratory expression, 
and its ultimate use as a diagnostic basis for delineating and naming Fragile X syndrome 
in the late-1970s and early-1980s.  Next, I explore the challenges of using this 
cytogenetic marker to identify carriers of the disorder, and attempts to identify treatments 
for Fragile X syndrome based on a limited cytogenetic understanding on the fragile X 
site.   
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During the mid-1980s, clinicians and researchers were perplexed by the unusual 
inheritance pattern of Fragile X syndrome in families.  I explore the various theories 
developed to explain the abnormal pedigrees, and the experimental demonstration of one 
of these theories based on observational chromosomal analysis in 1986.  This cytogenetic 
research was done five years before the fragile site could be molecularly characterized, 
and offered important evidence that a novel genomic mechanism was at play in causing 
Fragile X syndrome and other disorders with similar inheritance patterns.  This chapter 
explores how clinicians and researchers took advantage of chromosomal analysis in the 
years before large-scale DNA sequencing was possible to delineate, diagnose, prevent, 
treat, and explain Fragile X syndrome, while at the same time exploring unanticipated 
structural and functional characteristics of the human genome.  
In chapter 3, I explore the genetic characterization of another clinical disorder, 
based upon chromosomal analysis.  Prader-Willi syndrome was first described in 1956, 
and mounting cytogenetic evidence suggested a genomic basis during the 1970s.  In 
1981, Prader-Willi syndrome became one of the first genetic disorders to be associated 
with a microscopically visible, de novo deletion on a human chromosome.  As a result, 
during the early-1980s, Prader-Willi syndrome was seen as an exemplar of a new type of 
disorder, which could be delineated and diagnosed based on a discrete cytogenetic 
marker.  It became associated with a discrete genomic abnormality and location, on the 
long arm of chromosome 15.   
To the surprise of researchers and clinicians however, in 1987 another clinically 
and historically distinct genetic disorder was associated with the same exact visible 
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chromosomal deletion.  Angelman syndrome looked nothing like Prader-Willi syndrome 
in the clinic, and yet it seemed to be caused by the same exact genomic etiology.  This 
posed a problem for medical geneticists, who had argued that genetic diseases could be 
thought of as either the same or different based on the mutation that caused them.  
Clinicians and researchers never suggested that Prader-Willi and Angelman syndromes 
might in fact be the same, but instead began to explore alternative explanations.  
Cytogenetic analysis provided the first evidence for the mechanistic different between 
them.  It was demonstrated chromosomally, and later molecularly, that which parent a 
patient inherited the deletion from made the difference in terms of which syndrome 
affected them.  This finding revolutionized the ways in which clinicians and researchers 
thought about the structure and functionality of the human genome.  In 1989, this was the 
first demonstration in humans of an ‘epigenetic’ phenomenon known as genetic 
imprinting.  This history offers a window into the continuing development of 
biomedicine during this period, as the interests and aims of basic and clinical researchers 
became closely aligned. 
Chapter 4 looks at a second case of what one might call ‘genetic intersection’: an 
unusual instance in which two clinically and historically distinct disorders are found to be 
associated with the exact same genomic abnormality.  DiGeorge and Velo-Cardio-Facial 
syndromes were both independently described and named, in distinct times and places, 
based on clinical analysis alone.  During the 1980s, chromosomal analysis suggested a 
genomic cause for DiGeorge syndrome, which was eventually determined to be a small 
deletion on chromosome 22.  Similar to the case of Prader-Willi and Angelman 
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syndromes, DiGeorge and Velo-Cardio-Facial syndromes became associated with the 
exact same genomic deletion in the early-1990s.  Unlike the previous case however, this 
finding was widely pointed to as evidence that these two disorders were in fact two 
historically distinct forms of the same clinical disorder.   
In making this argument, some clinicians and geneticists pointed to the parable of 
the blind men and the elephant.  As they described it, researchers had been distracted all 
along by their own specialties and interests, and overlooked what this instance of genetic 
intersection had finally made apparent to them.  DiGeorge and Velo-Cardio-Facial 
syndrome were the same exact disorder: there had always been just one elephant in the 
room.  Following the association of these two disorders with the same genomic deletion, 
debates have been ongoing over the appropriate name for this syndrome.  Some have 
promoted 22q11 deletion syndrome, a designation that directly links that clinical disorder 
to a genomic location and chromosomal band.  The distinctions between this story, and 
the one presented a chapter early offer a useful opportunity to reflect on the constantly 
evolving relationship between clinical and laboratory findings in medical genetics as well 
as the professional and institutions implications of disease nosology.     
My concluding chapter examines how and why chromosomal depictions continue 
to shape the ways in which biomedical professionals interact with the genome in the post-
Human Genome Project era.  Indeed, even with a complete DNA reference sequence at 
their fingertips, clinicians and geneticists have persisted in thinking and communicating 
about the human genome using a visual nomenclature originally developed for 
chromosomal analysis in the 1970s.  An excellent example of this is the prominent place 
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that standardized depictions of the human chromosome set continue to have as signposts 
and navigation tools in online genomic databases, such as the University of California, 
Santa Cruz Genome Browser.  Mindful of this, I examine how and why older, less 
exacting – and often incommensurable – languages of description are maintained, and 
relied upon, for the analysis and presentation of results in science and medicine.  In doing 
so, I explore how clinicians and researchers use techniques of visualization to help make 
the genome, more legible for themselves and their colleagues. 
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CHAPTER 1 
Seeing and Analyzing the Human Genome at the Level of Chromosomes 
 
In 1982, Victor McKusick, Physician-in-Chief of the Johns Hopkins University 
School of Medicine, published a commentary entitled, “The Human Genome Through the 
Eyes of a Clinical Geneticist.”   At the time, McKusick was a central figure in the 
burgeoning field of medical genetics, a discipline populated by both Ph.D. trained 
geneticists and physicians interested in the role of genetics in human disease.  In his 
article, which reflected on the previous 25 years of advancement in medical genetics, 
McKusick noted, 
 
The advances which started in 1956 have provided the clinical geneticist 
with his organ.  Now the clinical geneticist is in the same position as the 
nephrologist with his kidney, the cardiologist with the heart, and so on.  
He has an organ that he can biopsy, of which he can analyze disordered 
structure and function, and which he can attempt to repair (McKusick, 
1982, 7). 
 
As the title of his paper suggests, the organ that McKusick was referring to is the human 
genome.  During the early-1980s, McKusick, and other prominent figures in the genetics 
community, increasingly began discussing the human genome using anatomical points of 
reference.  As McKusick put it in his 1982 paper, genomic analysis provided the field of 
medical genetics with a “neo-Vesalian model” for identifying and understanding genetic 
diseases (McKusick, 1982, 22). In this chapter, I explore how the human genome was 
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visualized, conceptualized, dissected, and mapped at the level of chromosomes during the 
1970s and 1980s. 
The human genome is often referred to as an abstract informational database, 
comprised of billions of DNA nucleotides.  Indeed, it has widely been presented in the 
postwar period as a code to be ‘cracked’, as well as scanned and analyzed, at the 
molecular level.  Analysis of the human genome however, frequently has also taken place 
at the level of its most basic, and visible, components: the human chromosomes.  Since 
the 1960s, the observational approach of chromosomal analysis has provided human and 
medical geneticists with the opportunity to look for and locate various genes and disease 
etiologies within the human genome.  Throughout the 1970s and 1980s, McKusick 
maintained and updated a visual depiction of this process, which was based upon 
standardized depictions of the human chromosome set (McKusick and Ruddle, 1977; 
McKusick, 1982, 1984, 1986a, 1988). 
As I will demonstrate throughout this chapter, during the 1970s and 1980s, the 
human genome became an important, an increasingly well-defined, object of both 
scientific and anatomical investigation.  While descriptions of the genome in the 1970s 
often referred to it quite abstractly as being composed of ‘all the human genes or genetic 
material’, by the early-1980s, medical textbook definitions of the human genome were 
becoming increasingly bounded by, and literally ‘embodied’ within the human 
chromosome set.  Over this time, conceptions of the human genome, among clinicians 
and biomedical researchers, became increasingly chromosomal and anatomical, at the 
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same time that standardized depictions of the human chromosome grew more-and-more 
linearized and ‘genomic’.   
Conceptions and representations of genetic disease paralleled these developments.  
In this chapter, I also explore the making of a new system of disease nosology within the 
field of medical genetics.  Rather than being dependent on clinical presentations to 
delineate, diagnose, and classify genetic disorders, during the postwar period, medical 
geneticists increasingly looked to the genome as a new and valuable arbiter.  It was 
assumed that mutational analysis could provide a more accurate and reliable means of 
distinguishing different diseases, compared to the diverse and often confusing array of 
signs and symptoms seen in the clinic.  Indeed, embedded within depictions of what 
McKusick called the ‘morbid anatomy’ of the human genome was the idea that every 
genetic disease could be associated with a unique location in the genome, thereby giving 
it a distinct identity.   
Throughout this dissertation, I explore the application of this nosological system 
in postwar biomedical thinking and practice.  My case studies highlight various problems 
and complications that arose over this time, issues that transformed chromosomal 
analysis into an unexpectedly productive experimental system for geneticists more 
broadly.  A historical analysis of these cases offers a window into the evolving ways that 
clinicians and biomedical researchers have thought about the human genome, and its role 
in human disease, since the late-1960s.   
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Counting Chromosomes in the 1950s 
 1953 is often pointed to as a landmark year in the history of genetics, because it 
marked the proposal of a double helical structure for DNA.  This important finding 
shaped the trajectory of molecular biology for years to come, by helping to explain DNA 
replication and facilitating the cracking of the DNA code over the next decade, thus 
adding to the informational basis of genetics research.  While the identification of the 
DNA double helix is also regarded as an important moment in the history of medical 
genetics, Victor McKusick often pointed to another event, three years later, as being 
central to the origin of the field, “medical genetics has become established as a clinical 
specialty, as the culmination of developments that began in 1956 with the description of 
the correct chromosome number in man” (McKusick, 1997a, 1). 
Until the early-1950s, the chromosome number in man was believed to be 48, not 
46 (Kottler, 1974; Martin, 2004).  Identifying the correct chromosome number is widely 
regarded as a significant finding in medical genetics, because in the years after its 
stabilization, a variety of syndromes associated with abnormal numbers of chromosomes 
were identified.  The most notable among these, Down, Turner, and Klinefelter 
syndromes, were each linked to specific chromosomal abnormalities within five years of 
1956.  As McKusick put it in his 1997 history of medical genetics, “With the discovery of 
specific microscopically visible chromosomal changes associated with clinical disorders, 
beginning with Down syndrome in January 1959, medical genetics acquired an anatomic 
base.  Medical geneticists now had their specific organ – the genome – just as 
cardiologists had the heart and neurologists had the nervous system” (McKusick, 1997a, 
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1).  Indeed, the year 1956 matters for medical geneticists because it marks the moment at 
which the size and scope of the human genome, the field’s organ, was for the first time 
concretely defined. 
Histories of medical genetics often highlight the 1956 demonstration, by Joe-Hin 
Tijo and Albert Levan, that humans normally possess 46 chromosomes (Tijo and Levan, 
1956).  As Aryn Martin has pointed out however, while “communal closure around the 
new number,” did not occur until 1956, the revolution in medical genetics associated with 
1956 actually began with the introduction of a number of new techniques beginning in 
the early-1950s (Martin, 2004, 936).  Foremost among these was the uptake of the 
chemical colchicine, which arrests cells at a point in their reproductive cycle when 
chromosomes are visible (they usually are not), and the use of a hypotonic (low salt) 
solution to spread out the chromosomes in a cell, thus making them easier to differentiate 
and count (Martin, 2004).  
 As Martin has suggested, the introduction of these new techniques began to 
change the way that human geneticists thought about chromosomes, even before 1956.  
Referencing a paper by American cytogeneticist T.C. Hsu (1952), in whose lab the 
hypotonic technique was first (accidently) identified and used,4 Martin notes that Hsu,  
 
Also lined up the chromosomes in pairs by length and named them (by 
number).  This, I suggest, changed the counting game from the question 
‘How many?’ to the question ‘Are all members accounted for?’ An 
                                                 
4 As Martin (2004) notes, an ‘invisible technician’ was initially responsible for ‘the 
hypotonic miracle’, having made a ‘mistake’ in mixing solutions. 
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analogy would be counting how many people are in a room versus taking 
attendance (Martin, 2004, 935-6).  
 
Establishing the correct human chromosome number therefore, was an important step in 
bounding the human chromosome set, allowing for ‘normal’ versions of it to be 
distinguished from various ‘pathological’ ones (Canguilhem, 1991). 
During the early-1950s, human geneticists developed new expectations for the 
counting of chromosomes.  And, by the end of the decade, the number of chromosomes 
that an individual was seen to possess became much more meaningful medically, “A 
count of 47 is no longer indicative of a poor counting methodology or a challenge to the 
established count, but of a body marked by genetic difference” (Martin, 2004, 938).  
Indeed, by the close of the 1950s, abnormal chromosomal counts were seen as very 
significant observational findings in the clinic.  And, as I explore here, over the coming 
decades, the human chromosome set would be further transformed into a standardized 
object for biomedical thinking and research, thereby creating various new methods for 
‘doing’ genetics that were based on the observational approaches of cytogenetics. 
In 1959, French clinician Jerome Lejeune famously reported that patients with 
Down syndrome appeared to possess one additional chromosome: for a total of 47 instead 
of 46 (Lejeune et al, 1959).  Once it was recognized that chromosomal abnormalities 
could be associated with particular clinical syndromes, a call went out for the 
establishment of a system for naming individual chromosomes.  The development of an 
internationally standardized chromosomal nomenclature system was undertaken at a 1960 
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meeting of cytogeneticists in Denver.  After much social and technical negotiation, the 
participants decided upon a system in which each of the non-sex chromosomes (the 
autosomes) would be numbered by their relative size, with the largest becoming 
chromosome one.  The sex chromosomes remained named X and Y, even though the X 
chromosome is closer in size and shape to chromosome 7 and the Y is most similar to 
chromosome 22 (Denver Study Group, 1960; Lindee, 2005).   
This standardized nomenclature system has, since 1960, frequently been the basis 
for constructing human karyotypes, where all of the chromosomes in one cell are 
represented together in one picture.  During the 1950s, karyotypes were often drawn by 
hand with the assistance of a camera lucida.  However, as cytogeneticist Malcolm 
Ferguson-Smith has described, by the end of the decade, photographic cameras were 
being affixed directly to microscopes (Interview with Malcolm Ferguson-Smith, 5 
December 2003, conducted by Peter Harper).5  When a karyotype is constructed in this 
way, a photograph is taken of a cell is in which all of the chromosomes appear to be 
visible and out enough to be differentiated.  After the photograph is developed, each 
individual chromosome is cut out and rearranged by its relative size.  Karyotyping is used 
to help identify and systematically name abnormalities in the chromosome set, for 
instance an extra copy of chromosome 21, the cause of Down syndrome.   
 
 
                                                 
5 Interview with [Malcolm Ferguson-Smith, 5 December 2003]. Interviews with Human 
and Medical Geneticists series, Special Collections and Archives, Cardiff University, 
Cardiff, UK. 
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Creating a Standardized Representation of the Human Chromosome Set 
The human chromosome set may be visually represented in a variety of ways.  
While karyotypes involve the direct cut-and-paste organization of microscopic 
photographs, chromosomes have also been represented throughout the postwar period 
using idealized drawings called ‘ideograms’.  Chromosomal ideograms depict the 
distinctive features of each human chromosome, including two arms (each chromosome 
has a long and a short arm), a centromere, which separates the two arms, and ‘satellites’ 
(additional material at the end of certain chromosomes).  Chromosomal locations are 
always identified relative to the centromere: those close to the centromere are ‘proximal’ 
and those further away are referred to as ‘distal’.   
In 1960, the Denver Study Group individually numbered each chromosome, and 
developed ideograms to represent the human chromosome set (Denver Study Group, 
1960).  Throughout the 1960s however, it remained quite difficult, if not impossible, to 
distinguish various chromosomes that were of similar size and shape.  Reflecting this 
reality, cytogeneticists often referred to the human chromosomes as being members of 
seven visually distinguishable groups: A (1-3), B (4, 5), C (6-12, X), D (13-15), E (16-
18), F (19, 20), and G (21, 22, Y).  These groupings were officially recognized during a 
follow-up meeting to the Denver Study Group, held in London in 1963 (London 
Conference, 1963).  Within each group, individual chromosomes were very difficult to 
tell apart, a situation that was particularly problematic for the C group, which is made up 
of eight members, including the X chromosome.   
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The inability to differentiate individual chromosomes greatly limited the 
specificity with which chromosomal abnormalities could be identified and 
communicated.  For example, one could report that a ‘B group’ chromosome was lacking 
its short arm in patients with a certain clinical disorder.  However, one could not say for 
certain if the impacted chromosome was 4 or 5.  Later, another cytogeneticist might find 
a similar aberration in a different group of patients, but not know if the same 
chromosome was affected.  Indeed, as the 1960s went on, this inability to differentiate 
chromosomes greatly limited the capability of medical geneticists to associate clinical 
disorders with particular, visible chromosomal aberrations (Hirschhorn et al, 1973). 
Following the Third International Congress of Human Genetics meeting, held in 
Chicago in 1966, a committee similar to the Denver Study Group met to further improve 
the existing cytogenetic nomenclature (Chicago Conference, 1966; Lindee, 2005).  One 
of the most significant outcomes of this 1966 gathering was the designation of a standard 
abbreviation for the long and short arms of each human chromosome.  It was quickly 
agreed upon that the short arm of each chromosome should be abbreviated ‘p’ for petit.  
According to American cytogeneticist Kurt Hirschhorn however, the debate over what to 
call the long arm of each chromosome was extended and contentious.  Multiple 
participants at this, and other, nomenclature meetings have suggested to me that much of 
the disagreement took place along national lines, particularly among French and German 
members (Interviews with Uta Francke, February 27, 2012; Kurt Hirschhorn, January 26, 
2012; Dorothy Warburton, May 11, 2011).   
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At the 1966 meeting, a debate lasted late into the night over what to call the long 
arm of chromosomes, particularly given that a francophone designation had already been 
attached to the short arm.  As Hirschhorn tells the story, sometime after midnight, Lionel 
Penrose, that year’s Congress president, walked into the room where the meeting was 
being held, and was surprised to find that the discussion was ongoing.  Informed that the 
designation ‘p’ had been decided upon for the short arm of chromosomes, Penrose 
immediately suggested that the long arm should be called ‘q’.  This was not because ‘q’ 
had any sort of linguistic significance, but instead because ‘p + q = 1’ was a well-known 
equation (named after Hardy and Weinberg) in population genetics.  Hirschhorn 
paraphrased Penrose’s successful argument in this way, “If you have ‘p’ for the short 
arm, use ‘q’ for the long arm: ‘p + q = 1’, you got the whole chromosome” (Interview 
with Kurt Hirschhorn, January 26, 2012).6  Apparently, this settled the debate.  
Ultimately, this decision was just one of many compromises in an ongoing international 
discussion about how to divide the human chromosome set into standardized subsections.  
 
Moving Out of “The Doldrums” in the Early-1970s 
As the 1960s went on, the “golden age” of cytogenetics, during which a number 
of clinical disorders were associated with visible chromosomal abnormalities, came to 
close.  The continued inability to distinguish individual human chromosomes greatly 
limited the potential specificity of cytogenetic diagnosis.  In reference to this very 
                                                 
6 Peter Harper offers a similar account involving ‘p + q = 1’ during his interview with 
David Harden.  Interview with [David Harnden, 18 March 2004]. Interviews with Human 
and Medical Geneticists series, Special Collections and Archives, Cardiff University, 
Cardiff, UK. 
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problem, McKusick, quoting his colleague Margery Shaw, has referred to the late-1960s 
as a time when clinical cytogenetics was “in the doldrums” (McKusick, 1997a, 8).  The 
1970s, on the other hand, proved to be a revolutionary time for the field, with the 
development new chromosome staining techniques.  
Quinacrine (Q) banding was introduced in 1968 (Caspersson et al, 1968), 
followed by Giemsa (G) banding and reverse (R) banding around 1970 (Seabright, 1971).  
These new techniques produced distinguishable banding patterns on each human 
chromosome, allowing for them to be visually differentiated under the microscope.  The 
banding techniques take advantage of the differential condensation of DNA within each 
chromosome.  On G-banded chromosomes, more densely compacted regions stain more 
darkly, while on R-banded chromosomes the ‘reverse’ happens.  The density of a 
chromosomal region often reflects the number of genes present within it: less dense 
regions usually have more genes (Sumner, 1990). 
The ability to concretely differentiate each chromosome was a key contribution of 
new banding techniques, but this was only the beginning.  These chromosomal bands also 
created visible and reproducible landmarks on each chromosome, meaning that they 
could be broken down into additional regions and sub-regions based on their bands.  This 
advance was very important in that it allowed cytogeneticists to speak reliably in terms of 
much more than just the long or short arm of a certain chromosome.  Now, a 
chromosomal aberration, such as the deletion, duplication, or translocation of genetic 
material, could be defined by its specific physical band location along a chromosomal 
arm.  This improved the visual resolution of chromosomal analysis, made laboratory 
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results more reliable and reproducible, and represented a first important step towards 
creating a genomic map at the visual level of human chromosomes.  
In order to make use of banding, cytogeneticists once again had to agree on a 
nomenclature system.  An international committee was convened to do so in 1971 
following the Fourth International Congress of Human Genetics meeting in Paris.  The 
1971 meeting featured many of the same members as the one five years earlier in 
Chicago, and similar international tensions.  At the time, G-banding and R-banding were 
the two most common methods for creating chromosomal bands.  Mary Seabright (1971), 
a British cytogeneticist, had developed the most commonly used technique for G-
banding, which was widely adopted in the US and much of Europe.  R-banding was a 
French innovation, and its use was largely exclusive to France (Interview with Dorothy 
Warburton, July 21, 2011).   
The Paris Committee’s primary challenge was to create a nomenclature system 
that incorporated both G and R banding.  As American participant Dorothy Warburton 
has told me about coming to a consensus, “it wasn’t easy”.  The patterns created by G 
and R bands were essentially exact opposites: dark G-bands went unstained by R-
banding, and dark R-bands were not stained by G-banding.  As a result, the debate was 
over which regions of each chromosome were banded and which were not.  Those who 
did R-banding wanted to number the visible bands down each chromosome as 1, 2, 3.  G-
banding proponents wanted the same numbering system, but with the dark bands that 
they saw (Interview with Dorothy Warburton, July 21, 2011).   
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A breakthrough came, according to Warburton, when committee chairperson John 
Evans suggested a compromise: chromosomes should not be thought of as having regions 
that were either banded or not, but instead, the bands on each chromosome should be 
understood as continuous: light then dark then light again.  This way, a standard 
numbering system could be adopted, and the darkness or lightness of a band would 
simply depend on which banding method was used.  So, following the 1960 chromosome 
numbering system and the 1966 arm-lettering compromise, members of the 1971 
committee created a consensus nomenclature that named each visible chromosomal band, 
whether dark or light.  Chromosomal arms were broken down into anywhere from one to 
four regions, which were then further divided by the bands visible in each.  The 
committee worked in groups to decide how many bands could be seen on each 
chromosome and to draft representative ideograms (Interview with Dorothy Warburton, 
July 12, 2011). 
Each band was identified by the chromosome (1-22, X, Y) and arm (p or q) on 
which it was located, followed by a number identifying the region (beginning with 1 at 
the centromere), and finally with a second number to designate the specific band.  For 
example, the band 15q12 (pronounced 15 – q – 1 – 2) is located on the long (q) arm of 
chromosome 15, and is the second visible band (2) in the first region (1) from the 
centromere.  Ideograms showing all of the (about 400) visible chromosomal bands in the 
human chromosome set were included in the conference report (Paris Conference (1971), 
1972) (Figure 2).  This standardized nomenclature provided the basis for the system that 
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geneticists use to the present day, for identifying the genomic location of various 
chromosomal abnormalities, genes, and disease etiologies. 
 
 
 
 
 
Figure 2  X-shaped, banded chromosomal ideograms, first developed in 1971.  This 
image was originally published in Paris Conference, 1971 (1972).  Reprinted with 
permission from the March of Dimes. 
 
 
Visualizing ‘High-Resolution’ Chromosomes 
During the 1970s, cytogeneticists began to experiment with capturing 
chromosomes in a somewhat less condensed state under the microscope, in the hope that 
they would reveal additional, visible bands.  This new technique, known as ‘high-
resolution’ chromosomal banding, began to spread by the end of the decade (Yunis, 
1978).  High-resolution chromosomes had more than double the number of visible bands, 
and with this technique in place, another international standardization meeting was held 
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in Paris in 1980 to update the existing nomenclature.  Committee members maintained 
the 1971 system, and divided existing bands into sub-bands by adding a decimal to the 
end of the current designation.  For instance, the second sub-band of 15q13 became 
known as 15q13.2 under the revised nomenclature (ISCN, 1981).   
Debates arose once again however, over which original band was being divided 
into new sub-bands.  In G-banding, light bands are understood to be less condensed than 
dark bands.  Therefore, it did not make logical sense that a new high-density dark band 
could be derived from an existing, low-density light band.  Because of this and other 
ongoing debates (which continued in correspondence afterwards), the meeting turned into 
what participant Uta Francke described to me as a “shouting match” (Interview with Uta 
Francke, February 27, 2012).  As a result, the report from this meeting, held in May of 
1980, was not published until well into the next calendar year.  Ultimately, the goal of 
what was now formally called the ‘International System for Cytogenetic Nomenclature 
(ISCN)’ Standing Committee was to maintain an internationally acceptable and 
standardized system for identifying chromosomal bands.  To accomplish this, small or 
theoretical discrepancies and disagreements had to be sidelined in favor of having one 
system that everyone, whether they primarily practiced G or R-banding, could use.   
In a 1982 letter sent to ISCN committee member David Harnden, one committee 
member, a human geneticist, commented on the continuing disagreements among 
committee members concerning band standardization by noting, “The guiding principle 
of ISCN is clearly the written word, not the ideogram.  To worry about minor artistic 
inaccuracies in such a highly stylized diagram is pedantic” (From the ISCN Papers, May 
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1980 meeting records).7  Indeed, the ideograms were not necessarily meant to capture the 
most accurate or logical description of what chromosomes looked like.  Instead, they 
depicted a nomenclature system that was created through compromise.  The most 
important goal of the standardization committee was to promote a single naming system, 
and not necessarily the most theoretically accurate one.   
This said, with the advent of high-resolution chromosomal banding, it had 
become increasingly clear that the black-and-white limitations of the 1971 compromise 
failed to capture what cytogeneticists were actually seeing under the microscope.  While 
the official ISCN report in 1981 maintained the all black-and-white banding pattern, 
committee member Uta Francke was allowed to publish, as part of the report, a separate 
set of G-banded ideograms.  These high-resolution ideograms had the same nomenclature 
as the official ISCN bands, except that instead of being exclusively black and while, they 
showed multiple shades of gray.  Francke’s goal was to more accurately represent what 
cytogeneticists actually saw under the microscope, so as to improve the visibility of small 
chromosomal aberrations (Francke, 1981; ISCN, 1981) (Figure 3). 
 
 
                                                 
7 The ISCN papers are currently privately held, and were made available to me, by 
geneticist Uta Francke.  The collection is located at the Stanford University School of 
Medicine, Palo Alto, CA.  
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Figure 3  Rod-shaped ideogram of chromosome 1 showing shades of grey.  This series of 
ideograms was published in the same report as the ISCN (1981) ideograms and largely 
looks the same, except for the differential coloring (Francke, 1981).  Reprinted with 
permission from Uta Francke. 
 
The cytogeneticists involved in creating and maintaining this chromosomal 
nomenclature system clearly recognized that they were working with fluid entities, which 
were in a constant state of flux during the life of a cell.  Any drawing of a chromosome 
only captures it at one brief moment and cannot necessarily be directly and logically 
related to how that same chromosome looks at a different point of condensation.  
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However, the intention of ideograms was not demonstrate or explain the physiological 
process of chromosome condensation, but instead to identify and designate the most 
reliable, and therefore useful visual landmarks that could be used for analyzing, and 
communicating about, the human chromosome set in a standardized manner.   
While standardization committee meetings were often contentious and drawn out 
affairs, in the end cooler heads had to, and did, prevail in favor of compromise and 
consistency.  The ideograms produced by these meetings were important for the 
exchange of clinical and scientific findings.  In addition, these ideograms became an 
internationally shared representation of what the human genome looked like, and an 
important basis for its physical mapping, as well as for increasingly commonplace efforts 
to ‘locate’ genetic disease etiologies within the genome.   
 
The Changing Look of the Human Chromosome Set 
 Since the first set of human chromosomal ideograms were proposed by the 1960 
Denver Study Group, ten standardization committee updates have been published, with 
the most recent coming in 2009.  Many of these revised editions suggested only small 
adjustments to the existing system, but a few provided a significant overhaul of the 
previous edition, most noticeably in the form of chromosomal ideograms with new 
banding patterns.  Such major revisions occurred in 1971, 1981, 1995, and 2005.  While 
each of these updates revealed the impact of novel cytogenetic techniques on 
chromosomal analysis, I argue that the new sets of chromosomal ideograms also offered 
novel ways of seeing the human genome.  In addition, they reflected new conceptions of 
 
 
44 
how genes and disease etiologies could be located and analyzed within it.  Here I focus 
on the changes that were made to chromosomal ideogram depictions in 1971 and 1981. 
 The chromosomal ideograms developed by the 1960 Denver Study Group have 
two distinguishing features when compared to those produced in later decades.  First, the 
chromosomes are depicted as solidly colored bodies: no banding techniques were yet 
available to provide each ideogram with a distinctive pattern.  Secondly, each 
chromosome looks like some variation of the letter X (Figure 2).  In a 1963 follow-up 
meeting held in London, the chromosomes were officially broken down into seven, 
lettered groups, as described above.  These groupings were based on variations in the 
chromosomes’ X-like shapes, as well as their relative size.  Group A chromosomes are 
large and ‘metacentric’, meaning that their centromere is centrally located, making their 
long and short arms close to the same size.  Group B and C chromosomes, on the other 
hand, are among those called ‘submetacentic’, since their long arms are significantly 
larger than their short arms.  Group D and G chromosomes are ‘acrocentric’, meaning 
that the short arm is too small to easily be seen (London Conference, 1963). 
 In 1971, the chromosomal ideograms went from being solidly colored to banded, 
reflecting the development of Q, G, and R banding techniques.  Otherwise, these 
ideograms remain X-shaped, like those published by the Denver Study Group (Paris 
Conference (1971), 1972) (Figure 2).  An entirely new set of ideograms, with new 
banding patterns, was not published again until the 1981 ISCN report (ISCN, 1981).  
However, two intervening updates in 1975 and 1978 included human chromosomal 
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ideograms that were not X-shaped, but rather looked like long, narrow rods (Paris 
Conference (1971), Supplement (1975), 1975; ISCN, 1978).   
These ideograms were created to facilitate comparisons among the banding 
patterns of human and other primate chromosomes (Interview with Uta Francke, 
February 27, 2012; Paris Conference (1971), Supplement (1975), 1975) (Figure 3).  The 
revisions were regarded at the time as supplements to the 1971 Paris conference, as 
opposed to a full overhaul (ISCN, 1985).  However, this new way of depicting 
chromosomal ideograms makes it clear that, in the mid-1970s, geneticists were beginning 
to think differently about what chromosomal analysis could reveal about the physical 
organization of the genome, and about how standardized ideograms of the human 
chromosome set could be used to depict these findings.  
Undoubtedly, there were multiple reasons for this move from depicting 
chromosomal ideograms as X-shaped to rod shaped.  As Uta Francke, who was a 
consultant to the 1981 Paris committee, has explained to me, part of the reason to switch 
from X-shaped to rod-shaped ideograms was for efficiency: more ideograms could be fit 
on one page (Personal Communication with Uta Francke, via email, March 28, 2012).  
Indeed, during the mid-to-late-1970s, when comparing the chromosomal ideograms from 
different primates was a major feature of the nomenclature committee’s publications, this 
made a lot of sense because rod-shaped chromosomes were easier to line up next to each 
other (Paris Committee (1971), Supplement (1975), 1975; ISCN, 1978).  Another factor 
by the late-1970s was the introduction of high-resolution chromosome banding, described 
in the previous section.  Because high-resolution chromosomes were captured in a less 
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dense state, they tended to look more rod-like than X-shaped.  Indeed, by 1980 rod-
shaped chromosomes were closer to what geneticists actually saw under the microscope. 
 I want to suggest however, that this incremental shift from X-shaped to rod-like 
ideograms between 1971 and 1981 also reflected new conceptions of the sort of 
knowledge that chromosomal analysis could provide to human and medical geneticists.  
X-shaped chromosomal ideograms, as they were depicted up through 1971, represented 
important functional units of cellular reproduction.  These ideograms appeared X-shaped 
because they were actually depicting two exact copies of the same chromosome (joined at 
the centromere), which were about to split apart in the formation of two genetically 
identical cells.  Chromosomal analysis up to this point was mostly focused on identifying 
large chromosomal abnormalities.  With the wider uptake of chromosomal banding in the 
early-to-mid-1970s however, the aims of cytogenetic analysis began to shift.  It was now 
possible to identify, and communicate about, more specific locations than entire 
chromosomes, or large portions of them.  As a result, the human chromosomes were 
coming to be understood as more than just units of cellular reproduction: they were also 
increasingly seen as the basic, observable, and map-able subsections of the genome.   
This facilitated early attempts to produce a ‘physical map’ of the human genome, 
which involves the direct association of genetic characteristics with distinct landmarks in 
the genome.  This is different from, but often closely associated with, the older technique 
of ‘linkage’ or ‘genetic’ mapping, famously practiced in T.H. Morgan’s fly lab to identify 
the relative location of genes or other traits on individual chromosomes.8  Rather than 
                                                 
8 For more on mapping in the Morgan Lab see: Kohler (1994). 
 
 
47 
determining the relative distance between genes, physical mapping seeks to associate 
genetic traits not with fixed genomic locations, which in the 1970s and 1980s were often 
defined by visibly distinct chromosomal bands (McKusick, 1988).  
 The human genome is generally conceived of at the molecular level as being a 
linear chain of DNA.  As the medical genetics textbook The Metabolic Basis of Inherited 
Disease put it in 1978, “All genetic mapping data are consistent with the hypothesis that 
the genome is a linear unbranched structure” (Stanbury et al 1978, 41).  With this 
conception of the human genome in mind, it would not have made much visual or logical 
sense to map genes and other genetic traits onto X-shaped chromosomes.  This said, there 
was no indication in the reports of the standardization committee published in 1975, 
1978, or 1981 that this shift from X-shaped to rod-like chromosomes was meant to make 
the human genome more map-able.  Nor is it my intention to argue for a causal link in 
either direction between ideogram linearity and genome map-ability.   
Rather, I suggest that this alteration in depiction reflects a shift in how geneticists 
conceptualized the relationship between the assumed linearity of the human genome and 
the associated observational characteristics of the human chromosome set.  
Chromosomes went from being countable entities, with which certain clinical disorders 
could be associated, to visibly comparable and ‘dissectible’ linear units of the human 
genome, within which the etiologies of disease could be definitively located.  In the next 
section, I demonstrate this same shift in another way: by tracing evolving definitions of 
the term ‘genome’ within the published biomedical literature specific to human genetic 
disease.  I argue that, during the 1970s and 1980s, the human genome was being 
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conceptually and visually remade, at the level of chromosomal analysis, into a clinically 
and biologically important, physical part of the human anatomy. 
 
Evolving Conceptions of the Human Genome 
It is commonly held that German botanist Hans Winkler coined the term 
‘genome’ in 1920 as a hybrid of the words ‘gene’ and ‘chromosome’ (McKusick and 
Ruddle, 1987).  However, an alternative interpretation, offered by Joshua Lederberg and 
Alexa McCray in 2001, holds that the suffix ‘ome’, used by Winkler in 1920, instead 
referred to, “a holistic abstraction, an eventual goal, of which only a few parts may be 
initially at hand,” as in the use of “biome” to refer in a general sense to all life in a 
particular earth environment (Lederberg and McCray, 2001, 9).9  In this section, I trace 
the term ‘genome’ in biomedical textbooks from the late-1960s through the 1980s.  My 
findings suggest a shift in the use of ‘genome’: from being an abstract way to identify all 
of an individual’s genetic material or genes, to a term referring more specifically to a 
physically embodied and discretely bounded anatomical entity.  
A number of texts aimed at geneticists interested in human disease were in print 
during the 1970s.  ‘Genome’ only appears in a couple of these texts, and when it does, it 
is described in quite abstract terms.  The glossary of McKusick’s text Human Genetics 
(1969), defines the genome quite simply as, “The total genetic endowment” (203), while 
the 1973 edition of Genetics in Medicine, a textbook by physician James S. Thompson 
and Ph.D. geneticist Margaret W. Thompson, defines genome in its glossary as, “The full 
                                                 
9 All of the world’s deserts or oceans constitute a biome.  
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set of genes” (361).  Beyond this, the term genome does not appear in the index or the 
main text of other medical genetics texts available during the 1970s such as, An 
Introduction to Medical Genetics (Roberts, 1973), and Medical Genetics: Principles and 
Practice (Nora and Fraser, 1974).10 
 Discussions and definitions of the human genome were equally absent in more 
general medical texts during the 1970s.  The term genome is not used in either the 1971 
or 1975 editions of the Cecil Textbook of Medicine (Beeson and McDermott, 1971; 
1975).  In the 1979 update, genome is not listed in the textbook’s index.  However, in a 
chapter on genetics, physician Alexander G. Bearn does muse, quite abstractly, “It is 
apparent that despite the acceleration in discovery of new genetic entities 90 per cent of 
the human genome remains to be discovered” (Beeson et al, 1979, 31).  Genome does, in 
fact, appear the 1970 and 1974 editions of another prominent general medical text, 
Harrison’s Principles of Internal Medicine.  The term can be found in a chapter 
contributed by McKusick, which refers to the genome in 1970 as “the rest of the genetic 
make-up”, and in 1974 as “the genetic background” (Wintrobe et al, 1970, 14; Wintrobe 
et al, 1974, 323).  Following McKusick’s departure as author of this chapter however, 
genome completely disappears from the 1977 and 1983 editions of Harrison’s, in which 
physicians Joseph L. Goldstein and Michael S. Brown contributed a similar chapter on 
genetics and disease (Thorn et al, 1977; Petersdorf et al, 1983). 
                                                 
10 The medical texts chosen for this survey were influenced in large part by a list, meant 
for small medical libraries, of recommended selections by topic (Brandon and Hill, 
1979). 
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 During the 1980s, the term genome became both more prominent and more 
precisely defined in medical genetics and general medicine textbooks.  The 1986 edition 
of Thompson and Thompson’s Genetics in Medicine states, “The term genome refers to 
the full DNA content of the chromosome set” (Thompson and Thompson, 1986, 6).  An 
Introduction to Medical Genetics (1985) by physicians J.A. Fraser Roberts and Marcus 
Pembrey refers to genomic DNA as, “the nuclear DNA of the chromosomes” (Roberts 
and Pembrey 1985, 104).  Physician James J. Nora and Ph.D. geneticist F. Clarke Fraser 
define genome as, “The complement of genes found in a set of chromosomes”, in the 
1981 edition of Medical Genetics: Principles and Practice (Nora and Fraser 1981, 497).  
In the 1985 update of the Cecil Textbook of Medicine, contributor John L. Hamerton, a 
human geneticist, notes, “The term genome refers to the full DNA content of the 
chromosome set” (Wyngaarden and Smith 1985, 138).  Genome also appears once again 
in the 1987 edition of Harrison’s Principles of Internal Medicine, in which physician and 
cell biologist Arthur Beaudet compares the genome to a series of books which, “can be 
envisioned as being bound into 46 volumes, each the equivalent of one chromosome” 
(Braunwald et al 1987, 296). 
While the human genome was certainly associated with the human chromosome 
set by geneticists before 1980, the findings from these medical textbooks clearly shows 
that there was a shift in the importance and meaning of the term genome for medical 
geneticists, and physicians more broadly, between the early-1970s and mid-1980s.  When 
used in the 1970s, genome generally referred to the abstract concept of ‘all the genetic 
material or genes’ possessed by an individual.  By the mid-1980s however, as the term 
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became increasingly commonplace, it was more often defined in the context of the human 
chromosome set.  Indeed, during 1980s, the human genome came to be understood as a 
discrete object of scientific interest among human and medical geneticists, and one that 
was physically and conceptually embodied within a visible part of the human anatomy: 
the chromosomes. 
 
Victor McKusick and Postwar Medical Genetics 
 This chapter has, so far, described how the genome became increasingly 
understood as embodied by the human chromosome set during the 1970s and 1980s, and 
in turn how standardized representations of chromosomes themselves became 
increasingly linearized and ‘genomic’ over this time.  My focus now shifts to how 
chromosome level depictions of the human genome were used to shape conceptions of 
genetic disease at this time.  Central to this story is the work of Victor McKusick, and his 
influence on the field of medical genetics during the postwar period.  After a brief 
overview of McKusick’s biography, I turn to a discussion of the new basis for genetic 
disease noslogy, which he helped to create and promote through his well-known catalog 
of human genetic disorders, Mendelian Inheritance in Man. 
McKusick has frequently been referred to as the ‘father’ of postwar medical 
genetics.  Obituaries of McKusick appearing in Science, Nature Genetics, and the Lancet 
after his death in 2008 highlight his status in the field, as does the Award Description 
provided for the Lasker Award for Special Achievement in Medical Science, which 
McKusick received in 1997 (Lasker Foundation, 1997; Collins, 2008; Oransky, 2008; 
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Rimoin, 2008).  Reed Pyeritz, a student of McKusick’s, has told me that he was a “pretty 
towering figure” in the field of medical genetics, even in the mid-1970s, and that he is 
among a group of just four or five individuals who could be considered as having 
founded this medical specialty in America (Interview with Reed Pyeritz, April 18, 2012).  
Indeed, McKusick was heavily influential in the fields of human and medical genetics 
during the last five decades of this life, and certainly one of the most important figures 
who shaped conceptions of the human genome, including its size, scope, functionality, 
and impact on biology and medicine in the postwar period.11    
Born in Parkman, Maine in 1921, McKusick received an M.D. from Johns 
Hopkins University School of Medicine in 1946, where he became a faculty member a 
year later, specializing in cardiology.  As part of his cardiology research, McKusick 
became interested in Marfan syndrome, a genetic disorder associated with heart defects.  
McKusick tracked the inheritance pattern of this disorder in his patients, ultimately 
leading to a wider interest in other inherited disorders (McKusick, 1980, 2006; Stafford, 
2008).  As he recounted in a 2006 autobiography, McKusick was surrounded by multiple 
other, more senior, faculty members at Hopkins, during the 1950s, who were also 
interested and knowledgeable in genetics, including Bentley Glass and Barton Childs.  
Additionally, he suggested that he was heavily influenced by Curt Stern’s 1949 textbook 
Principles of Human Genetics.  In 1957, McKusick was installed as director of the J. Earl 
Moore Clinic at Johns Hopkins, where he developed a Division of Medical Genetics.  As 
                                                 
11 For more on the status and role of McKusick in postwar medical genetics see: Lindee, 
2005; Comfort, 2012. 
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McKusick has told it, colleagues warned him about shifting focus from cardiology to rare 
genetic disorders, calling the move “professional suicide” (McKusick, 2006, 5).   
 During the late-1950s and 1960s, McKusick went on to train a number of major 
figures in the field of medical genetics, including David Rimoin and Alan Emery, editors 
since 1983 of the text Principles and Practice of Medical Genetics, as well as David 
Weatherall, author of The New Genetics and Clinical Practice, Malcolm Ferguson-Smith, 
long-time editor of the journal Prenatal Diagnosis, and Peter Harper, author of A Short 
History of Medical Genetics (2008).  McKusick also helped to develop the Short Course 
in Medical and Experimental Mammalian Genetics, which is held annually at the Jackson 
Lab in Bar Harbor, Maine.  This two-week course has been responsible for educating 
thousands of clinicians about the research and practices of medical genetics since it began 
in 1960 (Stafford, 2008; Comfort, 2012).   
 Victor McKusick however, is perhaps best known for his catalog of genetic 
disorders, Mendelian Inheritance in Man (MIM).  First published in 1966, MIM grew out 
of a series of annotated reviews of medical genetics that McKusick and colleagues had 
been compiling since 1958.  Ultimately, these were organized into catalogs on X-linked, 
recessive, and dominantly inherited disorders, which were put into a computer database 
beginning in 1964.  Successive editions of MIM were published in 1966, 1968, 1971, 
1975, and so forth until the final print edition in 1998.  The catalog expanded with each 
edition, providing a visible demonstration of the growth and success of the field of 
medical genetics.  Students occasionally referred to the brightly colored books as “green 
genes” and “blue genes” when distinguishing among 1970s era editions (McKusick, 
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1981, 67).  In 1987, MIM became available electronically as Online Mendelian 
Inheritance in Man (OMIM) (McKusick, 2006).  
In MIM, McKusick offered a particular conception of and perspective on human 
genetic disorders.  He argued that the study of genetic disorders provided valuable 
insights concerning the normal human genetic make-up, 
 
Genetic disorders give us insight into the normal.  These catalogs of 
hereditary traits are like photographic negatives from which a positive 
picture of man’s genetic constitution can be made . . . Physicians have a 
unique opportunity to contribute to knowledge of what Richard Lewontin 
referred to as ‘man’s mutational repertoire’ (McKusick, 1968, ix). 
 
Additionally, McKusick emphasized the direct correlations that medical genetics 
expected to find between genetic mutations and specific clinical disorders, 
 
In medical genetics there is little place for expressions such as ‘spectrum 
of disease,’ ‘disease A is a mild form, or a variant, of disease B,’ and so 
on.  They are either the same disease, if they are based in the same 
[genetic] mutation, or they are different diseases.  Phenotypic [clinical] 
overlap is not necessarily any basis for considering them fundamentally 
the same or closely related (McKusick, 1968, xi).  
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A major goal of medical genetics was to help clarify the delineation of particular 
disorders, whose identity was confused by variable or overlapping clinical expression.  
Indeed, if every genetic disorder could be mapped to one discrete location (or perhaps 
multiple locations) in the genome, this could greatly improve diagnosis, clinical 
understanding, and potentially treatment.  McKusick’s contribution to this process was in 
the collection and organization of diseases and other genetic traits in MIM.  As I describe 
in the next section, this also included participation in workshops, which facilitated the 
mapping of genes and disease etiologies in the human genome. 
  
Mapping the Human Genome at the Level of Chromosomes 
In her book, Moments of Truth in Genetic Medicine (2005), which looks at the 
first decade of medical genetics, Susan Lindee argues,  
 
[McKusick] was an early and eloquent proponent of what I call the 
cataloging imperative: the increasingly powerful idea among medical 
geneticists that the compilation of a list (or, later, map) of genetic traits, 
birth defects, and diseases in human populations could transform medical 
practice and patient care (Lindee, 2005, 81). 
 
Lindee suggests further that McKusick was, “collecting with a remarkable passion and 
with an explicitly medical agenda that has been fully realized in the international effort to 
map and sequence human genes, the Human Genome Project” (Lindee, 2005, 81).   
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McKusick’s interest in ‘collecting’ genetic diseases, and mapping their etiologies 
to particular genomic locations, in many ways defined, throughout the 1970s and 1980s, 
the way that human and medical geneticists thought about the geography and scope of the 
human genome.  McKusick himself was not among the first researchers to propose what 
became the Human Genome Project (HGP) during the mid-1980s (McKusick, 1997a).  
However, he did feel that the Gene Mapping workshops, which he helped to found, lead, 
and promote during the 1970s and 1980s, represented an important foundational basis for 
the HGP.   
In a draft history of the HGP, written in 1998 McKusick suggested, “Since 
mapping all the genes in the human is a goal of the Human Genome Project, the Human 
Genome Project (HGP) can be said to have begun in the summer of 1973 when the first 
human genome mapping workshop was convened in New Haven by Frank Ruddle” 
(McKusick Papers, Box 509623, ‘Hx of HGM 98’ folder, 1).   Indeed, McKusick’s 
leadership, in the 1970s and 1980s, of the Human Gene Mapping workshops, offered 
geneticists with an early glimpse of what mapping the genome would look like and mean 
for the study of human genetics and disease. 
 In 1986, at a Cold Spring Harbor symposium on mapping and sequencing the 
human genome, Victor McKusick gave a presentation about the status of the human gene 
map.  At the time, approximately 900 genes had been mapped to specific human 
chromosomes and chromosomal locations (McKusick, 1986b).  McKusick later described 
this presentation as being “an eye-opener to the molecular geneticists present” 
(McKusick, 1997a, 18).  Indeed, as McKusick notes, and in line with the history of 
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Robert Cook-Deegan (1994), the initial impetus for the Human Genome Project came not 
from the human or medical genetics community, but rather from molecular biologists 
(McKusick, 1997a).  As it turned out however, these molecular biologists were largely 
unaware of the extensive human genome mapping that had already been taking place 
since 1968, and in an organized manner since 1973 (McKusick, 2006). 
 The first genes mapped in man were located on the X chromosome, for the simple 
reason that X-linked disorders could be identified based on pedigree analysis because 
they generally only affected males, as in the case of hemophilia and color blindness.  
Roger Donahue, a student of McKusick’s, linked the first gene to an autosomal 
chromosome in 1968.  Donahue traced a visible abnormality that he had identified in his 
own karyotype through various other members of his family.  He was eventually able to 
link this visible marker, located on chromosome 1, to a set of genes known as the Duffy 
Blood group, which code for red blood cell molecules.   Reflecting on Donahue’s 
research process, McKusick later mused, “As every good graduate student in genetics 
should, Donahue studied his own chromosomes” (McKusick, 1981, 67).   
 Donahue’s finding happened around the same time as other significant 
innovations that contributed significantly to human gene mapping in the 1970s.  The first, 
as I have already discussed, was the development of chromosomal banding techniques, 
which offered hundreds of unique and reproducible chromosomal locations (Caspersson 
et al, 1968; Seabright, 1971).  Another was the development of somatic cell hybridization 
techniques involving the fusion of rodent and human cells.  The formation of these hybrid 
cells, which initially contain full human and rodent genomes (usually mouse or hamster), 
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occurs very rarely, but can be facilitated by chemical manipulation and particular viruses.  
As the hybrid cells go through continuous rounds of reproduction, most of the human 
chromosomes are lost, while all rodent chromosomes remain.  Some human 
chromosomes however, may be retained, especially if they contain a gene that is 
necessary for cell survival in a particular selective medium (Harris and Watkins, 1965).   
Somatic cell hybridization proved to be of great value to human gene mapping 
because researchers could test for hybrid cells that continued to express a particular 
human protein (Weiss and Greene, 1967).  If a human protein was still produced by a 
hybrid cell, this meant that its gene must be on one of the human chromosomal fragments 
still present.  In combination with the uptake of G-banding in the early-1970s, somatic 
cell hybridization helped to facilitate the mapping of hundreds of human genes to certain 
chromosomal locations over the next decade.  Because it brought about the mixing and 
recombination of chromosomes from different cells, a cellular process that generally only 
occurs as part of sexual reproduction, J.B.S. Haladane famously referred to cell 
hybridization as “an alternative to sex” (McKusick, 1981, 76).     
 In 1973, the first Human Gene Mapping workshop was held in New Haven, 
Connecticut under the leadership of Frank Ruddle, a Yale geneticist and early adopter of 
somatic cell hybridization for gene mapping.  The gathering was funded by the March of 
Dimes organization, which already had a longstanding relationship with McKusick, and 
role in the funding education of medical geneticists through supporting the annual Short 
Course in Medical and Experimental Mammalian Genetics.  At the time of the first 
workshop, very few genes had been mapped to specific chromosomes.  However, by the 
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fourth workshop held in Winnipeg in 1977, at least one gene had been mapped to each 
human chromosome (McKusick, 2006).   
This was a significant intellectual accomplishment for those involved in gene 
mapping, even if it was only the tip of the iceberg as far as the entire human genome was 
concerned (McKusick, 1980).  Why was it so meaningful to have associated at least one 
gene with every chromosome?  Part of the answer to this question can be found in a 
lecture that McKusick had given in 1969 at the 3rd International Conference on 
Congenital Malformations.  It was in this forum that he first publically proposed that the 
entire human genome should be mapped on a detailed level.  In this talk, he spoke about 
human chromosomes metaphorically as continents, 
 
The chromosomes of man are still largely terra incognita. The 
developments in human cytogenetics in the last 10-15 years have shown 
us the gross outlines of the continents . . . In a pitifully small number of 
instances we know pairs of neighbors residing somewhere on one of the 
continents, which are the chromosomes in this geomorphic anatomy. But 
in few instances do we know which chromosomes continent carries which 
gene . . . Combined with a mapping of the fine structure of the gene should 
be an all-out effort at mapping the chromosome continents (McKusick, 
1970, 408). 
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By mid-1976, human geneticists had succeeded in at least planting a flag on every 
continent in the human genome, and from there would further explore the landscape of 
each.  Indeed, by identifying at least one gene on each human chromosome, human 
geneticists had expanded the reach of their knowledge and capabilities to the entirety of 
the human genome. 
 The next year, McKusick and Frank Ruddle published a report on the status of the 
human gene map in Science.  Included in this paper was a map of the human genome, 
depicted at the level of banded chromosomes.  The chromosomes were each represented 
by an ideogram, based on the rod-shape ideogram drawings provided by the 1975 
supplement to the 1971 Paris conference.  Each chromosome had one or more genes 
mapped to it, designated most often by a three-letter abbreviation, placed at the 
approximate location on the chromosome to which that gene had been mapped.  The 
result is a one-page, schematic view of the human genome, divided into 24 chromosomes, 
with one or more genes mapped to each.  As depicted in the image, the genome is 
‘haploid’ and male: only one copy of each chromosome is shown and both an X and Y 
chromosome are present (McKusick and Ruddle, 1977; McKusick, 1980) (Figure 4).   
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Figure 4 Map of human genes with known genomic locations, depicted on ideograms 
similar to those from the 1975 supplement to the 1971 Paris conference.  This image was 
initially published in McKusick (1980).  Reprinted with permission from The Alan 
Mason Chesney Medical Archives of The Johns Hopkins Medical Institutions. 
 
 
62 
A similar one-page image of the human gene map was also published in the 1978 
and 1983 editions of MIM as well as various papers that McKusick published on the 
anatomy of the human genome in the early-1980s (McKusick, 1978, 1980, 1981, 1982, 
1983).  The density of genes on each chromosome expanded quickly over this time, and 
by 1986 the gene map depiction spanned four pages instead of just one (McKusick, 
1986a).  Why represent the human gene map in this way?  I would suggest that the 
depiction of genes laid out on chromosomal ideograms quite successfully represents the 
human genome visually as both a cartographic and anatomical object.  As Sismondo 
(2004, 215) has argued in reference to the Human Genome Project, the practice of 
cartography has a “fiction of completeness . . . Maps ask to be completed” through the 
filling in of missing information.  The growing gene map as depicted on chromosomal 
ideograms had a similar effect: it showed which areas of the genome were well 
represented, and what regions remained largely unexplored. 
One set of genes that were of particular interest to McKusick, and other medical 
geneticists, were those directly involved in the etiology of various genetic diseases.  
During the 1970s, McKusick’s maps were largely limited to specific gene designations.  
However, in the early-1980s, McKusick began creating separate maps, which he called 
the “Morbid Anatomy of the Human Genome,” depicting the genomic location of disease 
etiologies as well.  As I describe in the next sections of this chapter, these maps were part 
of McKusick’s larger interests in making geneticists and clinicians see and understand the 
genome as part of the human anatomy.    
  
 
 
63 
The Human Genome as an Anatomical Entity 
 I began this chapter by noting that Victor McKusick often spoke of the human 
genome (and alternatively the human chromosomes) as being the “organ” of molecular 
genetics, equating it with the heart for cardiologists and the kidneys for nephrologists 
(McKusick, 1982, 1997a, 2001).  This fit into McKusick’s larger conception of the 
genome as being part of the human anatomy, “The chromosomes and the linear 
arrangement of the genes they carry are part of human anatomy” (McKusick, 1981, 78).  
McKusick cites multiple sources for this conception of the genome, including the 
influential human geneticist Curt Stern and biochemical geneticist Charles Scriver 
(McKusick, 1997b, 2001).  Clearly McKusick found the reference to be of great 
descriptive and rhetorical value, as he used it in most every paper he published on the 
human genome between 1980 and his death in 2008.  
McKusick was not alone in his use of anatomical analogies when speaking about 
the human genome in the early-1980s.  In this Nobel lecture, the molecular biologist Paul 
Berg also made a similar anatomical reference in talking about the genome and its 
relevance to medicine, 
 
Just as out present knowledge and practice of medicine relies on a 
sophisticated knowledge of human anatomy, physiology, and 
biochemistry, so will dealing with disease in the future demand a detailed 
understanding of the molecular anatomy, physiology, and biochemistry of 
the human genome . . . We shall also need physicians who are as 
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conversant with the anatomy and physiology of chromosomes and genes 
as the cardiac surgeon is with the structure of the heart and the circulatory 
tree (Berg 1981, 285). 
 
Charles Scriver also adopted an anatomical metaphor in speaking about the 
genome during the early-1980s, referring to genomic mapping as akin to a “neo-Vesalian 
anatomy” (Scriver, 1982, 496).  In the early-1980s, McKusick also picked up on this 
concept, publishing a paper entitled “The Human Genome Through the Eyes of Mercator 
and Vesalius”.  The article looked at the use of both cartographic and anatomical 
metaphors for thinking and speaking about the genome.  In terms of the cartography of 
the genome, McKusick states, “The landmarks in the maps are the [chromosomal] bands 
revealed by special staining” (McKusick, 1981, 77).  However, as he goes on to explain 
in the paper, “This is a cartographic metaphor, but an anatomic metaphor is equally apt” 
(McKusick, 1981, 78).  
Indeed, analyzing the human genome was not just as a mapping project, but also 
as an anatomical exercise, in the tradition of Vesalius.  Adopting the same phrasing as 
Scriver in a 1986 paper, McKusick noted, “Knowledge of the chromosomal and genic 
anatomy of Homo sapiens has given clinical genetics (and medicine as a whole) a neo-
Vesalian basis” (McKusick 1986b, 19).  In his account of the early history of the Human 
Genome Project, Gene Wars (1994), Robert Cook-Deegan recounts that such references 
to the neo-Vesalian nature of genome mapping were quite successful in attracting funding 
sources for the project, particularly from the Howard Hughes Medical Institute (Cook-
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Deegan 1994, 120).  Seemingly, these historical and anatomical references made 
mapping the human genome more legible to a wider audience.    
 When pointing to the ‘neo-Vesalian’ basis of human genetics, McKusick and 
Scriver were referencing the work of Andreas Vesalius, a 16th century physician, famous 
for his anatomical images published in On the Fabric of the Human Body (1543).  The 
frontispiece of this text, which McKusick published as part of his 1981 paper, “The 
Human Genome Through the Eyes of Mercator and Vesalius”, depicts Vesalius teaching 
human anatomy by directly pointing to a newly dissected human body.  This was in 
contrast to the existing norm during the 16th century, when an instructor would read 
directly from the fourteen hundred year-old text of Galen, while standing apart from the 
dissected body (Carlino, 2001). 
To the present day, Vesalius is remembered in the western medical community as 
having brought direct observation of the dissected human body back to the forefront of 
research and teaching in human anatomy.  In The Secrets of Women: Gender, Generation, 
and the Origins of Human Dissection (2006) however, Katherine Park counts Vesalius 
among various 15th and 16th century figures who have been inaccurately remembered as 
heroes because they, “braved persecution and censure in the service of art and science” 
(21).  As Park suggests, continued reference to these individuals does, “important cultural 
work”, providing, “foundation stories that confirm deep-seated Western institutions about 
the scientific origins of modernity – institutions that continue to inform the writing of 
even specialists in the field” (Park 2006, 21). 
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Indeed, late-20th century physicians like McKusick and Scriver regarded Vesalius 
as a revolutionary figure, who had an impact on future centuries of medical thinking and 
practice.  References to the ‘neo-Vesalian’ nature of late-20th century human genetics 
were rhetorically valuable for making the argument that the genome mattered to medical 
practice because it was physically and visually a part of the human anatomy.  In addition, 
just as the work of Vesalius was seen as reshaping medicine in the 16th century and 
beyond, during the 1980s, anatomical exploration of the human genome was similarly 
presented by McKusick and Scriver as being likely to have revolutionary implications for 
medicine in the decades to come.     
  
The ‘Morbid Anatomy’ of the Human Genome 
As part of addressing the anatomy of the human genome in his 1981 paper, 
McKusick commented on the localization of disease genes,  
 
For an ever increasing number of diseases the chromosomal location of 
the mutant gene responsible is known.  In many of these instances this 
location is known because the enzyme which is deficient has been 
assigned to a specific location. In most of these disorders the evidence is 
strong that it is indeed the structural gene for the enzyme that is mutant in 
the given disease (McKusick, 1981, 79). 
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Similar to the ways in which diseases may be located in the bodies of patients, their 
etiological cause may also be located in the human genome.  McKusick referred to this 
practice as looking at the ‘morbid anatomy’ of the human genome, pointing to the 18th 
century work of Giovanni Morgagni in locating the ‘clinical pathology’ of a disease in 
certain bodily organs (McKusick, 1997a, 422; McKusick 2001, 2289).   
Additionally, McKusick often spoke of “dissecting the human genome”, further 
playing up a neo-Vesalian interpretation of the human genome and what researchers 
could physically do to it (McKusick, 1980, 1981, 1982 1997b).12 
In his 1982 paper, “Window Panes of Eternity. Health, Disease, and Inherited 
Risk”, Scriver similarly pointed to this way of thinking about the human genome noting, 
once again in reference to Vesalius’ 1543 anatomy text,  “Another revolution in anatomy 
is occurring; it is chromosomal and genetic cartography achieved by mapping of genes to 
specific chromosomes and bands on chromosomes and the delineation of nucleotide 
sequences in specific genes, respectively. We are beginning to possess chromosomal 
                                                 
12 McKusick sought more than just a morbid anatomy of the human genome, however.  
He also called for a comparative evolutionary anatomy, a functional anatomy, and a 
developmental anatomy (McKusick, 1981, 79).  These terms closely resemble various 
sub-disciplines of classical biological study.  The human genome’s evolutionary anatomy 
would allow it to be compared to the genomes of various other organisms, its functional 
anatomy would describe the way its genes, and interactions among them, led to particular 
clinical outcomes, and its developmental anatomy would reveal various ways in which 
the arrangement of particular genes affected their functionality (McKusick, 1981).   
Indeed, McKusick seems to have hoped to re-appropriate the human genome as 
an important feature in both biological and medical research.  As previous scholars have 
demonstrated, much of genetics research since the 1930s had been biochemical in nature, 
and often was not specifically oriented toward human characteristics (Abir-Am, 1982; 
Kay, 1993, 2000; Keller, 2000; Rheinberger, 2008).  The ability to visualize and compare 
human chromosomes made possible by the introduction of banding in the 1970s however, 
made these anatomical entities newly useful for more classical medical and biological 
research. 
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addresses for Mendelian disease” (Scriver 1982, 496).  Scriver now refers to gene 
mapping during the 1970s and early-1980s as “the genome project of the day”.  As a 
member of the HHMI medical advisory board during the 1980s, he was a major 
proponent of funding this ongoing research.  Scriver has described his interest in gene 
mapping at the time to me in this way, “There was lots of initial episodic work, where a 
certain gene might be mapped to a certain particular region of a chromosome, and so a 
mosaic was being built up.  I was interested in seeing the whole picture being completed” 
(Interview with Charles Scriver, May 30, 2012).  During the 1970s and 1980s, it was 
McKusick who laid out the conceptual and visual framework for doing just this. 
 Starting with his 1982 paper, “The Human Genome Through the Eyes of a 
Clinical Geneticist”, McKusick began publishing what he called “The Morbid Anatomy 
of the Human Genome”.  To illustrate this ‘morbid anatomy’, McKusick began with the 
24 human chromosomal ideograms (1-22, X, Y), which were shown with banding 
patterns based on the 1981 Paris Conference, and arranged them into an idealized 
karyotype.  Along each chromosome, genetic diseases, which had been mapped to certain 
genomic locations, were identified.  Some disorders were known only to be linked to a 
specific chromosome, while others were associated with a particular chromosomal region 
or band (McKusick 1982).  
Reed Pyeritz, a medical geneticist, and former student of McKusick’s, has 
described the impetus for maps depicting the morbid anatomy of the human genome to 
me in this way, 
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When people started laying out the 23 sets of chromosomes, the 
ideograms, and then had next to [each] where a gene had been identified, 
[McKusick] said, ‘that’s all well and good, but you can often map a 
phenotype [like Marfan syndrome] to a specific site on a chromosome 
before you know what the cause is’ (Interview with Reed Pyeritz, April 
18, 2012). 
 
In effect, the morbid anatomy diagrams acted to breakdown the visual divide between 
laboratory and clinical knowledge: the anatomical markers of clinical disorders could 
also be located and observed within the human genome, at the visual level of 
chromosomes.  As McKusick saw it, “this is what a geneticist does” (Interview with Reed 
Pyeritz, April 18, 2012). Just as Morgagni had associated clinical disorders with the 
anatomy of particular organs during the 18th century, McKusick felt that a major goal of 
20th century geneticists should be to give human diseases a neo-Vesalian basis by 
locating them in discrete, visible regions within the genome.  
Updated versions of the morbid anatomy of the human genome appeared 
frequently in print.  For instance, morbid anatomy maps were included in the 1983 and 
1986 editions of MIM (McKusick 1983; 1986c).  New editions of the morbid anatomy of 
the human genome were also included in various medical genetics texts during the 1980s 
including, The Metabolic Basis of Inherited Disease (Scriver et al, 1989) and Genetics in 
Medicine (Thompson and Thompson, 1986).  In addition, the morbid anatomy was 
published along with an interview of McKusick in a 1984 issue of the Journal of the 
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American Medical Association, and in a four part series appearing in the journal Medicine 
between 1986 and 1988 (McKusick 1984; 1986a; 1987a; 1987b; 1988).  Indeed, during 
the mid-1980s, this “neo-Vesalian” depiction of the human genome had made its way 
more widely into the biomedical literature.  With each new map, McKusick captured the 
ongoing “dissection” of the human genome, while presenting a particular way of seeing 
and thinking about the genome to his fellow geneticists and clinicians, who, by the mid-
to-late-1980s, appear to have widely adopted it in their own texts (McKusick 1982, 88). 
Like the anatomical prints in Vesalius’ Fabrica, McKusick’s human gene map 
and ‘morbid anatomy’ of the human genome map were artistic depictions of the 
genome’s anatomy.  These maps were based upon idealized representations of each 
chromosome, as captured by chromosomal ideograms.  In addition, the gene locations 
presented by them were quite crude, with little or no indication of the distances between 
individual genes.  More than anything, the genome map was meant as a database for 
collecting and depicting existing information, which would be used as a basis for future 
research.  As McKusick put it in his 1986 report on “The Morbid Anatomy of the Human 
Genome” published in Medicine, “Just as [Vesalius’] de corporis humani Fabrica (1543) 
was the basis for the physiology of Harvey (1628) and the pathology of Morgagni (1761), 
the chromosome information is the foundation for our understanding and management of 
genetic disease in man” (McKusick, 1986a, 2). 
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The Human Genome Goes Full Circle 
 In this chapter, I have demonstrated how standardized depictions of the human 
chromosome set evolved during the 1970s and 1980s, just as conceptions of the human 
genome were also shifting among medical professionals.  Between 1971 and 1981, 
chromosomal ideograms became increasingly linearized and densely packed with over 
800 distinct bands, providing a standardized visual language for dividing up and 
identifying discrete locations on each human chromosome.  At the same time, beginning 
around 1980, various clinically oriented geneticists, such as McKusick and Scriver, began 
talking about and depicting the anatomical aspects of the genome.  This way of thinking 
about the human genome, as both observable and embodied, led to a noticeable shift in 
how the genome was discussed in medical texts between the 1970s and the 1980s.  The 
genome was no longer referred to abstractly as ‘all of the human genes’.  Rather, 
definitions and representations of the genome became increasingly embedded in and 
bounded by visual depictions of the human chromosome set.   
 In the 1987 edition of Harrison’s Principles of Internal Medicine, a new figure 
was added to the text, which perfectly captures the simultaneous evolution of 
standardized chromosomal ideograms and embodied conceptions of the human genome.  
This image combines selected elements of McKusick’s human gene map and ‘morbid 
anatomy’ of the human genome, but in a new way.  Previously, the chromosomal 
ideograms in these figures had been organized like a karyotype: with chromosomes lined 
up side by side, often in order by size.  In this figure however, the chromosomal 
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ideograms were lined up end-to-end in a circle, from chromosome 1 to 22, followed by Y 
and X, with “THE HUMAN GENOME” printed in the middle (Brauwald et al, 318). 
This way of depicting the human genome is interesting for a number of reasons.  
First, and most importantly, it takes the ongoing process of linearizing the chromosomal 
ideograms to make them more ‘genomic’ one step further: the human genome was now 
depicted as a continuous linear arrangement of all 24 human chromosomes, placed end-
to-end.  While each chromosome remains physically distinct, this image offers a 
particular view of the genome that allows it to be seen and mapped as a continuous 
whole, instead of in 24 distinct parts.  Another fascinating result of this way of 
illustrating the human genome is how similarly it is in setup to the standard depiction of 
bacterial and viral genomes.  Instead of being broken down into chromosomes, these 
genomes are comprised of one undivided loop of genetic material.  Hence, such genomes 
can be sequenced or mapped continuously, beginning and ending at any point.  Depicting 
the human genome, which is anatomically divided into 24 pieces, in this way, suggests a 
similar (conceptual) continuity.  The human genome becomes a single, bounded entity 
that can be broken down visually into a continuous series of chromosomal bands, instead 
of into 24 individual chromosomes, each having their own unique banding pattern. 
Indeed, “THE HUMAN GENOME” captures in one image, the various 
conceptual shifts that I trace in this chapter.  In being physically comprised by the human 
chromosome set, the genome was presented as a component of the human anatomy.  As 
part of becoming embedded in the chromosomes however, the human genome’s 
presumed linearity clearly was not lost.  Rather, as I have described, presumptions of 
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linearity literally reshaped how standardized chromosomal ideograms were drawn.  The 
arrangement of these chromosomal ideograms from end-to-end into a closed circle 
demonstrates dual understandings: the human genome is at once physically embodied by 
discrete entities, and yet conceptually continuous and linear.  In this image therefore, we 
see the human genome presented as a discrete scientific object: one that could be 
understood, described, and visually observed as a physically bounded whole.    
  
Conclusion 
 Throughout this chapter, I have argued that, during the 1970s and 1980s, the 
human genome became increasingly embedded – conceptually, physically, and visually – 
within standardized depictions of the human chromosome set.  After decades of being 
regarded and referred to in abstract terms, such as ‘all of the human genetic material or 
genes’ the genome began to be understood and analyzed in ways that made it increasingly 
tangible and anatomical, and thereby more relevant to the interests and daily practices of 
clinical researchers and medical geneticists.  In addition to providing an anatomical basis 
for conceptions of the human genome, its association of with human chromosomal 
nomenclature has also helped to establish the genome as a scientific object.  Indeed, the 
standardized visual nomenclature of the human chromosome set provides a universal 
language not only for identifying and communicating about chromosomal attributes, but 
genomic locations as well.   
The establishment of the human genome as a scientific object was an iterative 
process: one which involved shifting definitions of the term ‘genome’, along with 
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evolving standardized depictions of human chromosomes.  Additionally, the development 
of the genome as a scientific object involved new ways of thinking about, and visually 
representing, how human disease can be identified, observed, mapped, and potentially 
understood at the chromosomal level.  While the human genome has frequently been 
situated primarily within the informationally oriented domain of molecular and computer-
based biology, this study demonstrates that, during the 1970s and 1980s, the genome was 
conceptually re-appropriated as a tangible and valuable object of study among the more 
visually oriented practitioners of human and medical genetics.  Just as Scriver has put it, 
the human genome could be seen as “a mosaic” in the 1980s, that was growing ever more 
densely filled in as the process of gene and disease mapping continued (Interview with 
Charles Scriver, May 30, 2012).13 
Indeed, McKusick’s ‘morbid anatomy’ diagrams helped to establish the human 
genome as an object amenable for broad-based biomedical research, by taking an 
idealized representation of the biologically ‘normal’ human chromosome set, and using it 
to map the genomic location of clinically-defined ‘pathological’ disorders.  This seamless 
alignment of the normal and the pathological – the known biological and medical 
characteristics of the human genome – forms an important basis of contemporary 
biomedical research.14  Therefore, along with molecular biology and its informational 
                                                 
13 This statement is reminiscent of Daston (2008, 110) on scientific observation, “Science 
depends crucially on its own ontologies, so very different from commonsense ontologies, 
painstakingly assembled from diverse shards of evidence as a mosaic is assembled from 
tiny stones of diverse color and shape.  It is observation, grounded in trained, collective, 
cultivated habit, that fuses these bits and pieces into a picture– often a literal picture 
crafted by the techniques of scientific visualization.” 
14 This concept I draw from: Keating and Cambrosio (2003,72). 
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approaches, the observational analysis of chromosomes is deeply embedded in 
biomedicine’s postwar development.  With this in mind, continued recognition and 
analysis of observational approaches in postwar human genetics is likely to facilitate at 
once a broader and more nuanced understanding of the mid-to-late-20th century birth of 
biomedicine.  
In upcoming chapters, I continue to trace the development and use of banded 
chromosomal analysis for improving the delineation, diagnosis, and understanding of 
genetic disorders.  Throughout the 1970s and 1980s, the visual scanning of banded 
chromosomes provided new ways of seeing and identifying clinically characterized 
genetic disorders.  Throughout this era, human and medical geneticists attempted to apply 
chromosomal analysis to identifying new, more exact techniques of delineating disorders.  
These novel methods were based in the association of clinical outcomes with particular 
genomic locations and visual genetic aberrations, rather than the more variable and 
confusing presentation of disease in human bodies.   
As I explore, chromosomal methods for delineating human disease were at times 
quite successful, while, in other instances, they produced confusing and frustrating 
results.  In working through these complications however, human and medical geneticists 
increasingly came to conceptualize the human genome in ways directly shaped by the 
visual analysis of chromosomes.  As I argue, in the decades before the Human Genome 
Project began in earnest, chromosomal analysis provided an unexpectedly valuable 
experimental system for both the clinical delineation and mechanistic understanding of 
genetic disorders.  In the course of this, chromosomal analysis also facilitated the 
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development of new, increasingly complex understandings of the structure and function 
of the human genome more broadly. 
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CHAPTER 2 
Interpreting an ‘In Vitro’ Phenomenon: The Delineation, Diagnosis, Prevention, and 
Treatment of Fragile X syndrome 
 
In this chapter, I look at the role of chromosomal analysis in the history of a 
particular form of inherited intellectual disability, now known as Fragile X syndrome.  
Fragile X syndrome is believed to be the second most common cause of inborn 
intellectual disability (Smith and Berry, 1983; Sutherland and Hecht, 1985; Nussbaum 
and Ledbetter, 1986; McKusick, 1987; Kaufmann et al, 2002).  Aside from intellectual 
disability however, patients affected by Fragile X syndrome have been regarded as being 
quite ‘normal’ in clinical appearance (Turner, 1983).  Fragile X syndrome is one among 
many forms of ‘non-specific’ X-linked intellectual disability, referring to its lack of other 
highly relevant clinical features (Gerald, 1981).  The delineation of Fragile X syndrome 
was facilitated by the identification of two associated visual markers in the 1970s, one of 
which – the fragile X site – became the disease’s namesake during the next decade. 
The fragile X site is one of more than 100 ‘fragile’ sites that have been identified 
in the human genome, based on observational, chromosomal analysis.  Fragile sites are 
believed to reflect specific structural characteristics of the human genome.  Because of 
their wide distribution throughout the genome, they have also proven to be valuable 
visual markers for mapping various locations.  The fragile X site discussed in this chapter 
is unique among these genomic features in that it is associated with a clinical disorder 
(Hecht, 1988).  As I describe here, the correlation between the fragile X site and Fragile 
X syndrome was, for decades, both highly confusing for, and of significant interest to, 
clinicians and genetics researchers.  Indeed, while it proved to be a valuable 
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chromosomal marker of Fragile X syndrome when visible, the inheritance pattern of the 
fragile X site, and its associated form of intellectual disability, did not fit neatly with 
existing assumptions about Mendelian traits and genomic stability.  
The laboratory history of the fragile X site parallels the broader history of 
chromosomal analysis between the late-1960s and early-1990s in revealing ways.  
Indeed, this marker was identified before chromosomal banding was developed (see 
previous chapter) and was integrated into the new ‘genomic’ understanding of the human 
chromosome set during the 1970s and 1980s.  Likewise, the clinical history of Fragile X 
syndrome offers a window into thinking about intellectual disability, more broadly, 
during the postwar period.  By the late-1970s, it was widely accepted that Fragile X 
syndrome was ‘X-linked’ in two related ways.  Because the disorder only seemed to 
cause significant intellectual disability in males, it was assumed to be caused by a 
recessive trait inherited on the X chromosome, of which females possess two copies, 
while males have just one.  In addition to this pattern of clinical expression, Fragile X 
syndrome is also ‘linked’ to a microscopically visible “lesion” on the X chromosome 
(Pembrey et al, 1985, 713).   
During the postwar period, clinicians and genetics researchers looked for the 
visible markers of disease both within the clinically visible body and the chromosomally 
visible human genome.  Fragile X syndrome offers an exemplary historical case study of 
a genetic disorder that was delineated, diagnosed, and understood based on visible 
markers from both the laboratory and the clinic.  Since the late-1950s, the human 
chromosome set has increasingly been understood as a part of the human anatomy, where 
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the visible markers and mechanistic causes of genetic disease intermingle.  This has had 
implications for how clinicians and researchers think about and study the etiological 
causes of, and potential treatments for, Fragile X syndrome and other genetic disorders.  
In this chapter, and throughout this dissertation, I explore the impact that evolving 
understandings of the relationship between the human chromosome set and genome have 
had on the thinking and practices of postwar human and medical genetics.   
 
Mid-20th Century Perspectives on X-linked Intellectual Disability 
In 1943, British physician James Purdon Martin and human geneticist Julia Bell, 
both at the National Hospital in London, published a report on a family showing an 
inherited form of what appeared to be X-linked intellectual disability.  X-linked disorders 
often only affect males, because the causative genetic trait is located on the X 
chromosome, of which females have two copies, and males have only one.  If a female 
inherits one aberrant X-linked genetic trait, its negative effects may be overridden by a 
normal copy of that genetic entity on her other X chromosome.  However, since males 
have only one copy of the X chromosome, if they inherit a mutant genetic trait on it, they 
generally are affected by it clinically, because they have no normal copy to potentially 
override or mitigate these effects.   
Among two generations of the family described by Martin and Bell (1943), eleven 
males were affected by intellectual disability, along with two females, though their 
symptoms were much milder.  Unlike other forms of intellectual disability, such as Down 
syndrome and phenylkeoluria (PKU), no additional clinical manifestations were noted as 
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part of this inherited form of intellectual disability, which was described as involving an 
extremely limited vocabulary and not progressing past the mental capacity of a young 
child (Martin and Bell, 1943).  At the time, these researchers regarded the family 
pedigree they described as being an isolated case of X-linked intellectual disability.  
Referring to the Colchester Study report (Penrose, 1938), the authors noted that, among 
1280 cases of intellectual disability studied, British geneticist Lionel Penrose, “found 
insufficient evidence to support the view that sex-linked genes played a significant part in 
the etiology of mental defect – a testimony to the rarity of such a history as the one now 
described” (Martin and Bell, 1943, 157).  Though the Colchester Study demonstrated that 
there was a higher incidence of intellectual disability among males, Penrose concluded 
that this did not have a simple genetic basis, but was the result of several factors (Kevles, 
1985, 162).  With this in mind, and given the lack of other similar pedigrees in the 
published literature, Martin and Bell concluded that the family they described was a rare 
case, instead of a more widely representative one. 
Over the next thirty years, several additional reports of other families affected by 
similarly ‘non-specific’ forms of X-linked intellectual disability were published (Allan at 
al, 1944; Renpenning et al, 1962; Dunn et al, 1963; Roboz and Pitt, 1969).  In 1965, 
physician John M. Opitz and colleagues reported on an extended family with 20 
intellectually disabled males.  This family became the basis of a Ph.D. thesis done by 
Robert Lehrke in the years thereafter on the genetic basis intellectual disability.  Lehrke 
concluded that there existed one or more X-linked genes that were the cause of the higher 
incidence of intellectual disability in males (Lehrke, 1972).  This was a controversial 
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conclusion at the time, both among Lehrke’s doctoral examiners, and other human 
geneticists (Turner and Opitz, 1980; Turner, 1983).  After all, as Lionel Penrose (1963) 
suggested, given that humans have 22 other chromosomes, why should the X 
chromosome in particular play an important role in intellectual disability? 
Lehrke however, was not alone in arguing for the significant impact X-linked 
genes on intellectual disability.  During the early-1970s, an English study with similar 
results was published (Davison, 1973), as were reports from Australian researchers 
Gillian and Brian Turner (Turner et al, 1970; Turner et al, 1971; Turner et al, 1972).  
Gillian Turner was working at this time, in a clinic for the intellectually handicapped, and 
therefore was exposed to a large and diverse number of cases, the genetic basis of which 
intrigued her.  One day, Turner began going through a number of photographs of 
intellectually disabled males, to look for common physical traits, and noticed to her 
surprise, that many were quite ‘normal’ looking.  As Turner later put it, “We gradually 
woke up to the fact that to be ‘normal looking’ in a moderately mentally retarded 
population was relatively abnormal” (Turner, 1983, 10).  In these cases, the absence of 
any additional clinical effects beyond intellectual disability was regarded as so unusual as 
to be a visual marker of a unique disorder. 
Turner noticed that the majority of ‘normal’ looking males with intellectual 
disability had other males in their family that were similarly affected.  This was not the 
case for most intellectually disabled males that had more distinctive clinical features 
(Turner, 1983).  Multiple reports were published based on this finding (Turner et al, 
1970; Turner et al, 1971), in which it was suggested that these normal looking males had 
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a previously described X-linked disorder, ‘Renpenning Syndrome’ (Renpenning et al, 
1962).  Turner and her colleagues published an even larger study the next year, with 
similar results (Turner et al, 1972).  As she continued to examine sets of brothers with 
non-specific intellectual disabilities in the Australian state of New South Wales, Turner 
eventually came across an interesting clinical finding: in some cases the affected brothers 
possessed unusually large testicles (also known as macro-orchidism) (Turner, 1983).   
Testicle size is a feature that may be easily overlooked in the clinic; and, even 
when noticed, is difficult to accurately measure.  In 1966, Andrea Prader (one of the 
physicians who first identified Prader-Willi syndrome, the topic of chapter 3) developed 
an ‘orchidometer’ for the measurement of testicles, which was comprised of a series of 
egg-shaped standards of known volume to be used for comparison (Prader, 1966).  What 
could be considered a ‘normal’ testicle size was not yet well established in the early-
1970s, as volume varied greatly by age and, some hypothesized, among different races 
(Turner, 1983).  Turner et al (1975) reported on two families in which all of the males 
affected by an X-linked form of intellectual disability were also found to have testicles 
that were approximately twice the normal volume, as established by Zachmann et al 
(1974).  In this paper, Turner and colleagues also noted a previous study that had 
mentioned the presence of enlarged male genitals in a family affected by X-linked 
intellectual disability, which was published earlier in the decade by a Ph.D. candidate in 
Sao Paulo, Brazil (Escalante, 1971).  Multiple follow-up studies reported similar findings 
over the next few years, and established that the macro-orchidism in these cases did not 
 
 
83 
result from an independent hormonal abnormality (Cantu et al, 1976; Biederman et al, 
1977; Ruvalcaba et al, 1977).   
Was this clinical feature part of the disorder that caused X-linked intellectual 
disability?  A patient with macro-orchidism who was not intellectually disabled was 
knonwn in the medical literature (Nisula et al, 1974), demonstrating that the two features 
did not always occur together.  However, as Bowen et al (1978) pointed out, the 
consistent occurrence of macro-orchidism in families with otherwise non-specific X-
linked intellectual disability was strong evidence that these two clinical outcomes were 
related.  What clinicians and researchers needed in the mid-1970s was a third marker, 
common to this population, that could dispel doubts that the group was clinically distinct.  
As it happened, another researcher had already identified such a marker based on 
observational, chromosomal analysis in the late-1960s.  However, as I describe in the 
next section, various technical complications delayed the demonstration of its clinical 
significance. 
 
A Chromosomal Marker for X-linked Intellectual Disability 
In 1969, Yale University School of Medicine physician Herbert Lubs reported on 
the discovery of a new type of chromosomal abnormality.  He described it as “an unusual 
secondary constriction . . . seen at the ends of the long arm of a group C chromosome 
[referring to chromosomes 6-12 and X]”.  The aberration “gave the appearance of large 
satellites”, greater in size than any of the satellites that normally appeared on certain 
other chromosomes (Lubs, 1969, 234).  Lubs had discovered this ‘secondary constriction’ 
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while studying the chromosomes of a boy affected by a severe form of intellectual 
disability.  Often times, when chromosomal aberrations are identified in patients with 
clinical abnormalities, the chromosomes of one or both of their parents are also analyzed, 
so as to determine whether or not the abnormality is inherited.  If the same aberration is 
found in a parent who is not similarly affected clinically, it is generally assumed that it 
represents a benign form of ‘normal’ genetic variation.  
In this case, after finding the secondary constriction in the intellectually disabled 
boy, Lubs analyzed the chromosomes of the boy’s intellectually normal mother and his 
similarly affected brother.  These two family members also showed the exact same 
chromosomal aberration.  In response to this finding, Lubs noted, “Initially, it appeared 
that the secondary constriction was not clinically significant since it was present both in a 
normal mother and her abnormal son” (Lubs, 1969, 241).  Upon further analysis 
however, the same secondary constriction was also found in multiple individuals in the 
patient’s extended family, some of who showed a similar form of intellectual disability.  
It was noticed, in fact, that only males who possessed this secondary constriction were 
affected by intellectual disability.  Females with the marker were reported as showing no 
clinical effects (Lubs, 1969).     
Touting the importance of this new chromosomal marker to the future of clinical 
cytogenetics, Lubs suggested that such secondary constrictions might “prove to be the 
most important group of cytogenetic abnormalities both because they are common and 
because they may permit prevention of clinical disease” (Lubs, 1969, 231).  Unlike other 
chromosomal abnormalities that had been identified in the previous decade, such as 
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trisomy 21 in Down syndrome patients, Lubs’ marker was heritable, and thereby could be 
tracked in families.   With this in mind, Lubs suggested that, “descriptive human 
cytogenetics is entering a new and important phase.”  Indeed, identifying smaller, 
heritable chromosomal anomalies, such as this one, was significant because, “they may 
permit prevention of clinical disease by identifying high-risk marriages and allowing 
subsequent amniocentesis and abortion of abnormal fetuses if requested by the family” 
(Lubs, 1969, 231).   
Lubs could see that this secondary constriction occurred on a ‘C group’ 
chromosome, a classificatory unit that is comprised of chromosomes 6-12 and X.  As I 
described in the previous chapter, it was very difficult to visually discriminate each C 
group chromosome at this time, as they are all similar in size and shape.  The specific 
chromosome upon which the secondary constriction occurred therefore, could not be 
easily determined visually.  However, since the marker was associated with intellectual 
disability only when present in males, and never when seen in female family members, 
Lubs inferred that it was likely an X-linked trait.  Indeed, while Lubs used other 
laboratory methods to aid in demonstrating that the secondary construction occurred on 
the X chromosome,15 it was the inheritance pattern of the related clinical disorder that 
first suggested that this would be the case.  It was not yet clear how the secondary 
constriction caused intellectual disability, but since this clinical outcome was only seen in 
males, the genetic trait itself seemed to be located on the X chromosome (Lubs, 1969). 
                                                 
15 This included a more exacting measurement of the chromosome’s length and width, as 
well as an analysis of when during the cell reproductive process it was replicated (Lubs, 
1969). 
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Lubs’ ‘Marker X’ chromosome was one of three secondary constrictions that 
were independently reported by various cytogeneticists between 1968 and 1970.  A year 
earlier, Jerome Lejeune in France had identified a similar heritable marker on 
chromosome 2 (Lejeune et al, 1968).  And, in 1970, another was reported on 
chromosome 16 by American cytogeneticists Ellen Magenis and Frederick Hecht 
(Magenis et al, 1970).  Unlike the Marker X however, neither of these visible 
chromosomal anomalies were associated with abnormal clinical outcomes.  In their 1970 
report, Magenis and Hecht referred to the chromosomal abnormality they had identified 
as a ‘fragile site’, a term that was widely adopted by geneticists thereafter.16  
As it turned out, the immediate impact of Lubs’ fragile site, in both in the 
laboratory and clinic, was minimal.  No other researchers reported a similar X 
chromosome fragile site again for seven years (Giraud et al, 1976; Harvey et al, 1977).  
In fact, discussion of fragile sites largely disappeared from the scientific and medical 
literature during the first half of the 1970s.  This delay had not occurred because Lubs’ 
paper had gone unnoticed: it was published in the American Journal of Human Genetics, 
and cited when the fragile X site was once again identified in the mid-1970s.  Indeed, as 
Gillian Turner later noted, she, and likely others, had been in pursuit of finding the 
Marker X chromosome in patients ever since Lubs’ report (Turner, 1983, 12).  Rather, 
researchers stopped reporting on fragile sites in the early-1970s quite literally because 
they stopped seeing them under their microscopes.   
                                                 
16 Lubs however, continued to prefer the use of “Marker X chromosome” (Lubs, et al, 
1984). 
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The disappearance of fragile sites did not occur because of an existing need for 
some technological advance to improve visibility: in fact, quite the opposite was the case.  
While fragile sites were understood to be visual representations of certain heritable 
structural characteristics of the human genome, it was ultimately determined that they 
could only be seen in the laboratory under certain chemical conditions.  Australian 
geneticist Grant Sutherland eventually explained the disappearance of fragile sites from 
chromosomes in 1977, by demonstrating that a change in cell culture media by many 
cytogenetics laboratories around 1970 had inadvertently masked the sites (Sutherland, 
1977; Gerald, 1981).   
Following further experimentation, Sutherland determined that it was the presence 
of higher concentrations of folic acid in the new media that had led to the absence of 
visible fragile sites in the early-1970s.17  After this was widely reported, folic acid 
deficient media was once again adopted for studying fragile sites, along with the new 
protocols recommended by Sutherland (1979) (Interview with Loris McGavran, August 
20, 2012).18  At this point, research on fragile sites, as well as their clinical associations, 
began anew (Sutherland, 1979; Sutherland and Hecht, 1985).  Indeed, as it turned out, a 
technical change that was intended to improve chromosomal analysis (by enhancing the 
ability to cells to reproduce in culture) inadvertently disrupted the study of the fragile X 
site, at a key moment in the investigation of its associated genetic disease.  As I describe 
                                                 
17 Other cell culture factors such as pH also played an important role (Sutherland, 1979). 
18 Loris McGavran is a Ph.D. cytogeneticist who played an important role in bringing 
Fragile X testing to the University of Colorado Children’s Hospital in Denver during the 
early-1980s. 
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next, by the time that fragile sites began to appear again, the practices of cytogenetics had 
been evolved significantly.  
 
The Fragile X Marker in a New Era of Cytogenetics 
Much had changed between the Lubs’ report in the late-1960s and Sutherland’s in 
the late-1970s.  Cytogenetics had emerged from its “doldrums” into the revolutionary era 
of chromosomal banding (McKusick, 1997, 8) (For more on this, see the previous 
chapter).  Each human chromosome could now be visually differentiated based on its 
unique banding pattern.  As a result, standardized depictions of the human chromosome 
set also had changed quite significantly.  Additionally, chromosomal banding provided a 
visual set of physical landmarks throughout the human genome, which could be used for 
the purposes of mapping.  Genomic locations were now identified based upon a 
standardized visual nomenclature, built around the bands on each chromosome, which 
had been developed in 1971 (Paris Conference (1971), 1972). 
 Based on this visual nomenclature, various genetic elements were now being 
associated with particular genomic “addresses”.  For instance, a number of human genes 
and disease etiologies that had been visibly located in the human genome based on 
chromosomal analysis, among other techniques, were identified based on the 
chromosomal band in which they had been found (Scriver, 1982; McKusick, 1983).  
Lubs’ X-linked fragile site, along with the twelve others known by 1982, was also 
associated with distinct a genomic location.  In many cases, these fragile sites were 
named after the chromosomal band at which they appeared.  For instance, the fragile site 
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on chromosome two, initially identified by Lejeune was named after the band 2q11 and 
the fragile X site was referred to as Xq27-8 (Sutherland, 1979; Hecht, 1982).19 
With the rediscovery of the fragile X site, and its association with the genomic 
location Xq27-8, Gillian Turner and her colleagues began reexamining patients affected 
by X-linked intellectual disability and macro-orchidism cytogenetically.  Among 16 
families initially examined, Turner et al (1978) reported six families in which affected 
males showed both macro-orchidism and the fragile X site, and ten families in which 
intellectually disabled boys expressed neither.  In four of the six families, female carriers 
of the fragile X site were also visibly identified under the microscope, suggesting the 
potential for offering prenatal diagnosis (Turner et al, 1978).  In a number of families 
then, cases of ‘non-specific’ X-linked intellectual disability had now been associated with 
two visible markers, one clinical and the other chromosomal. 
Around this time, discussions began concerning the appropriate name for this 
newly delineated disorder.  Previously, eponyms such as Renpenning and Martin-Bell 
syndrome had been applied based on early reports of families with non-specific X-linked 
intellectual disability (Richards, 1970; Turner et al, 1970).  Since, researchers had 
returned to the original family studied by Renpenning et al (1962), and found that males 
showed neither macro-orchidism nor the fragile X site, suggesting that this was a distinct 
form of intellectual disability (Fox et al, 1980).  Turner and Opitz (1980) suggested a new 
designation, describing the distinguishing features of intellectual disability associated 
with the fragile X site and calling the disorder ‘Macro-orchidism Marker X syndrome’ 
                                                 
19 The fragile X site was seen as being right at the border between bands Xq27 and Xq28 
(Turner et al, 1978).  For more on this cytogenetic naming system see: chapter 2. 
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(MOMX).  They noted that it was unknown whether the family initially described by 
Martin and Bell (1943) possessed either of these delineating markers, making this 
eponym inappropriate. Other clinicians however, opposed the designation MOMX, 
because it made no reference to the most important feature in affected patients, 
intellectual disability (Kaiser-McCaw et al, 1980; Richards, 1981).   
In 1980, Randi Hagerman, a pediatrician at the University of Colorado, Denver 
who had read Gillian Turner’s 1980 paper associating intellectual disability with macro-
orchidism and the Xq27-8 fragile site, became aware of a male patient being cared for 
locally, who had intellectual disability and abnormally large testicles.  At the time, 
chromosomal analysis for the fragile X site was not available in Denver.  Hagerman 
worked with University of Colorado cytogeneticist Loris McGavran to make Fragile X 
cytogenetic testing available for this and other patients in the area.  The first test 
eventually came back positive for the fragile site.  As McGavran recounted to me, “It was 
pretty thrilling to get our first positive and start down that road” (Interview with Loris 
McGavran, August 20, 2012).  And indeed, over the next 18 months, Hagerman and 
McGavran identified about 25 additional similarly affected patients and diagnosed them 
both clinically and cytogeneticially with Fragile X syndrome (Interview with Randi 
Hagerman, March 2, 2012).20   
Noting that there was very little US literature at the time on this disorder, 
Hagerman and her colleagues decided to collectively write a book on the topic.  The book 
                                                 
20 Randi Hagerman is a physician who specializes in child development and behavior.  
She began her career at the University of Colorado, Denver and is now at the University 
of California, Davis, where she is part of the MIND institute. 
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was ultimately published in 1983 under the title The Fragile X Syndrome: Diagnosis, 
Biochemistry, Intervention (Hagerman and McBogg, 1983).  This term ‘Fragile X 
syndrome’ had already appeared in the published literature occasionally in the early-
1980s (Fox, 1980; Gerald, 1980; Jacobs, 1980).  Hagerman and her colleagues however, 
seem to be the first researchers to have fully embraced ‘Fragile X syndrome’ as the name 
for this disorder.  As Hagerman put it,  
 
“We decided to use the name Fragile X syndrome, because Marker X 
wasn’t interesting . . . and we were very struck with the fragile site.  So we 
said, ‘let’s call it Fragile X syndrome’ . . . There was a lot of confusion 
about what its name was, and we decided to use Fragile X syndrome 
consistently” (Interview with Randi Hagerman, March 2, 2012). 
 
A few years before this, Richards et al (1981) had demonstrated cytogenetically 
that family members from the Martin and Bell (1943) study did indeed possess the Xq27-
28 fragile site.  With this in mind, some clinicians maintained the use of ‘Martin-Bell 
syndrome’ during the mid-1980s (Opitz and Sutherland, 1984).  The name ‘Escalante 
syndrome’ was also suggested (Vianna-Morgante, 1982) during this time, but was 
opposed by some, who noted that Esclanate did not mention macro-orchidism in his 
original 1969 description of the disorder (and thereby did not have precedence over 
Lubs).  As a result, the term Escalante syndrome has not been widely adopted outside of 
Brazil (Turner, 1983; Opitz and Sutherland, 1984).  Indeed, while there were many 
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claims on the name of this disorder throughout the early-1980s, by the middle of the 
decade, the term Fragile X syndrome seems to have won out.   
Despite its importance in the clinical delineation and naming of Fragile X 
syndrome however, the association between the fragile X site and intellectual disability 
remained unclear in the mid-1980s.  Indeed, of the 17 fragile sites known at this time, 
only the one Lubs had identified on the X chromosome was associated with a genetic 
disease (Sutherland and Hecht, 1985).  Clinicians and researchers continued to ponder 
over whether these fragile sites were a form of ‘normal’ genetic variation, or if they 
might be associated with some sort of ‘pathological’ mechanism.  Whether the fragile X 
site itself somehow caused this clinical syndrome, or was just closely linked to a 
causative gene remained unclear (Hecht, 1982).  Indeed, while much about the 
mechanistic role of the fragile site in Fragile X syndrome remained unknown, clinicians 
and researchers were not hesitant to use their existing knowledge of the fragile site in 
attempting to better understand, and even treat this disorder.  In the next section, I explore 
how conceptions of the fragile X site based on observational, laboratory examination 
were applied in the course of searching for potential clinical treatments. 
 
The Fragile X Site as an In Vitro and In Vivo Phenomenon 
Chromosomal analysis, unlike other methods used for identifying the visual 
markers of human disease, takes place apart from the body (Landecker, 2007).  Cells are 
cultured from the skin, blood, or other patient tissue, and manipulated both chemically 
and physically in a variety of ways, so as to make chromosomes visible and analyzable 
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(Rapp, 2000, de Chadarevian, 2010).  When the human chromosomes are seen under 
laboratory conditions, it is anticipated that they look and act in much the same way as 
they do in the bodies of patients.  Indeed, to a significant degree, the veracity of clinical 
cytogenetics is based on the assumption that chromosomes can pass from the body into 
the laboratory without the loss, or significant alteration, of their physical characteristics.  
This said, clinicians are well aware of the fact that, inside the body and out, chromosomes 
are fluid entities that exist physically only for brief moments in the life of a cell, during 
its reproductive cycle, and that they are continuously moving through varying stages of 
condensation, organization, and genetic activity. 
Even with all this in mind however, fragile sites are particularly vexing.  As 
Sutherland (1979) demonstrated, most fragile sites only can be seen in cell media that 
lacks folic acid, meaning that specialized laboratory conditions are necessary to make 
certain chromosomes appear ‘fragile’.  The fragile X site has thus been referred to as, “an 
in vitro phenomenon”: one that is only made visible by laboratory manipulations 
(McGavran and Maxwell, 1983, 57).  Is the fragile X site actually ‘fragile’ when it is in 
the body?  Researchers do not have a good answer to this question, because they cannot 
see the X chromosome under normal bodily conditions.  However, as Loris McGavran, a 
cytogeneticist at the University of Colorado, Denver, put it, 
 
I don’t think that we ever had this concept that it [the fragile X site] would 
be manifest in vivo the same way, because then you would be wandering 
around with a lot of chromosome X deletions . . . we really thought that it 
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was an in vitro phenomenon (Interview with Loris McGavran, August 20, 
2012).    
 
Indeed, it was assumed that if the X chromosome acted in the same way in vivo as it 
appeared to in vitro, more severe clinical problems would have resulted.  Adding to this, 
it was shown that the cells of Fragile X patients were not themselves deficient in folic 
acid (Popovich et al, 1983).   
What implications did this have for the role of the fragile X site, as it exists in 
vivo, in causing intellectual disability?  While this remained unclear in the 1980s, some 
clinicians attempted to apply the laboratory understandings of the fragile X site to their 
thinking and trials aimed at finding a clinical treatment for Fragile X syndrome.  If folic 
acid in cell culture prevents the visible expression of the fragile X chromosomal “lesion” 
(Pembrey et al, 1985, 713), which is associated with intellectual disability, does this 
mean that treating patients with additional folic acid could in fact reverse the clinical 
effects of the Fragile X syndrome in the body?   
French physician Jerome Lejeune posed this very hypothesis in a 1982 letter to 
the Lancet (Lejeune, 1982).  Lejeune is famous for being the clinician who first identified 
the correlation between trisomy 21 and Down syndrome.  By the late-1970s, 
identification of trisomy 21 had become the primary indication for prenatal testing, and 
offered the opportunity for these pregnancies to be terminated if Down syndrome was 
diagnosed.  Lejeune however, being a devout Catholic, was publically very unhappy 
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about this application of his 1959 discovery (Cowan, 2008; Interview with Kurt 
Hirschhorn, January 26, 2012).   
In his 1982 letter to the Lancet, Lejeune lamented the fact that cytogenetic 
findings were being used for terminating pregnancies instead of finding cures, saying, 
“Interest in the in utero detection of the fragile X chromosome for the purpose of aborting 
affected fetuses seems to have blurred the real prospect open to research” (Lejeune, 1982, 
273).  Based on the existing cytogenetic knowledge about Fragile X syndrome, Lejeune 
saw hope for a cure.  He reported on a trial that he had conducted in which eight children 
clinically diagnosed with Fragile X syndrome were treated with high doses of folic acid.  
The results of this uncontrolled trial were very encouraging, with noticeable clinical 
improvement in seven of these children within the course of just a few weeks.  Lejeune 
also suggested that high doses of folic acid, when given to a pregnant female carrier, 
might prevent the disease from developing in utero (Lejeune, 1982).                
Multiple trials involving the treatment of Fragile X-affected individuals with high 
doses of folic acid were conducted soon thereafter, at first with some positive results 
being seen (Carpenter et al, 1983; Brown et al, 1984; Gustavason et al, 1985).   
Ultimately however, it was determined that folic acid was not a cure for Fragile X 
syndrome.  The fragile X site was seen less often in the cells of patients that had been 
treated with high doses of folic acid.  However, when a known fragile site inducing agent 
called 5-fluorodeoxyuridine was added to cell culture, the fragile X site appeared just as 
prominently as it had been before folic acid treatment (Brown et al, 1986; Fisch et al, 
1988; Neri et al, 1988).   
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Additionally, since folic acid is water soluble, meaning that much of every dose is 
immediately excreted, it would have been impossible for large enough amounts of folic 
acid to build up in the body, and especially the brain, to have clinical effects within a few 
weeks, as the Lejeune (1982) trial suggested (Opitz and Sutherland, 1984, 55).  While 
folic acid did not prove to be a preventative treatment or cure for Fragile X syndrome 
however, debate continues among clinicians over whether folic acid treatment for 
affected patients does at least improve attention span, hyperactivity, and behavior (Berry-
Kravis and Potanos, 2004; Interview with Randi Hagerman, March 2, 2012).  Indeedn, 
attempts to treat Fragile X syndrome with folic acid offer valuable insight into how 
clinicians and researchers interpreted the potential clinical implications of the laboratory 
finding that fragile sites are only visible in folic acid deficient media.  The fragile X site 
represented, for clinicians, a physical “lesion” (Pembrey et al, 1985, 713) in the 
chromosomes (and thereby in the human body and the genome, see chapter 1) of their 
patients.  As McGavran explained to me, “We’re used to thinking about chromosome 
mutations as themselves sort of a phenotypic marker” (Interview with Loris McGavran, 
August 20, 2012).  Indeed, to think of the fragile site like other visible bodily lesions fit 
with existing conceptions of the human genome, as at once anatomical and genetic.   
By chance, clinicians knew of a way to make the fragile X site disappear, at least 
in cell culture.  Based on this, they seemingly hoped that ‘fixing’ the fragile X site would 
somehow correct the genomic defect that they assumed caused Fragile X syndrome.  This 
came, despite the fact that clinicians had little knowledge about the etiological 
mechanism that they were trying to repair.  In the next section of this chapter, I further 
 
 
97 
explore attempts to use the fragile X site as a chromosomal marker for tracking Fragile X 
syndrome through a family.  During the 1980s, the fragile site continued to pose 
challenges to clinicians and researchers.  While frustrating, the variable expression of the 
fragile site did suggest new ways of thinking about this disorder. 
 
Expression of the Fragile X Site in Affected Families 
Despite its widespread association with a particular form of intellectual disability, 
some clinicians expressed doubts about the reliability of the fragile X site as a 
chromosomal marker for Fragile X syndrome.  Daker (1981), for instance, had identified 
two brothers who expressed the fragile X site, but did not have either macro-orchidism or 
intellectual disability.  Another paper published the same year raised doubts over whether 
the fragile X site was exclusive to just one distinct form of intellectual disability (Proops 
and Webb, 1981).  Additional studies performed in the early-1980s also found patients 
that had X-linked intellectual disability and macro-orchidism, but showed no sign of the 
fragile X site (Jennings et al, 1980; Herbst et al, 1981; Fishburn et al, 1983).  Indeed, the 
fragile X site did not prove to be as distinctive and reliable of a chromosomal marker as, 
for instance, trisomy 21 had for Down syndrome.21 
Another major complication inherent to the fragile X site, going back to Lubs’ 
initial identification of it in 1969, was that it rarely appeared in more than one-third of 
examined cells (usually out of 100-200 counted), even in severely-affected patients.  This 
                                                 
21 Though some complications also arose with the identification of trisomy 21 in some 
patients clinically diagnosed with Down syndrome as well (Gaudilliere, 2001; 
Santesmases, 2010). 
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variable expression of the fragile site occurred independently of the need for a folic acid-
deficient medium worked out by Sutherland (1979).  While the fragile X site was almost 
always visible, to some extent, in clinically affected males, in carrier females it was 
usually present in less than 10% of cells, and often not seen at all (Turner, 1983).22  The 
inconsistent expression of the fragile X site greatly complicated attempts to determine the 
carrier status of clinically normal females within Fragile X families, who were potentially 
at risk for having affected children (Fryns, 1986; Hogan, 2012).  
 Going back to the first clinical description of (what was later determined to be) 
Fragile X syndrome (Richards et al, 1981), Martin and Bell (1943) recognized that this 
form of intellectual disability did not exactly follow the normal inheritance pattern of an 
X-linked recessive trait.  Indeed, some female family members were affected by 
intellectual disability as well, though more mildly than their male relatives.  One possible 
explanation for this was that the genetic trait causing intellectual disability was in fact 
‘dominant’: meaning that a normal copy of this genetic entity could not fully overcome 
an aberrant copy, and prevent any sort of clinical expression.   
Another hypothesis for why females are sometimes mildly affected by X-linked 
intellectual disability involves the process known as X-inactivation or ‘Lyonization’, 
named after English geneticist Mary Lyon.  While females possess two copies of the X 
chromosome, only one of them is actively expressed in each of the body’s cells (Lyon, 
1962).  Which of the two X-chromosomes is expressed in each cell is usually the result of 
random chance, meaning that on average about half of the body’s cells express one X 
                                                 
22 Clinicians and researchers expected, for instance, to see the fragile X site in mothers, 
‘obligate carriers’ who had sons affected by Fragile X syndrome. 
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chromosome, while in the rest the other is active.  However, sometimes due to chance or 
genetic effects, one of the two X chromosomes is expressed more often in the body’s 
cells than the other.  In these cases, if an X chromosome with a certain mutation is more 
often expressed, its clinical effects may be seen in that patient (Puck and Willard, 1998).  
Some females then, will show clinical effects of an X-linked disorder that generally only 
affects males, because it is an X-linked recessive trait.23 
The mild expression of Fragile X syndrome in female heterozygotes (those who 
have one X chromosome with the fragile X site and one that appears normal) was studied 
cytogenetically throughout the 1980s.  It was estimated at this time that anywhere from 
one-third to one-half of all females who possessed the fragile X site on one of their two X 
chromosomes were affected by mild intellectual disability (Turner et al, 1980; Fishburn 
et al, 1983).  Such figures however, were complicated by the fact that the fragile X 
marker was not visible in all of the females who assumedly possessed it.  Therefore, it 
was often females who already had sons clinically affected by Fragile X syndrome 
(making them ‘obligate’ carriers) who were analyzed in order to determine the clinical 
presentation of fragile X heterozygotes (Fishburn et al, 1983).   
Multiple studies found that the clinical impact of Fragile X syndrome on female 
heterozygotes was correlated with the percentage of their cells that expressed the fragile 
X site (Jacobs et al, 1980; Fishburn et al, 1983; Fryns et al, 1986).  As one set of 
researchers noted, “We found the proportion of cells with the fragile X to be strongly 
correlated with the mental status and to be inversely correlated to with age in 
                                                 
23 An example of this has been described in the case of Duchenne muscular dystrophy, 
which is an X-linked recessive disorder normally only seen in males (Pena et al, 1987). 
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heterozygous females” (Jacobs et al, 1980, 487).  In males, similar trends were identified.  
Parents with two sons affected by Fragile X syndrome were asked to identify which one 
seemed to be ‘brighter’.  These qualitative results were then compared to the percentage 
of cells in each boy expressing the fragile X site.  It was found that the more intellectually 
capable brother of the two siblings often showed comparatively lower fragile X 
expression (Turner and Partington, 1988). 
The presence or absence of the fragile site in Fragile X syndrome was not a black-
and-white marker of disease, as would have been clinically desired.  While correlations 
seemed to exist between the degree of fragile X expression and clinical outcomes, these 
studies did not offer clinicians and researchers with a reliable option for carrier 
identification or prenatal diagnosis.  Though frustrating from one perspective, these 
findings continued to offer clues about the link between the chromosomal expression of 
the fragile site, and the clinical manifestation of this disorder.  During the 1980s, 
observational, chromosomal analysis gave clinicians and researchers an increasingly 
nuanced understanding of Fragile X syndrome, particularly in terms of the range of 
intellectual disability it caused in both males and females.  Additional chromosome level 
studies would eventually help researchers to better understand how the visible fragile X 
site was associated with the genomic cause of Fragile X syndrome. 
 
Tracing the Fragile X site Through Family Pedigrees 
To this point, I have primarily focused on the fragile X site as a diagnostically 
useful chromosomal marker for Fragile X syndrome in the clinical setting.  The fragile 
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site however, is also a genetic entity: one that moves through families, passing from one 
generation to the next.  When a relatively rare visible genetic abnormality, such as the 
fragile X site, is identified in multiple cousins within an extended family, clinicians and 
researchers generally assume that these individuals must have inherited the marker from a 
common ancestor.   This suggests that the abnormality should be visible in that person’s 
chromosomes as well.  In addition, when an inherited chromosomal aberration is 
associated with a particular set of clinical outcomes in a younger generation, clinicians 
expect to see the same symptoms in previous generations.  The fragile X site and Fragile 
X syndrome however, often did not meet these expectations, which left clinicians and 
geneticists perplexed about how this genetic trait moved through families. 
Many genetic disorders are caused by de novo mutations, which occur randomly 
during the reproductive process, rather than being inherited from a parent.  Patients 
clinically affected with Fragile X syndrome however, almost never have a de novo 
mutation (Brown et al, 1986).  Instead the disorder occurs in families over multiple 
generations.  For instance, cousins in multiple branches of the family that Martin and Bell 
first described in 1943 were affected by Fragile X syndrome, clearly suggesting that the 
causative trait had been passed down through a common relative.  As it turned out 
however, neither clinical symptoms of Fragile X syndrome, nor the fragile site itself 
could be traced back through the generations (Pembrey et al, 1985). 
 Throughout the 1980s, similarly perplexing Fragile X pedigrees were reported 
(Fryns and Van den Berghe, 1982; Gardener et al, 1983; Froster-Iskenius et al, 1984).  In 
each of these cases, Fragile X syndrome suddenly appeared in multiple branches of a 
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family, having never been seen previously (Sherman et al, 1985).  Brown et al (1986) 
analyzed two pedigrees of Fragile X-affected families, in which both the parents and 
grandparents of the affected patients showed neither the clinical symptoms of Fragile X 
syndrome, or the fragile X site.  In each case, the syndrome had appeared in 
grandchildren across multiple branches of the family, who did suffer from intellectual 
disability and showed the fragile site.  However, those who had clearly passed the trait 
down showed no clinical or chromosomal signs of it (Brown, 1986). 
The fragile X site, and its associated clinical effects, did not appear to be 
following the expected patterns of Mendelian inheritance.  In Fragile X families, 
clinicians were finding a tight correlation between seeing this chromosomal marker and 
intellectual disability in younger generations, but when they traced backwards in the 
family tree, both the fragile site and intellectual disability disappeared from view.  
(Froster-Iskenius, 1984; Sherman et al, 1985; Brown et al, 1986; Nussbaum and 
Ledbetter, 1986).  Indeed, the causative genetic factor for Fragile X syndrome seemed to 
always pass through multiple generations of a family before it was clinically expressed.  
As a result, this genetic trait was distributed throughout an extended family without any 
warning for decades before its clinical effects became apparent (Figure 5). 
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Figure 5  Pedigree from a family impacted by Fragile X syndrome.  Note that only 
individuals in younger generations are affected by intellectual disability (Brown, 1986).  
Reprinted with permission from John Wiley & Sons, Inc. 
 
 
 Various mechanistic theories for the unusual inheritance pattern of Fragile X 
syndrome were proposed in the mid-1980s.  Some researchers suggested that the 
insertion of a transposable element might somehow be involved in the sudden occurrence 
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of Fragile X syndrome (Friedman et al, 1986; Hoegerman et al, 1986).  Others proposed 
that the maternal uterine environment could play a role in the usual inheritance pattern of 
the disorder (Van Dyke et al, 1986).  Another set of theories was derived from an idea 
developed earlier in the decade by John M. Opitz.  He had previously proposed that a 
‘pre-mutation’ might be responsible for the inheritance pattern of another genetic 
disorder: achondroplasia, which also had been seen to appear suddenly in distant relatives 
(Opitz, 1981, 1984).  A pre-mutation is a genetic abnormality, which is benign in the 
patients who carry it, but may develop in future generations into a mutation with 
significant clinical implications.   
Pembrey et al (1985) applied Opitz’s theory to Fragile X syndrome, hypothesizing 
that a pre-mutation might be responsible for its unusual inheritance pattern.  As they put 
it, the idea that Fragile X syndrome “is inherited in a regular X-linked fashion is 
becoming untenable with the increasing number of reports of transmission through 
phenotypically normal males.”  Instead, these clinical researchers proposed, “an inherited 
sub-microscopic chromosome rearrangement involving the Xq27/8 region that causes no 
ill effect per se, but generates a significant genetic imbalance when involved in a 
recombination event with the other X chromosome” (Pembrey et al, 1985, 709).   
This hypothesis was meant to address multiple unique aspects of Fragile X 
syndrome transmission as observed in family pedigrees.  How was the causative genetic 
factor passed through family members in earlier generations with no visible clinical 
effects?  And why did the symptoms of Fragile X syndrome only appear when the genetic 
trait was passed from mother to child?  Pembrey and colleagues envisioned a sub-
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microscopic chromosomal event responsible for turning a pre-mutation into a causative 
mutation.  Their assumption was that the visible fragile X site, and its subsequent clinical 
effects in men and women, must come about due to an uneven recombination event 
between two X chromosomes, which must happen during the production of eggs in 
females with a pre-mutation.  Since males possess only one copy of the X chromosome, 
such a recombination event cannot occur during the production of sperm, thereby 
explaining why a pre-mutation can only be transformed into a causative mutation when 
this X-linked genetic abnormality passes from mother to child (Pembrey et al, 1985).   
 The model proposed by Pembrey and colleagues however, was purely theoretical.  
It was based on an analysis of family pedigrees, instead of laboratory experimentation.  
During the latter half of the 1980s, researchers were increasingly focused on attempting 
to characterize the fragile X site molecularly (Brown et al, 1988).  Indeed, it was widely 
assumed that only molecular level analysis of this genomic region could uncover the 
mechanism that explained the unusual inheritance pattern of Fragile X syndrome (Turner 
et al, 1986, 53-54).  This proved to be a multi-year challenge however, for various 
technical reasons (Interview with Robert Nicholls, April 5, 2012).  In this interim 
however, chromosomal analysis continued to provide valuable, and even experimental, 
insights about the fragile X site, which helped clinicians and researchers to better 
understand its genomic nature, and role in causing Fragile X syndrome. 
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Is X Chromosome Fragility Normal? 
One point of debate and uncertainty throughout the 1980s was over the threshold 
of fragile X expression sufficient to diagnose a carrier or affected individual.  Patricia 
Jacobs and colleagues suggested in a 1980 paper that expression of the fragile X site in at 
least 4% of cells was necessary for a positive diagnosis.  In a second paper published two 
years later, Jacobs suggested that 3% visibility was probably sufficient for the diagnosis 
of a female carrier (Jacobs et al, 1980; Rhoads et al, 1982).  Another group suggested that 
fragile site expression in 1% or more of examined cells was sufficient to diagnose carrier 
status (Herbst et al, 1981).  According to McGavran, the normal threshold for diagnosis 
in her laboratory was 5% fragile X site expression (Interview with Loris McGavran, 
August 20, 2012).   
Edmund Jenkins, who was the first cytogeneticist to successfully diagnose Fragile 
X syndrome in a prenatal sample, has suggested to me that his laboratory was more 
conservative, at least when it came to identifying an affected fetus.  He preferred to see 
10% fragile X cells before offering a positive diagnosis (Jenkins et al, 1981; Interview 
with Edmund Jenkins, May 26, 2011).  While Jenkins believed in the clinical value of the 
fragile X site, he felt that relatively high expression levels were necessary for accurate 
diagnosis of carriers and affected individuals, since the expression level of fragile X sites 
in the wider population of clinically normal individuals was not well established.   
Based on this own laboratory experience, Jenkins told me, “We found some 
morphologically similar lesions, that looked like fragile sites, in control people at very 
low frequencies.”  Whether or not clinically normal individuals (aside from carriers) 
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could show any fragile X site expression was a matter of debate at the time.  Jenkins 
recounted one instance to me from a conference where he was presenting on his 
laboratory experience with the fragile X site, “someone from the audience [another 
prominent cytogeneticist] said, ‘if you see one fragile site, that’s all you need’ and I said, 
‘well what about baseline and controls?’ and they said, ‘that’s just the way it is’” 
(Interview with Edmund Jenkins, May 26, 2011).24 
 If one fragile X site was seen among 100 examined cells in a fetus or a potential 
carrier, was this sufficient evidence to make a positive diagnosis?  Researchers and 
clinicians clearly were adamant about developing the most sensitive test possible, so long 
as it was still reliable.  As McGavran put it to me, “Reproducibility was one of our big 
deals” (Interview with Loris McGavran, August 20, 2012).  While getting accurate results 
was the number of goal of cytogeneticists, a 1984 review article pointed out, under the 
section heading “A doctor’s dilemma”, “The early 1980s are witnessing a rush to entice 
the fragile X to express itself reliably in lymphocytes, fibroblasts, amniocytes, and fetal 
cells” (de Arce and Kearns, 1984, 88).  In some cases, folic acid deficiency was not 
enough to induce sufficient fragile X visibility, so researchers supplemented the cell 
cultures with chemicals known to enhance fragile site expression.  Like McGavran and 
Jenkins, the authors of this article encouraged diagnostic caution, noting that the 
correlation between the amount of fragile X site expression and the long-term clinical 
severity of Fragile X syndrome remained unclear (de Arce and Kearns, 1984). 
                                                 
24 Edmund Jenkins is a Ph.D. cytogeneticist who has worked for over 30 years at the New 
York State Institute for Basic Research in Developmental Disabilities, in New York City. 
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Amongst all this, medical geneticists David Ledbetter of the Baylor college of 
Medicine, and Robert Nussbaum, at the University of Pennsylvania, began to wonder if it 
would be possible to chemically induce fragile X site expression in clinically normal 
individuals.  They hypothesized that folic acid deficiency alone would probably not be 
sufficient.  Chemicals such as flouorodeoxyuridine (FUdR) had previously been adopted 
to enhance fragile site expression, particularly for purposes of prenatal diagnosis 
(Tommerup et al, 1981; Jenkins et al, 1984).  Ledbetter and Nussbaum used FUdR to 
increase fragile site visibility, but they also began adding caffeine into cell culture as 
well.  This had a significant impact on fragile site expression (Ledbetter et al, 1986; 
Interview with David Ledbetter, March 21, 2012).25   
As many geneticists have been known to do, Ledbetter and Nussbaum began 
testing their own cells for fragile X site expression, assuming that they were not carriers 
of the mutant trait.26  With the addition of caffeine to cell culture, these researchers were 
able to detect very low-level expression of the fragile X site in their own cells and those 
of a chimpanzee (Interview with David Ledbetter, March 21, 2012).  Additionally, 
Ledbetter and Nussbaum demonstrated that clinically normal ‘transmitting’ males from 
fragile X families showed an intermediate level of fragile site expression, which fell in 
                                                 
25 David Ledbetter is a Ph.D. geneticist, who spent much of his career at the director of 
the Cytogenetics Laboratory at Baylor College of Medicine in Houston.  He has also 
directed the Division of Medical Genetics at the Emory University School of Medicine in 
Atlanta, and is now Chief Scientific Officer for the Geisinger Health System in Danville, 
Pennsylvania.  
26 One example of this, involving Roger Donahue who karyotyped his own chromosomes 
during his training (as many geneticists do), is discussed in the previous chapter.  Another 
well-known example is Craig Venter’s use of his own DNA for sequencing the human 
genome. 
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between that of clinically affected individuals and their own normal cells.  With caffeine 
induction, affected males showed fragile X site expression in 30-40% of their cells, 
normal transmitting males had 12% expression, and the two researcher’s cells showed 4-
5% fragile X site expression (Ledbetter et al, 1986).27 
As the observational cytogenetic analysis of Ledbetter and Nussbaum 
demonstrated, fragile site expression was not all-or-nothing, but always a matter of 
degrees: levels of fragile X expression could be seen to progressively increase from 
normal individuals, to clinically unaffected transmitting males, to affected patients 
(Ledbetter et al, 1986; Nussbaum and Ledbetter, 1986).  Everyone’s X chromosome is (at 
least) a little bit fragile.  This finding implied a dynamic continuum that had mechanistic 
implications for how the fragile site variably appeared in families and caused Fragile X 
syndrome.   
Indeed, Ledbetter and Nussbaum’s findings were the first experimental 
demonstration of the existing ‘pre-mutation’ theoretical model based on pedigree 
analysis.  The fragile X site was shown to progress from normal, to predisposed for 
mutation, to pathological over the generations of certain families.  The researchers 
suggested, based on these results – and in line with Pembrey et al (1985) – that a series of 
chromosomal recombinations involving the fragile X site region might initiate the 
development of a predisposed ‘carrier’ male or female, and then (in a later generation) 
the production of a causative mutation.  Interpreting their cytogenetic results to propose a 
DNA level theory, the researchers concluded, “Thus, our data suggest that a normal DNA 
                                                 
27 Fragile X site expression in chimpanzees was seen in 1.6% of cells, suggesting that this 
fragile site has a long evolutionary history (Ledbetter et al, 1986). 
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sequence at Xq27 [the fragile X site] may be altered to produce a continuous quantitative 
variation in fragile site DNA resulting in varying degrees of cytogenetic expression and a 
threshold for clinical manifestation of a mutation” (Ledbetter et al, 1986, 163). 
This finding came at an important time for clinicians and researchers interested in 
Fragile X syndrome.  Ultimately, it would take five more years for the fragile X site to be 
fully characterized molecularly.  When this did finally occur, the findings of Ledbetter 
and Nussbaum were largely verified.  Molecular analysis allowed for a DNA level 
explanation of the mechanism behind fragile X syndrome.  However, Ledbetter and 
Nussbaum’s chromosome level demonstration that the fragile site became increasingly 
prominent between clinically normal transmitters of Fragile X syndrome and clinically 
affected individuals offered significant insight into the complex relationship between this 
cytogenetic marker and its associated clinical disorder.  In addition, this observational 
experiment provided a new perspective on the impact of visible variations in genomic 
structure on human disease.  
 
A Molecular Genetic Explanation of Fragile X Syndrome 
 Throughout the late-1980s and into the early-1990s, clinicians and researchers 
attempted to locate, at the DNA sequence level, a gene, mutation, or abnormality that 
could account for the fragile X site as well as the clinical expression of Fragile X 
syndrome (Brown et al, 1988; Heilig et al, 1988; Nguyen et al, 1988; Dahl et al, 1989; 
Oostra, 1990).  In 1991, the exact location of the causative genetic trait for Fragile X 
syndrome was identified, and found in close proximity to the fragile site.  As Ledbetter 
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and Nussbaum’s earlier experiment had suggested, the structure of this genomic region 
seemed to change over the generations of a family.  
The molecular explanation of Fragile X syndrome was an international 
accomplishment (Interview with Randi Hagerman, March 2, 2012).   In 1991, papers 
from research teams in Australia, the Netherlands, France, and the United States were all 
significant contributions to the molecular characterization of the fragile site and its role in 
Fragile X syndrome. Vincent et al (1991) offered evidence that the Fragile X region is 
abnormally methylated in affected individuals (more on this below).  Yu et al (1991) 
molecularly demonstrated the instability of the fragile X site, showing that it sometimes 
grew significantly in size when passed down from mother to child.  Verkeck et al (1991) 
were able to sequence the DNA in this region, finding that it contained a gene, which 
these researchers named FMR-1 (fragile X mental retardation-1), as well as a long string 
of CGG trinucleotide repeats.  Fu et al (1991) found that the number of consecutive CGG 
repeats in the FMR-1 area was directly related with clinical outcome in Fragile X 
families.  Normal individuals appeared to have less than 52 CGG repeats in this region, 
while those with a ‘pre-mutation’ had between 52 and 200.  Pre-mutations were at risk 
for expanding further when passed from mother to child, with Fragile X-affected children 
having 200 or more CGG repeats, which became known as a ‘full mutation’. 
 Further analysis of Fragile X families suggested that there were no exact 
boundaries among normal individuals, those with a pre-mutation, or the presence of a full 
mutation.  In general, if one has less than 55 CGG repeats in the FMR-1 region, it is 
unlikely that there will be an expansion into a pre-mutation.  What defines pre-mutations 
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is instability: the likelihood of CGG expansion from one generation to the next, though 
only when passed from mother to child.  A full mutation begins at about 200 CGG 
repeats, but is actually defined by its direct affect on FMR-1 gene activity.  When 200 or 
more CGG repeats are present, this region often becomes ‘methylated’.  Methylation 
involves the addition of a small molecule onto certain nucleotides in the region, which in 
effect turns ‘off’ the FMR-1 gene.  The lack of FMR-1 gene product, (or its reduced 
activity, which occurs in females who possess a second, normal FMR-1 gene), is what 
causes the Fragile X syndrome clinical outcome (Oberle et al, 1991; Nolin et al, 1996).   
 This sequence-level analysis of the FMR-1 gene region helped to resolve many of 
the abnormal characteristics of Fragile X syndrome inheritance.  The pre-mutation theory 
turned out to be quite accurate, with molecular genetics providing an explanation for 
what defined a pre-mutation, how it became a full mutation over the generations of a 
family, and how a full mutation causes Fragile X syndrome.  It was also demonstrated 
that the prevalence of the visible fragile X site under the microscope is directly related to 
the presence, and relative size (in term of CGG repeats) of a full mutation (de Vries et al, 
1993).  This means that the fragile site was a visible effect of Fragile X syndrome, rather 
than its etiological cause.  Such a finding did not come as much of a surprise given the 
large number of other clinically benign fragile sites that had been identified by the late-
1980s (Hecht, 1988).       
Once the molecular techniques now used for Fragile X diagnosis were clinically 
proven in the mid-1990s, the era of using chromosomal analysis for the diagnosis of 
Fragile X syndrome was declared over (Jenkins et al, 1995).  Individuals possessing a 
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Fragile X pre-mutation or full mutation are now diagnosed using molecular genetic 
techniques.  This has allowed for those women at risk for having a Fragile X syndrome-
affected child to be much more accurately identified, and for more reliable prenatal 
diagnosis of the disorder.  Additionally, the ability to identify pre-mutation carriers of 
Fragile X syndrome has led to the recognition that these individuals are themselves at risk 
for certain clinical effects.  Females with a Fragile X pre-mutation are at risk for pre-
mature ovarian failure (Allingham-Hawkins et al, 1999), and many pre-mutation males 
experience Parkinsonian tremors and ataxia late in life (Hagerman and Hagerman, 2004; 
Hogan, 2012).  As a result, Fragile X pre-mutation status has also become an important 
indicator of potential clinical outcomes.   
The association of Fragile X syndrome with an expanded trinucleotide repeat also 
led researchers to hypothesize that other clinical disorders that seemed to grow worse 
over the generations of a family (a phenomenon also referred as genetic ‘anticipation’) 
might have a similar cause (Sutherland et al, 1991; Harper et al, 1992; Friedman, 2011).  
Over the next two years, both Huntington’s disease and Myotonic Dystrohy were 
demonstrated molecularly to also involve the expansion of trinucleotide repeats 
(MacDonald et al, 1993; Orr et al, 1993).  Indeed, the multi-step mechanism of Fragile X 
syndrome quickly became an important exemplar for thinking about how genomic 
abnormalities might play a role in other, similarly inherited genetic diseases.  While the 
identification of the CGG trinucleotide repeat in 1991 was the lynchpin in demonstrating 
this novel mechanism of disease development, the important contribution of 
observational chromosomal analysis should not be overlooked.  After all, it was the 
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cytogenetic analysis of Ledbetter and Nussbaum that first demonstrated to researchers 
that genomic abnormalities are not necessarily all-or-nothing, but rather that they may 
also be observed and thought of as occurring over a dynamic continuum from normal to 
pathological.      
 
Conclusion 
 In his 1982 paper, “Window Panes of Eternity. Health, Disease, and Inherited 
Risk”, geneticist Charles Scriver discussed heritable fragile sites in the human genome as, 
“Another example [that] illustrates how neo-Vesalian anatomy can be put to use” 
(Scriver, 1982, 498).28  Scriver highlighted the role that the Xq27-8 fragile site had in the 
clinical delineation of a particular, and prominent, form of intellectual disability.  He also 
noted the potential uses of this chromosomal marker for carrier and prenatal screening.  
Indeed, during the 1980s, the fragile X site came to be one exemplar of a novel way of 
naming, diagnosing, and understanding human disease: based on the visible association 
of a genetic disorder with a particular genomic location. 
 When Lubs first identified the Marker X chromosome in 1969, he recognized its 
diagnostic, and preventative, value within families impacted by inherited intellectual 
disability.  As this chapter traces however, by the time the fragile X site was re-identified 
in the late-1970s, its potential stretched beyond just clinical diagnosis.  At this point, the 
fragile X site became integrated into a newly developing conceptual framework, based on 
the standardization of the human chromosome set and evolving conceptions of the human 
                                                 
28 For more on Scriver’s concept of genome mapping as a “neo-Vesalian” anatomy, see 
the previous chapter. 
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genome as an object of clinical research.  This visual abnormality was now understood to 
be the Xq27-8 fragile site, a unique genomic characteristic, which had potential 
implications for understanding novel structural and functional characteristics of the 
human genome, and their role in causing disease.29  
 As I suggest throughout this dissertation, the human chromosome set (and the 
human genome) is as a place in the body where the visual markers and etiological causes 
of disease are understood to intermingle.  This way of thinking among human and 
medical geneticists can be seen in various attempts to correlate the relative expression of 
the fragile X site with the severity of its clinical impacts.  It is also made particularly 
apparent by various attempts to treat Fragile X syndrome in the clinic through the 
application laboratory knowledge about how the fragile X chromosome “lesion” could be 
fixed by adding folic acid to cell culture.   
While the mechanistic correlations between the visible fragile X marker and 
intellectual disability remained unexplained by clinicians and researchers during the 
1980s, these individuals continued to assume that they could come to better understand 
Fragile X syndrome, and identify potential treatments, with the help of knowledge 
collected from sustained observational, chromosomal analysis.  As Loris McGavran put it 
to me,  
 
                                                 
29 Indeed, I have been told that Lubs has said in jest that the implications of the Marker X 
chromosome have become so complex that sometimes he wishes he had never discovered 
it (Phone Interview with Charles A. Williams, March 16, 2012). 
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Not knowing the mechanism [of Fragile X syndrome], we were just so 
fascinated by what it could be.  And, living for almost 10 years not 
knowing was pretty interesting.  It allowed us to ask questions that 
probably were not very smart, but still interesting (Interview with Loris 
McGavran, August 20, 2012).   
 
Indeed, the clinicians and researchers who examined Fragile X syndrome cytogenetically 
did not always know what they were looking at (or for) under the microscope.  
Nonetheless, observational analysis of the fragile X site produced new and interesting 
research questions, and novel directions for improving the clinical understanding of 
Fragile X syndrome, and simultaneously, the functional role of the human genome in 
genetic disease more broadly. 
 This historical case study of Fragile X syndrome highlights the importance and 
influence of chromosomal analysis in postwar biomedicine.  While the desire to develop 
molecular level understandings of disease certainly was prevalent among clinicians and 
geneticists during this era, the central role and contributions of ‘observational’ 
cytogenetics should not be overlooked.  Indeed, seeing the fragile X site under the 
microscope was the original and definitive basis for delineating and naming Fragile X 
syndrome.  In addition, the localization of the fragile X site pointed geneticists toward a 
particular genomic “address” for continued chromosomal and molecular research.  As the 
experimental cytogenetic work of Ledbetter and Nussbaum and the clinical trials of 
Lejeune, among other examples, demonstrates researchers and clinicians were not sitting 
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on the sideline waiting for a molecular characterization of this disease.  Rather, they took 
full advantage of existing knowledge and opportunities, based on chromosome level 
analysis, to further examine the etiology and potential treatment options for Fragile X 
syndrome. 
 While Fragile X syndrome may be thought of today as a molecular disease, the 
history of its delineation and diagnosis during the 1970s and 1980s highlights the visual 
culture of postwar biomedicine.  Along with many other genetic disorders, Fragile X 
syndrome was integrated into a larger visual framework of human disease during this 
time, which highlighted the unique genomic location and nature of individual disorders.  
Following its observational localization in the genome, Fragile X syndrome gained both 
an anatomical “neo-Vesalian basis” and a likely genetic etiology.  It, along with Prader-
Willi syndrome, which I discuss in the next chapter, was an exemplar of a new way of 
locating diseases in the human body.  Based on its genomic location at Xq27-8, Fragile X 
syndrome could be further examined, leading to new mechanistic understandings of its 
cause, and of the human genome’s functionality in disease more broadly.    
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CHAPTER 3 
Establishing and Reimagining a Genomic Exemplar: Prader-Willi Syndrome and its 
Unanticipated Relationship with Angelman Syndrome 
 
 This chapter examines the history of two clinically distinct diseases: Prader-Willi 
and Angelman syndromes.  Unlike Fragile X syndrome, each of these disorders was 
clinically delineated and diagnosed decades before being associated with a visible 
chromosomal marker or genomic location.  Indeed, until the late-1980s, there was no 
reason to believe that the historical trajectories of these two syndromes would ever 
intersect.  This changed in 1987 however, when multiple clinical teams reported that the 
same chromosomal aberration had been identified in patients clinically diagnosed with 
each disorder.  Suddenly, these two distinct diseases, with their independent histories, 
social interest groups, and clinical identities became chromosomally, and genomically, 
related.   In this chapter, I explore the lead up to this finding, as well as its long-term 
implications for biomedical conceptions of the human genome, and its structural, as well 
as functional, role in disease. 
 As I described in Chapter 1, medical genetics introduced a new nosological 
system to clinical diagnosis during the postwar period, based on the idea that many 
human diseases could be associated with discrete locations in the human genome.  
Cytogenetic analysis, and in particular the development of chromosomal banding in the 
1970s, offered clinicians and researchers the opportunity to identify visible abnormalities 
in the human chromosome set, and specify their standardized genomic location.  This 
system was further enhanced later in the decade by the development of high-resolution 
chromosomal analysis.  As Victor McKusick put it in a 1988 grant application to 
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establish a center for genomic analysis at Johns Hopkins, “The refinement of high 
resolution cytogenetics of extended chromosomes increased the precision of mapping and 
revealed small deletions and other changes that were important initial clues to the 
location of mendelian disorders . . .” (McKusick Papers, Box 2010-081-53, “Program 
Project Grant-Mapping the Chromosomes of Man”, 1988 Grant Application Folder, 157).  
Indeed, the human genome, seen at the microscopically visible level of chromosomes, 
had become an entity that clinicians and researchers increasingly turned to in order to 
‘locate’ new markers of disease. 
During the early-1980s, Prader-Willi syndrome was a regularly cited example of 
this ability to chromosomally identify genetic diseases in the human genome (McKusick, 
1981, 79; McKusick, 1982, 17; Scriver, 1982, 498).  As I describe presently, this came 
about after the association of Prader-Willi syndrome with a small, but still 
microscopically visible, deletion of genetic material on chromosome 15.  Over time, it 
became apparent that this deletion could not be seen in the genome of all individuals 
clinically diagnosed with Prader-Willi syndrome, but it was present often enough to 
suggest that the aberration played a role in the disorder’s etiology.   
Similar to Fragile X syndrome, the association between Prader-Willi syndrome 
and a visible chromosomal abnormality did not prove to be as straightforward or reliable 
as the correlation between Down syndrome and trisomy 21.  The deletion’s not infrequent 
absence in clinically diagnosed Prader-Willi patients kept clinicians and geneticists 
guessing about the nature of this chromosomal marker and its role in causing the disease.  
However, it was not until the late-1980s, when this deletion was also identified in patients 
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clinically diagnosed with Angelman syndrome, that clinicians and researchers began to 
recognize that Prader-Willi syndrome’s relationship with the chromosome 15 deletion 
was more complex than previously anticipated.  This finding forced clinicians to rethink 
the apparent ease with which, in the early-1980s, most cases of Prader-Willi syndrome 
could be cytogenetically delineated and diagnosed.  
As I describe in this chapter, medical geneticists never seriously discussed or 
debated the possibility, during the late-1980s, that Prader-Willi and Angelman syndrome 
were in fact two historically distinct forms of the same genetic disease.  These two 
disorders were simply too different in their clinical expression to possibly have the exact 
same genetic cause.  Indeed, at this time, most clinicians and researchers felt that there 
was something still unseen in the human genome that could account for such different 
clinical outcomes being caused by the same chromosomal deletion.  As evidence 
mounted that the chromosome 15 deletions in both Prader-Willi and Angelman patients 
were the same, in terms of their genomic location and size, researchers began to consider 
novel conceptions of human genome functionality that could account for what they saw 
in the clinic.  
 This chapter offers another example of the dual role of chromosomal analysis as 
both a diagnostic tool and experimental system in postwar biomedicine.  As in the case of 
Fragile X syndrome, the simple presence or absence of a visual cytogenetic marker alone 
was not sufficient to reliably diagnose Prader-Willi syndrome.  Ultimately however, the 
complications incurred in course of chromosomally analyzing Prader-Willi, and later 
Angelman, patients led to long-term improvements in diagnosis, as well as a better 
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understanding of the human genome and its role in disease.  This historical instance, I 
argue, is representative of the important part that the human genome has played as a 
conceptual space in the development of contemporary biomedicine (Hogan, 2013a).  As I 
describe, the chromosomally examined and depicted human genome became a location 
where the conventions, questions, and interests of clinical and basic genetics continue to 
intersect and intermingle. 
 
The Clinical Delineation of Prader-Willi Syndrome 
 In 1956, Swiss clinicians Andrea Prader, Alexis Labhart, and Heinrich Willi 
reported on nine children affected by obesity, short statue, abnormally small genitals 
(cryptorchidism), intellectual disability, and muscle weakness during infancy (Prader et 
al, 1956).  In the five years following this initial report, other clinicians also described 
children with similar attributes (Jenab et al, 1959; Dunn et al, 1961, Laurance, 1961).  
Prader and Willi alone published a follow-up paper five years later, in which they 
reported on five additional affected children (Prader and Willi, 1961).  In a paper on 
delineating different forms and causes of muscle weakness (hypotonia) early in life, 
Zellweger et al (1962, 599) noted that, “‘Floppy’ or ‘limp’ infants and children are 
encountered frequently”, in the clinical setting.  Among those cases he and his colleagues 
had seen, ten were similar to the syndrome that Prader, Labhart, and Willi had described 
seven years earlier (Zellweger et al, 1962).   
 Prader-Willi syndrome was clinically differentiated from other forms of infant 
hypotonia by the sudden onset of obesity in children around the age of three.  Evans 
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(1964, 207) described the early childhood progression of Prader-Willi syndrome in this 
way, “They remain feeble and emaciated for a time; then the wasting gives way to 
obesity.”  Indeed, Prader-Willi syndrome was defined by this uniquely cruel twist, in 
which very weak, poorly feeding infants, just as they seem to be getting better, suddenly 
developed a voracious appetite.  Without careful, and difficult dietary regulation, these 
children quickly grew to be dangerously obese.   
Some clinicians referred to Prader-Willi syndrome, and other conditions like it, as 
“Pickwickian-like syndrome” in reference to the Charles Dickens character (Jenab et al, 
1959, 23; Zellweger and Schneider, 1968, 597; Hawkey and Smithies, 1976, 155).  It has 
also been suggested that a short and overweight child depicted in Velazquez’s famous 
painting Las Meninas was affected by Prader-Willi syndrome (Hawkey and Smithies, 
1976, 152).  Some reports of Prader-Willi syndrome during the 1960s identified 
individuals who were likely affected, but not fully obese.  These young male patients 
however, were overweight and showed distinctly abnormal fat distribution, described as 
resembling that of an older woman, with accumulation in the buttocks and thighs 
(Forssman and Hagberg, 1964).  Another report referred to the fat distribution in Prader-
Willi patients as being “feminine”, (Juul and Dupont, 1967, 19). 
It was quickly recognized that Prader-Willi patients were at great risk for 
developing debilitating adult-onset diabetes by their teenage years due to their obesity 
(Evans, 1964).  Unfortunately, these patients not only showed a ravenous appetite for 
food, but also seemed to have a slower than normal metabolism.  Evans (1964) recounted 
a case in which a 500-calorie daily diet was necessary to help a 16 year-old male Prader-
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Willi patient to lose weight and overcome diabetic symptoms (a normal daily diet for this 
individual would be 2500 calories).  In some early cases, such diets were quite successful 
for treating patients.  This however, did not change their voracious appetite, so 
maintaining a healthy weight was a challenge (Evans, 1964). 
Prader-Willi patients were also recognized as being intellectually disabled (Buhler 
et al, 1963; Engel and Hogenhuis, 1965).  Evans (1964) described eight Prader-Willi 
patients who were developmentally delayed and had IQs between 41 and 87.  Some of 
these individuals seemed to improve intellectually as they grew older, though only one 
patient was able to attend a normal school.  Engel and Hogenhuis (1965) described three 
additional affected individuals as having an IQ between 60 and 80, a level regarded as 
below normal, but still ‘mild’ in terms of intellectual disability.  In comparison, the 
majority of males affected by Fragile X syndrome have ‘moderate’ intellectual disability, 
with IQ scores between 35 and 49 (Hagerman et al, 1983, 41).  Most children affected by 
Prader-Willi syndrome required special education, but only a few were regarded as 
‘ineducatable’ in the 1960s.  Indeed, some showed improved IQ scores and acuity with 
age (Evans, 1964; Laurance, 1967).   
 Discussions of what to call this distinct clinical syndrome began appearing in the 
medical literature during the mid-1960s.  Engel and Hogenhuis (1965) suggested “H2O 
syndrome” referencing the disorder’s primary distinguishing features of hypotonia in 
infancy, hypomentia (intellectual disability), and obesity beginning around age three.  
Another set of researchers suggested that a third H should be added to the description to 
account for the common presence of hypogonadism (small or hidden testicles), making it 
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“HHHO syndrome” (Zellweger and Schneider, 1968).  In 1968, a letter to the Lancet 
described three additional cases of this disorder under the title “Prader-Willi syndrome” 
(Spencer, 1968, 571).  It is unclear why Labhart’s name was excluded from this 
designation (perhaps it was because he had not been a co-author on the Prader and Willi 
(1961) follow-up report).  The eponym Prader-Willi syndrome has been widely used ever 
since, though the disorder has also occasionally been referred to as Prader-Labhart-Willi 
syndrome as well (Cassidy et al, 1984; Magenis et al, 1990).30 
 During the 1960s, the disorder that eventually became known as Prader-Willi 
syndrome featured a rather unique clinical signature.  What set the disorder apart from 
others like it was its distinct two-stage natural history, from ‘floppy’ infants to 
overweight young children.  Seeing these two stages in progression within a single 
patient made for an easier clinical diagnosis.  However, when viewed in isolation, either 
the weakness or obesity could easily be mistaken for another disorder.  From a treatment 
perspective, preventing obesity before it took hold was the most promising strategy.  
Ideally, clinicians would be able to make the diagnosis of Prader-Willi syndrome before 
the transition to overeating began.  But, based on clinical presentation alone, this was 
often difficult to do, especially in such physically weak and poor feeding infants.  As I 
discuss in the next sections, the identification of another visual sign of Prader-Willi 
syndrome, this time a chromosomal marker, promised to improve both diagnosis and 
treatment.  
                                                 
30 Some have suggested that Langdon Down, the British clinician best known for 
identifying Down syndrome in the mid-19th century, was also the first person to describe 
Prader-Willi syndrome, in 1887 (Kousseff and Douglass, 1982; Bonuccelli et al, 1982; 
McKusick, 1987) 
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Associating Prader-Willi Syndrome with a Chromosomal Marker 
Clinicians and geneticists who examined early cases of Prader-Willi syndrome 
frequently performed chromosomal analysis on their patients, with a few findings of 
interest.  While many patients appeared to have normal karyotypes (Laurence, 1961; 
Dubowitz, 1967; Juul and Dupont, 1967; Cohen and Gorlin, 1969), Dunn et al (1961) 
identified an extra G group (21, 22, Y) chromosome in one patient with Prader-Willi 
features.  Two years later, a translocation involving two D group (13, 14, 15) 
chromosomes was seen in one individual who appeared clinically to have Prader-Willi 
syndrome.  Similar D group translocations had previously been seen in normal 
individuals by other clinicians though, calling into question whether this aberration in 
fact played a role in the patient’s disorder (Buhler et al, 1963).  In 1969, a woman was 
reported who also had a D group translocation, and appeared clinically normal, but had 
experienced multiple miscarriages (Lucas, 1969).  Ridler et al (1971) identified an extra 
chromosome in a clinically diagnosed Prader-Willi patient, though it appeared smaller 
than any of the normal human chromosomes.  Based on its visible structure, the 
chromosome was reported to be an extra, duplicated fragment from either the D or G 
group. 
As in the case of Fragile X syndrome, a major problem with these early reports of 
abnormalities in Prader-Willi patients was that the exact identity of the chromosomal 
aberrations was unknown.  The extra chromosomes reported by Dunn et al (1961) and 
Ridler et al (1971) may have represented the duplication of a G group chromosome (as 
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happens in Down syndrome), or the presence of an extra small piece of another 
chromosome.  Likewise, the D group translocations reported by other clinicians might 
have involved any of three different chromosomes (13, 14, 15).  Once again, it was the 
introduction of banding techniques in the early-1970s that helped to resolve these issues 
of uncertainty.  Cytogenetic banding offered clinicians a more definite knowledge of 
which chromosomes were involved in the abnormalities they observed, and what 
portions, if any, of these chromosomes were lost or duplicated. 
In 1976, with the aid of chromosomal banding, an individual clinically diagnosed 
with Prader-Willi syndrome was seen to have an unbalanced chromosomal translocation 
involving the fusion of both copies of chromosome 15 (Figure 6).  The researchers who 
saw this translocation microscopically, inferred that at least the short arm, and perhaps a 
small portion of the long arm of one copy of chromosome 15 had been deleted (Hawkey 
and Smities, 1976).  Such a specific description of this translocation would not have been 
possible five years earlier, before the introduction of new chromosomal banding 
techniques (Hirschhorn et al, 1973).  In response to their finding, the authors stated, “it 
would be tempting to speculate that the number 15 chromosome is involved in this 
pathogenesis [Prader-Willi syndrome].  However, as the great majority of cases had 
normal karyotypes it may be that the chromosomal abnormality in our patient was 
unrelated to the clinical condition” (Hawkey and Smithies, 1976, 156). 
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Figure 6  Karyotype from a Prader-Willi patient showing a translocation involving both 
copies of chromosome 15.  Reproduced from Journal of Medical Genetics, Hawkey and 
Smithies, vol. 13, pp. 152-163, 1976, with permission from BMJ Publication Group Ltd. 
 
 
 
A second report of an unbalanced translocation also involving chromosome 15 in 
two Prader-Willi syndrome patients came a year later.  Based on these findings, Fraccaro 
et al (1977) suggested that all individuals clinically diagnosed with Prader-Willi 
syndrome should be evaluated for anomalies of chromosome 15.  This publication was 
followed by multiple other reports over the next four years of Prader-Willi syndrome 
patients showing chromosome 15 translocations (Zuffardi et al, 1978; Fleischnik et al, 
1979, Wisniewski et al, 1980).  In some instances, the researchers were able to more 
specifically identify what portions of chromosome 15 had been affected by the 
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translocation.  For instance, Zuffardi et al (1978) noted that the visible chromosomal 
region 15q11-15 had been lost in one of the translocations they observed in a Prader-
Willi patient.  By the end of 1980, it was quite clear to clinicians that Prader-Willi 
syndrome was in some way associated with a genetic abnormality on chromosome 15. 
While this series of reports suggested that Prader-Willi syndrome had something 
to do with chromosome 15, a translocation involving this chromosome could not be 
considered as either a necessary or sufficient cause of the syndrome.  Translocations were 
only seen in a few affected patients, and family members of these patients sometimes 
appeared to have the same translocation, but showed no clinical signs of Prader-Willi 
syndrome (Smith and Noel, 1980).  As one group of researchers put it, “Normal 
karyotypes have been found in many cases of Prader-Willi syndrome.  These could be 
assumed to be due to a deletion of 15p undetectable by present cytogenetic techniques” 
(Zuffardi et al, 1978).   
It was thought that the chromosome 15 translocations, which clinicians were 
seeing in certain patients affected by Prader-Willi syndrome, likely involved some loss of 
genomic material.  As I describe in the next section, the further improvement of 
cytogenetic methods in the late-1970s helped to provide geneticists with the visual 
resolution necessary to identify a common chromosomal deletion in many Prader-Willi 
patients.  Based on these techniques, Prader-Willi syndrome became associated with 
particular chromosomal bands, and a specific genomic location, in the early-1980s.  As a 
result, the disorder came to be an exemplar of the promise of using cytogenetic analysis 
in describing the ‘morbid anatomy’ of the human genome. 
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The Application of High Resolution Chromosomal Analysis to Prader-Willi 
Syndrome 
Throughout the 1970s, human and medical geneticists were working on various 
methods to improve the visual resolution of chromosomal analysis.  Functionally, 
chromosomes are a highly condensed form of DNA, the compaction of which varies 
greatly during the process of cell reproduction.  This makes chromosomes look different 
under the microscope at each stage.  During the late-1970s, the promise of ‘high-density’ 
cytogenetic analysis was recognized.  This technique involves arresting cellular 
reproduction at a stage when chromosomes are less condensed (and hence more stretched 
out) than usual, meaning that smaller aberrations might be visible.  In effect, staining 
chromosomes when they are less condensed means that more bands are visible, thereby 
improving the resolution of analysis (Yunis et al, 1978).31     
In the late-1970s, Ph.D. student David Ledbetter, having read the Hawkey and 
Smithies (1976) report of a chromosome 15 translocation in Prader-Willi syndrome, 
began to wonder if high-resolution chromosomal banding might reveal a deleted 
chromosomal region in affected patients.  At the time, Ledbetter was a member of the 
Baylor College of Medicine cytogenetics laboratory, run by clinical geneticist Vincent 
Riccardi.  Ledbetter was actually working in this laboratory part time as a technician, in 
order to make money as he pursued his dissertation research on primate chromosomal 
evolution in the nearby laboratory of T.C. Hsu (Interview with David Ledbetter, March 
                                                 
31 For more on the impacts of ‘high-density’ chromosomal banding on standardized 
depictions of the human chromosome set, see chapter 1. 
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21, 2012).32  Riccardi’s laboratory was involved, at the time, in applying high-resolution 
techniques to diagnose a form of kidney cancer, the Wilms’ tumor, based on a visible 
deletion on chromosome 11 (Riccardi et al, 1978; Riccardi et al, 1980).   
According to Ledbetter, a sample from a Prader-Willi patient came into the 
Baylor cytogenetics laboratory one day, thus giving him the opportunity to see if high-
resolution chromosomal analysis would reveal a chromosome 15 aberration.  Ledbetter 
was already quite experienced in identifying small deletions in patients with Wilms 
tumor, and so when he saw the karyotype of the Prader-Willi patient, he was able to see 
that one copy of chromosome 15 looked smaller than the other, suggesting a small 
deletion.  To verify this finding, a new sample was acquired from the patient, and 
Riccardi set up blinded analysis.  Ledbetter was still able to pick out the deletion in this 
one patient.  Based on this, samples from five additional patients, also blinded, were 
acquired from a Prader-Willi researcher in Boston, and Ledbetter was once again able to 
identify the same chromosome 15 deletion in the affected patients.  This suggested a 
reliable, and potentially informative, visual correlation between the chromosome 15 
aberration and Prader-Willi syndrome (Interview with David Ledbetter, March 21, 2012).     
In a 1981 New England Journal of Medicine article, Ledbetter et al (1981) 
reported that they were able to identify the same deletion on the long arm of chromosome 
15 in the karyotypes of four out of five patients clinically diagnosed with Prader-Willi 
syndrome.  The specific genomic location of this deletion, based on visual chromosomal 
nomenclature, was 15q11-13 (Figure 7).  Ledbetter followed-up on his initial report with 
                                                 
32 For more on Ledbetter, see chapter 2. 
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a larger cytogenetic study of PWS patients published the next year.  He found the very 
same 15q11-13 deletion in many more PWS patients, though only 19 of the 40 analyzed 
(Ledbetter et al, 1982).  The same year, another group of researchers published similar 
results, 14 Prader-Willi syndrome patients had been cytogenetically analyzed, and seven 
showed a 15q11-13 deletion (Butler et al, 1982).   
Clearly this deletion was associated with Prader-Willi syndrome, but why was it 
only visible in about half of all patients?  Were there multiple causes of this disorder, or 
was the deletion simply too small to be seen microscopically in many patients 
(Bonnucelli et al, 1982)?  With possible clinical implications in mind, Ledbetter et al 
(1982) suggested that the two cytogenetic sub-populations of Prader-Willi syndrome 
patients, those with and without a visible 15q11-13 deletion, should be examined for 
variability in their clinical outcomes.  Studies of larger cohorts of PWS patients in the 
following years continued to find that almost half showed no 15q11-13 deletion.  Very 
little in the way of clinical variations were found however, among the deletion and non-
deletion groups (Reed and Butler, 1984; Butler et al, 1986).  Differences that were 
identified included lighter skin tone and hair color, along with increased sun sensitivity, 
in Prader-Willi patients with a visible 15q11-13 deletion.  Individuals with this deletion 
also showed greater homogeneity of fingerprint patterns (Butler et al, 1986).   
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Figure 7  Chromosome 15 ideogram showing the location of the visible deletion in 
Prader-Willi patients.  Also, comparative images of chromosomes with and without the 
deletion.  Reproduced with permission from New Englad Journal of Medicine, Ledbetter 
et al, vol. 304, pp. 325-329, 1981, Copyright Massachusetts Medical Society. 
 
 
During the mid-1980s, clinicians widely agreed that Prader-Willi syndrome was 
somehow associated with chromosome 15 anomalies.  How these visually observed 
cytogenetic abnormalities were involved in the clinical expression of Prader-Willi 
syndrome however, remained unclear.  In 1986, clinicial cytogeneticist Arabella Smith 
noted, “While an association between chromosome 15 abnormality and the Prader-Willi 
syndrome is clearly apparent and undisputed, there is debate as to whether this 
relationship is causal” (Smith, 1986, 278).  Indeed, while the visual correlation seemed 
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undeniable, one team of researchers surmised that the chromosome 15 deletion seen in 
many Prader-Willi patients might be a chromosomal effect of the disorder, rather than its 
etiological cause (Kousseff and Douglass, 1982). 
Uncertainty about the functional role of chromosome 15 aberrations in Prader-
Willi syndrome did not stop clinicians and researchers from touting the importance of 
these visual markers in the clinic.  McKusick noted in 1981 that the association of Prader-
Willi syndrome with chromosome 15 anomalies helped to distinguish it from other 
conditions characterized as eating disorders, thus giving it a genetic basis.  As McKusick 
put it, “Like other problems lumped together as eating disorders, this has often been 
viewed as a psychiatric state and the organic basis revealed by the chromosomal 
aberration has been in my experience a relief to families of the afflicted.  This finding 
adds another stone to the foundations of an organic basis of morbid obesity” (McKusick, 
1981, 80).  Indeed, even if Prader-Willi syndrome’s visual association with chromosome 
15 did not explain the exact nature of its etiology, it did offer families peace of mind, 
knowing that the cause of obesity was genetic, rather than psychological.   
 The next year, Charles Scriver pointed to the value of being able to associate 
clinical disorders with genomic locations, noting that even though not all patients with a 
particular syndrome may show the associated chromosomal marker, knowledge of the 
link could still be used to identify the genes and biochemical pathways etiologically 
involved.  In his paper, Scriver suggested, “Careful study of these and other syndromes 
[Wilms’ tumor, retinoblastoma, and Prader-Willi] will determine whether enzyme 
phenotypes can be used systematically to diagnose the chromosomal phenotype 
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prospectively.  This represents an interesting development in genetic counseling and a 
novel application of gene mapping and cytogenetics” (Scriver, 1982, 498).  While 
uncertainty remained concerning the relationship between visible chromosome 15 
aberrations and Prader-Willi syndrome, the marker could still be used in the laboratory 
and the clinical in attempts to improve the treatment and understanding of the disorder. 
 Indeed, during the early-1980s, the microscopically visible 15q11-13 deletion 
became an important exemplar of a new way of doing medical genetics.  With the 
example of cytogenetic analysis of Prader-Willi patients specifically in mind, Scriver 
suggested that high-resolution chromosome banding was a “technology clearly capable of 
further refining the morbid anatomy of human disease” (Scriver, 1982, 496).  This 
statement was followed by a full-page figure depicting McKusick’s ‘morbid anatomy’ of 
the human genome diagram.  New cytogenetic capabilities had been successfully used to 
associate Prader-Willi syndrome with a unique, and visible, anatomical location in the 
human genome.  Just as the 15q11-13 deletion had helped to give Prader-Willi a genetic 
basis, and distinguish it from Froelich syndrome and other clinical disorders, high-
resolution chromosomal seemed to promise improvements in the delineation and 
diagnosis of other diseases.  Later in the 1980s however, an unanticipated complication 
arose: the same 15q11-13 deletion was identified in multiple patients diagnosed with a 
very different clinical disorder.  In the next section, I offer a clinical history of this 
distinct disease. 
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The Clinical Delineation of Angelman Syndrome 
 In 1965, British pediatrician Harry Angelman reported on three cases of what he 
called ‘Puppet’ children.  These children all suffered from inborn intellectual disability, 
and showed similar physical abnormalities.  Of their clinical attributes Angelman noted, 
“Their flat heads, jerky movements, protruding tongues and bouts of laughter give them a 
superficial resemblance to puppets, an unscientific name but one which may provide easy 
identification” (Angelman, 1965, 681).  These children were developmentally delayed, 
severely disabled intellectually, and suffered from frequent epileptic seizures (Angelman, 
1965).  Angelman later recounted that what convinced him to publish on these three 
patients, as being affected by a unique and distinct clinical syndrome, was coming across 
the painting “Boy with a Puppet” by Giovanni Caroto while on vacation in Italy.  He said 
of this moment, “The boy’s laughing face and the fact that my patients exhibited jerky 
movements gave me the idea of writing an article about the three children with a title of 
Puppet Children.  It was not a name that pleased all parents but it served as a means of 
combining the three little patients into a single group” (Williams, 2011).  The delineation 
of this syndrome was entirely visible and impressionistic.  Though Angelman’s name for 
the syndrome was understandably offensive to affected families, it ultimately helped 
other clinicians to see the disorder in their own patients.   
Another group of clinicians reported on two additional similarly affected patients 
in 1967, referring to this disorder as ‘Happy Puppet’ syndrome.  These clinicians said of 
Angelman’s initial account of this syndrome, “It was immediately apparent to us that two 
patients whom we had studied for several years conformed to his description” (Bower 
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and Jeavons, 1967, 298).  Clearly, Angelman had succeeded in capturing the gestalt of 
this syndrome through its name, thereby making it more likely that other clinicians would 
see it.  A third account of a patient with severe intellectual disability and similar clinical 
characteristics appeared in the literature again five years later.  The individual was 
diagnosed as having “Angelman’s (‘Happy Puppet’) Syndrome” (Berg and Pakula, 
1972).  Many additional reports of the syndrome were published over the next decade, all 
based on Angelman’s original clinical description and name (Mayo et al, 1973; Elian, 
1975; Kuroki et al, 1980; Dooley et al, 1981).   
In 1982, U.S. clinicians Charles Williams and Jamie Frias noted six additional 
cases of the disorder, and suggested that this syndrome might be less rare than had been 
assumed ten years earlier (Berg, 1972).  At the end of their report, the clinicians put 
forward a new potential name for the disorder remarking, “We feel that the term ‘Happy 
Puppet’ is inappropriate as the patient’s family may feel the term is derisive and 
derogatory.  For this reason, and despite the limitation of eponymic designations, we 
propose the name of this disorder should be Angelman syndrome” (Williams and Frias, 
1982, 460).  Another group of clinicians made a similar call at about the same time for a 
new “less imaginative, eponymous designation” (Dooley et al, 1981, 624).  As other 
historical syndrome case studies in this dissertation also demonstrate, clinicians are often 
hesitant to move away from an existing name for a syndrome when it plainly describes 
the disorder’s symptoms.  In this instance though, it was argued that despite its 
descriptive accuracy, a name like ‘Happy Puppet’ syndrome was both offensive and not 
in keeping with medical precedent (Dooley et al, 1981; Williams and Frias, 1982).  No 
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less, while Angelman syndrome was widely adopted in the mid-1980s, the ‘Happy 
Puppet’ designation has not fully disappeared (Willems et al, 1987; Brown and 
Consedine, 2004; Sarkar et al, 2011).  
 Many of the early studies on this syndrome included chromosomal analysis, but 
none of them identified any microscopically visible abnormalities (Angelman, 1965; 
Bower and Jeavons, 1967; Berg, 1972; Dooley et al, 1981).  Williams and Frias (1982) 
identified an inversion within chromosome 3 in an Angelman syndrome patient, but 
suspected that it was benign, since no genomic material appeared to have been lost as a 
result.  As Charles Williams later noted to me, “We had no idea of what causation was.  I 
think if any anything we presumed it was possibly a single gene disorder, although we 
didn’t know that either . . . there was some recurrence in families” (Interview with 
Charles Williams, March 16, 2012).33 
For the most part, Angelman syndrome was seen to occur sporadically, suggesting 
that the causative mutation, if there was one, happened de novo.  As Williams alluded to, 
the disorder was occasionally identified in siblings (Kuroki et al, 1980; Pashayan et al, 
1982; Willems et al, 1987); however, this was not seen frequently enough to infer that 
Angelman syndrome was inherited (Willems et al, 1987).  Indeed, well into the 1980s, 
the disorder’s etiological basis and genetic characteristics (if any) remained unknown to 
the clinical community.  All of this would change in 1987 however, with two independent 
reports of a small chromosome 15 deletion in multiple Angelman syndrome patients.  
                                                 
33 Charles Williams is a Pediatrician and Medical Geneticist at the University of Florida.  
He has spent much of his career doing research pertaining to Angelman syndrome, and 
played a central role in the founding of the Angelman Syndrome Foundation in the 
United States. 
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This event brought about a previously unanticipated chromosomal relationship with 
Prader-Willi syndrome, and forced clinicians and researchers to reassess their 
assumptions about the anatomical and etiological relationship between visible genomic 
locations and abnormalities, and clinical disease.  
 
Prader-Willi and Angelman Syndrome As Chromosomally Related 
In 1987, Prader-Willi syndrome researchers became aware of a set of vexing 
cytogenetic findings: in two clinical reports, the 15q11-13 chromosomal deletion was 
seen in multiple patients, who by clinical analysis, were affected by a disorder that was 
not Prader-Willi syndrome.  Lawrence Kaplan and colleagues reported on three patients 
with this chromosomal aberration, but heterogeneous clinical outcomes.  One patient 
showed what could be interpreted as a mild case of Prader-Willi syndrome, another was 
diagnosed with Angelman syndrome, and a third patient was identified as having 
Williams syndrome, which shares some similar attributes with Angelman syndrome, 
including intellectual disability, abnormal facial features, and a happy demeanor (Kaplan 
et al, 1987).  Another publication that year by Ellen Magenis and colleagues identified 
two additional, unrelated, patients with the 15q11-13 deletion, who were not affected by 
Prader-Willi syndrome.  Magenis had initially presented these cases at a 1987 national 
Prader-Willi syndrome meeting in Houston, Texas, not knowing what clinical disorder 
these patients had.  A clinical geneticist in the audience named Charlotte Lafer, 
recognized the patients as having Angelman syndrome (Interview with Charles Williams, 
March 16, 2012; Magenis et al, 1987).  
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As I outlined in previous sections, Prader-Willi and Angelman syndrome are two 
very different disorders clinically.  Therefore, it was quite confusing for clinicians and 
researchers to hear that they had been associated with the same chromosomal aberration.  
Some suggested that the cytogenetic analysis done of Prader-Willi and Angelman 
patients was not yet high-resolution enough to identify the subtle differences in the 
deletions that caused Prader-Willi and Angelman syndromes.  Kaplan et al (1987, 45) 
suggested in their paper, “It is proposed that different molecular abnormalities involving 
specific points or segments along the long arm of chromosome 15 might account for the 
clinical diversity seen among these and other patients”.  This position was echoed by 
Magenis et al (1987, 837), “Further resolution of these syndrome and their clinical 
characteristics will likely be at the molecular level”. 
These clinical researchers were suggesting that what could not be seen at the level 
of chromosomes would be resolved at the level of molecular markers.  In making this 
argument, Magenis et al (1987) cited the work of Donlon et al (1986), who had been 
working on developing molecular ‘probes’ for this region of chromosome 15.  Such 
probes were able to interact specifically with particular areas of a chromosome at the 
DNA level, while still being visible under the microscope because of an attached 
radioactive trace.  It was assumed that the chromosomal deletions that cause Prader-Willi 
and Angelman syndrome would be differentiated using this technique.  In this case, it was 
expected that one probe would not be able to attach to chromosome 15 in Prader-Willi 
patients, and another probe would not be able to affix itself in Angelman patients.  This 
would indicate that adjacent, but distinct (though perhaps overlapping) regions were 
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differentially deleted in these patients.  Donlon (1988) however, found this not to be the 
case.  Even at the molecular level, the deletions in patients with Prader-Willi and 
Angelman syndrome seemed to be the same. 
At about the same time Robert Nicholls, a postdoctoral fellow at Harvard, was 
also using molecular techniques to study the chromosome 15 deletion in Prader-Willi and 
Angelman patients.  He found similar results.  According to Nicholls, “We found first 
that the deletions, using the DNA probes that we had access to, were actually the same 
size, and so that was kind of unexpected in the field” (Interview with Robert Nicholls, 
April 5, 2012).  Indeed, existing assumptions about the human genome, and its role in 
disease, could not account for how two very distinct clinical disorders might be caused by 
a deletion in the same genomic location.  Williams described the confusing situation to 
me in this way, “We had a good two to three years where people thought it must be the 
same gene, which causes the two syndromes . . . it took a while to sort that out” 
(Interview with Charles Williams, March 16, 2012).     
When asked if these genomic findings suggested to clinicians and researchers that 
Prader-Willi and Angelman syndrome were in fact historically distinct forms of the same 
genetic syndrome, Williams remarked to me, “They were totally different . . . Back then 
there wasn’t any sense that these are very similar disorders, they are quite different” 
(Interview with Charles Williams, March 16, 2012).  Indeed, it was assumed that some 
functional distinction must exist, which would explain how one genomic aberration could 
cause two clinical disorders.  While this finding complicated the cytogenetic diagnosis of 
Prader-Willi syndrome, it also opened the door to new ways of thinking about the human 
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genome and its role in disease.  As David Ledbetter put it to me, “There was a lot of 
frustration and curiosity . . . it was pretty puzzling” (Interview with David Ledbetter, 
March 21, 2012).  In the late-1980s, various theories and experiments were proposed to 
explain this unanticipated genomic link. 
With his molecular findings in mind, Donlon (1988) offered one hypothesis for 
the different clinical outcomes.  He suggested that instead of being caused by ‘dominant’ 
chromosomal deletions, Prader-Willi and Angelman syndromes might instead each 
represent, “ a compound recessive disorder . . . involving more than one gene” (Donlon, 
1988, 326).  Since the deletion associated with these two syndromes was so large, and 
likely contained 10-30 genes (in Donlon’s estimation), various combinations of recessive 
genes on the non-deleted chromosome 15 might lead to differing clinical outcomes.  
When there is no deletion on the other copy of chromosome 15, these clinical outcomes 
are prevented.  However, with the 15q11-13 genetic material on one chromosome 
missing, the remaining recessive genes are fully expressed, leading in some cases to 
either Prader-Willi or Angelman syndrome.  In additional, Donlon (1988) suggested that 
other syndromes with overlapping clinical outcomes might also be associated with such 
deletions and compound recessives. 
In 1989, Robert Nicholls, then at Harvard University, made an important 
observation: in patients with Prader-Willi syndrome, the 15q11-13 deletion, if present, 
was always inherited on the copy of chromosome 15 inherited from their father, who did 
not himself have the mutation (Nicholls et al, 1989).  Humans possess two copies of each 
of their chromosomes: one copy comes from their father and one from their mother.  
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Throughout the 1980s, clinicians were able to visually distinguish between different 
copies of chromosome 15 based on subtle variations on its short arm (Wachtler and 
Musil, 1980).  Interestingly, the observation reported by Nicholls et al (1989) had already 
been published on six years earlier by a different team of clinical researchers (Butler and 
Palmer, 1983).  However, Butler and Palmer (1983) had not inferred that this occurrence 
was unique to Prader-Willi syndrome.  Rather, they suggested that such de novo deletions 
might occur more often on paternally inherited chromosomes.   
At the time, Nicholls was a postdoctoral fellow in the laboratory of Samuel Latt, 
who had died in August 1988.  The team of researchers he had assembled however, 
proved to be highly productive in the year after his passing.  Also in 1989, cytogeneticist 
Joan Knoll, a colleague of Nicholls’ in Latt’s laboratory, reported on multiple cases in 
which patients with Angelman syndrome had inherited the 15q11-13 deletion on their 
maternal copy of chromosome 15 (Knoll et al, 1989).  This provided further evidence that 
differential inheritance indeed did play a role in clinical outcome for these syndromes.  
As Williams later put it, “Once there was recognition that the maternal deletion has a 
different syndrome, then everything caught fire” (Interview with Charles Williams, 
March 16, 2012).   
Closely related to Knoll’s report, Nicholls’ 1989 paper had discussed an 
interesting case of a patient affected by Prader-Willi syndrome who had no visible 
15q11-13 deletion.34  This individual did however, possess a different variety of 
chromosome 15 abnormality: he had inherited two maternal copies of chromosome 15, 
                                                 
34 Nicholls was second author on Knoll’s 1989 paper, and Knoll was second author on 
Nicholls’. 
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but no paternal copy, a condition referred to as ‘uniparental disomy’.  This finding 
provided even more evidence that there existed some difference between the maternally 
and paternally inherited copy of chromosome 15, leading to either Prader-Willi or 
Angelman syndrome in the clinic (Nicholls et al, 1989).  The difference, researchers 
knew, was most likely not in the DNA sequence itself, as chromosomes (aside from the 
Y) are not themselves gendered: a chromosome inherited paternally in one generation 
may have been passed down maternally in the previous generation.  
Ultimately, these findings also provided an explanation for why the 15q11-13 
deletion was not always visible in Prader-Willi syndrome patients.  Prader-Willi was 
caused by a paternally inherited deletion of 15q11-13, but the disease also occurred in 
instances when an individual inherited two normal maternal copies of chromosome 15 
and no paternal copy.  Angelman syndrome was clinically seen in the opposite case, 
when two paternal, but no maternal copy of chromosome 15 was inherited (Nicholls et al, 
1989).  These findings suggested a novel functionality of the human genome, called 
‘imprinting’ that had only previously been described in mice.  As Ledbetter has put it to 
me, “When Rob Nicholls published his paper, we all kicked ourselves for not figuring it 
out, because we should have been able to based on the mouse literature.  If any of us had 
paid attention to imprinting in the mouse, we should have been able to predict this” 
(Interview with David Ledbetter, March 21, 2012).  Genomic imprinting led to the 
expression of certain genes on one parental copy of a chromosome, but not the other.  
Indeed, the differential clinical outcomes in Prader-Willi and Angelman syndromes 
demonstrated that in humans, just as in mice, certain portions of the genome are always 
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‘turned off’ on one member of a chromosome pair (Knoll et al, 1989; Nicholls et al, 
1989). 
 
Further Analysis of Prader-Willi and Angelman Syndrome in the 1990s 
During the early-1990s, clinicians worked to better resolve the genetic basis of 
Prader-Willi and Angelman syndrome, and to further explain the previous decades’ often 
confusing chromosomal observations.  When abnormal clinical outcomes were initially 
noted in patients with a 15q11-13 deletion in 1987, it was suggested that those with non-
Prader-Willi phenotypes, eventually determined to be Angelman syndrome, might have a 
larger deletion than classic Prader-Willi patients (Greenberg et al, 1987).  By the early-
1990s however, it had become widely accepted, following the 1989 papers from Samuel 
Latt’s laboratory by Robert Nicholls, Joan Knoll, and their colleagues, showing that 
differential parental inheritance led to the vastly different clinical outcomes.  Based on 
the clinical and cytogenetic analysis of 17 Prader-Willi and Angelman patients, Ellen 
Magenis and colleagues noted that, on average, the chromsome 15 deletion in Angelman 
patients appeared under the microscope to be larger than in those with Prader-Willi 
syndrome (Figure 8).  Among the patients with either Prader-Willi or Angelman 
syndrome however, the visual size of the deletion did not seem to correlate with the 
severity of clinical effects.  Magenis and colleagues also suggested the possible role of 
uniparental disomy in these two disorders, citing the work of clinical researcher Judith 
Hall (Magenis et al, 1990). 
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Figure 8  Chromosome 15 ideogram depicting the relative cytogenetic size of 15q11-13 
deletions seen in Prader-Willi (left) and Angelman syndrome (right) patients (Magenis et 
al, 1990).  Reprinted with permission from John Wiley & Sons, Inc. 
 
 
In the early-1990s, clinicians and researchers continued to ponder how many of 
the cases of Prader-Willi and Angelman syndrome having no visible cytogenetic deletion 
were caused by uniparental disomy, versus a deletion that was too small to see 
microscopically.  Among 30 patients who were clinically diagnosed with Prader-Willi 
syndrome, but did not have a microscopically visible 15q11-13 deletion, Mascari et al 
(1992) found 18 had uniparental disomy of the maternal copy of chromosome 15, and 
another eight patients who had a deletion that was only detectable using molecular 
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techniques.  Four individuals showed no sign of a deletion or uniparental disomy, but 
each of these patients had clinically abnormal forms of Prader-Willi syndrome.  From 
this, it was inferred that about 20% of all cases of Prader-Willi syndrome was caused by 
uniparental disomy (Mascari et al, 1992).   
Uniparental disomy proved to be much less common in Angelman syndrome, 
only occurring 2-5% of the time.  Researchers believed that this was related to the 
relative prevalence of non-disjunction in female reproductive cells (when an ovum ends 
up with two copies of a certain chromosome instead of just one), which is the cause of 
other chromosomal disorders, such as Down syndrome.  It is suspected that the rapid 
increase in Down syndrome cases in women over age 35 is an effect of the increase in 
non-disjunction with maternal age.  A similar effect was demonstrated with Prader-Willi 
syndrome (Robinson et al, 1991).  It was further surmised that uniparental disomy often 
results from what is called a ‘trisomic rescue’: when a fertilized egg begins with three 
copies of chromosome 15, but then loses one early on in the development process.  If the 
embryo has received two maternal copies of chromosome 15 and one paternal, and the 
paternal copy is lost in this ‘rescue’, the embryo will develop with uniparental disomy.  
This is more commonly the case in Prader-Willi than Angelman syndrome simply 
because non-disjunction (and hence the presence of two maternal copies of chromosome 
15) is more prevalent in women.  Therefore, maternal uniparental disomy, leading to 
Prader-Willi syndrome, occurs much more frequently than Angelman syndrome due to 
paternal uniparental disomy (Nicholls, 1993).   
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 Very much like in the case of Fragile X syndrome, it was suggested in the early-
1990s that DNA methylation might also play a role in the differential expression of 
Prader-Willi and Angelman syndrome.  As I have already described, methylation 
involves the addition of a small molecule to certain DNA nucleotides in particular genetic 
regions, in effect turning them off.35  In Fragile X syndrome, methylation was determined 
to be the result of a causative genetic aberration (more than 200 CGG trinucleotide 
repeats) (Yu et al, 1992).  Prader-Willi and Angelman syndrome, on the other hand, 
appeared to be associated with the normal pattern of methylation (due to ‘imprinting’) on 
chromosomes.  Driscoll et al (1992) demonstrated that the 15q11-13 chromosomal region 
is differentially methylated based on its maternal or paternal origin, and that this 
methylation pattern can be used as a diagnostic test for Prader-Willi and Angelman 
syndrome.  These clinicians identified a gene, DN34, that was differentially methylated 
in the 15q11-13 region based on parental origin, thereby suggesting that it might be 
involved in the clinical expression of one or both of these disorders (Driscoll et al, 1992). 
 Over time, additional candidate genes for causing Prader-Willi and Angelman 
syndromes have been identified.  Ozcelik et al (1992) identified the SNRPN gene, which 
is located within the smallest deleted genomic region known in Prader-Willi patients.  
SNRPN was shown to be maternally methylated in mice, so clinicians assumed that it 
probably would be in humans as well.  Additionally, it was found that the SNRPN gene 
was specifically disrupted by chromosomal translocations in multiple Prader-Willi 
patients (Nicholls and Knepper, 2001).  Angelman syndrome is now thought to be cause 
                                                 
35 For more on this, see chapter 2. 
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by a specific gene, UBE3A.  This result is based on the finding that Angelman syndrome 
can be caused by a mutation in this gene alone (Matsuura et al, 1997; Kishino et al, 
1997).  This is not believed to be the case in Prader-Willi syndrome, which has never 
been associated with a specific mutation in any one gene alone, suggesting that it is likely 
caused by multiple maternally imprinted genes (Buiting, 2010). 
 Indeed, clinical and laboratory conceptions and understanding have evolved 
significantly over the past 30 years.  During the 1980s, Prader-Willi syndrome went from 
being representative of the ability to visually and discretely ‘locate’ a disease in the 
human genome using chromosomal analysis, to an exemplar (along with Angelman 
syndrome) of an entirely new form of genomic functionality.  As I discuss in the next 
section, clinicians and researchers looked to this new phenomenon, genomic ‘imprinting’, 
during the early-1990s as a possible explanation for a number of other complex genetic 
diseases.  It appears that experience with Prader-Willi and Angelman syndrome taught 
human and medical geneticists to think differently about the human genome and how its 
various dimensions of functionality impact clinical disease. 
 
Examining a New Exemplar of Genomic Functionality 
 What was the relevance of genomic imprinting to human and medical genetics 
more broadly?  This question was addressed by clinical geneticist Judith Hall in a series 
of papers published during the early-1990s.  Hall targeted multiple audiences with these 
reports, which appeared in the American Journal of Human Genetics, Development, 
Archives of Disease in Childhood, Current Opinion in Genetics & Development, and The 
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New England Journal of Medicine (Hall, 1990a, 1990b, 1990c, 1991, 1992).  At about the 
time that Robert Nicholls’ 1989 report on imprinting in Prader-Willi and Angelman 
syndromes first appeared, Hall was just returning from a Sabbatical year in the UK, 
where she had been working with mouse geneticists studying imprinting in mammals.  
Based on this experience, Hall already recognized the potential importance of imprinting 
in human and medical genetics (Interview with David Ledbetter, March 21, 2012).  The 
emerging Prader-Willi and Angelman story offered an excellent forum to present 
imprinting to the broader biomedical community. 
 In her 1990 American Journal of Human Genetics paper, Hall noted the potential 
value of genomic imprinting in explaining diseases that did follow normal inheritance 
patterns,   
 
One of the important challenges of contemporary genetics is to explain 
those traits and conditions that do not mendelize [show Mendelian patterns 
of inheriance].  It is in that regard that the concept of genomic ‘imprinting’ 
has assumed increasing importance, because it may provide an explanation 
for a remarkably diverse set of observations on conditions whose genetic 
transmission and expression does not conform to the predictions of single-
gene inheritance (Hall, 1990a, 857).  
 
Imprinting, suggested Hall, offered a new way of thinking about genomic functionality, 
and one that could open up new avenues of biomedical thought and research, “Genomic 
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imprinting appears to be a form of regulation, allowing another level of flexibility within 
the control and expression of the mammalian genome, and may explain why mutations in 
some parts of the mammalian genome function differently depending on whether they 
come from the father of the mother” (Hall, 1990a, 857).  It was no longer sufficient to 
consider just what genes a person possessed, but also from whom they were inherited.       
 Within each of her papers on genomic imprinting, Hall discussed Prader-Willi and 
Angelman syndromes as a prime example of how imprinting impacted the human 
genome and its role in genetic expression.  Based on what researchers had learned about 
the impacts of uniparental disomy in Prader-Willi and Angelman patients, and what had 
been observed in mice more generally, Hall suggested other human diseases in which 
imprinting might play a role. Researchers had found that in mice uniparental disomy was 
often associated with disorders that showed behavioral rather than structural 
abnormalities.  With this in mind, Hall pointed to other disorders, beyond Prader-Willi 
and Angleman syndrome, that might be caused by uniparental disomy based on clinical 
traits, “If one reflects on common human syndromes that are as yet unexplained, such as 
Rubinstein-Taybi syndrome, Cornelia de Lange syndrome, Williams syndrome, Russel-
Silver syndrome, etc. the possibility that they represent uniparental disomy for other 
chromosomes must be explored” (Hall, 1991, 144). 
 Targeting clinicians more broadly, Hall attempted in her 1992 New England 
Journal of Medicine article to use the example of Prader-Willi and Angelman syndrome 
to demonstrate why and how genomic imprinting could matter to them, “What do rare 
conditions such as the Prader-Willi and Angelman syndromes have to do with the real 
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world of the busy practitioner?  They seem esoteric and exotic, and yet these rare 
syndromes are windows into the world of a newly recognized phenomenon of inheritance 
called genomic imprinting” (Hall, 1992, 827).  Hall explained that imprinting was 
particularly relevant in the context of prenatal testing, when there was little else to rely on 
than the analysis of chromosomes, “There is urgent need to determine whether 
uniparental disomy will be a problem in the case of each of the other chromosomes, since 
there may be vary real consequences for prenatal diagnosis” (Hall, 1992, 828).   
Indeed, the role of imprinting and uniparental disomy in Prader-Willi and 
Angelman syndromes made it particularly clear that seemingly ‘normal’ karyotypes may 
in fact be aberrant in clinically significant ways.  Two cautionary reports were 
independently published on this in 1992 (Cassidy et al, 1992; Purvis-Smith et al, 1992).  
Each involved prenatal testing based on chorionic villus sampling (CVS), a technique 
that samples from the placenta rather than the amniotic fluid as in amniocentesis (Hogan, 
2013b).  In both cases, CVS results suggested trisomy 15, though the fetus appeared to be 
normal under ultrasound.  Not infrequently, trisomies are confined to the placenta, but do 
not affect the fetus due to the occurrence of a ‘trisomic rescue’ described in the previous 
section.  In each of these cases, amniocentesis later suggested that each fetus had a 
normal karyotype, and the pregnancies were continued to term. 
When born, each of the children showed muscle weakness, and eventually 
progressed to reveal signs of Prader-Willi syndrome in early childhood.  It turned out that 
each individual had uniparental disomy of the maternal copy of chromosome 15, thus 
causing Prader-Willi syndrome (Purvis-Smith et al, 1992; Cassidy et al, 1992).  Hall 
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(1992) highlighted the case uncovered by Cassidy and colleagues in making her argument 
for why widespread awareness about genomic imprinting was so important for the 
medical community.  Referencing the new era of laboratory and clinical thinking that 
Prader-Willi and Angelman syndrome had helped to bring about, Hall noted, “The 
concept of genomic imprinting is a difficult one for many physicians and scientists who 
were not trained to ask whether the sex of the transmitting parent makes a difference to 
the outcome.  But from now on we must ask this question about biological phenomena 
and all disease processes that may have a genetic component” (Hall, 1992, 828-9).  
Indeed, clinicians and researchers had to be on the look out, because even karyotypes that 
appeared ‘normal’ at first glance might in fact possess significant chromosomal 
abnormalities. 
In the next section, I discuss another interesting and unexpected occurrence, 
involving the at times confusing ‘look’ of Prader-Willi patients.  While the disorder’s 
association with chromosome 15 abnormalities improved its delineation and diagnosis 
during the 1980s, clinicians sometimes continued to see Prader-Willi syndrome when, 
genomically, it was not there.  Whether the term ‘Prader-Willi’ should be used 
exclusively to designate a specific genetic syndrome, or if it had value for describing a 
broader clinical presentation, was a matter of debate in the 1990s.  As I describe in the 
next section, the names of genetic disorders sometimes move out beyond the boundaries 
set by their discrete genomic localization. 
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‘Prader-Willi-like’ as a Clinical Category  
 In 1981, McKusick suggested that the association of Prader-Willi syndrome with 
chromosome 15 aberrations made it a genetic disease, thus distinguishing it from a 
broader array of clinically diagnosed dietary problems (McKusick, 1981).  Despite this 
however, the ‘look’ of Prader-Willi, in one interesting case involving Fragile X 
syndrome, has been identified as a clinical category, even in the absence of chromosome 
15 abnormalities.  The first instance of this was a report by J.P. Fryns and colleagues in 
1987.  Four patients clinically and cytogenetically diagnosed with Fragile X syndrome, 
also appeared to have ‘Prader-Willi-like’ characteristics, most notably, showing short 
stature and extreme obesity as young children (Fryns et al, 1987).    
J.P. Fryns, Bert de Vries, and colleagues reported on additional five patients in 
1993, clinically and cytogenetically diagnosed with Fragile X syndrome, but who once 
again showed distinct ‘Prader-Willi-like’ features.  Each of these individuals expressed 
the fragile X site and showed no sign of the 15q11-13 deletion.  Among family members 
also affected by Fragile syndrome, most did not show similar Prader-Willi characteristics.  
Unlike most Prader-Willi patients, these individuals did not show hypotonia as infants, 
nor was their obesity caused by a sudden change in eating habits.  Also, most patients 
showed more severe intellectual disability than is common to Prader-Willi syndrome.  
Many of these patients did however, have small testicles, a common feature of Prader-
Willi syndrome, rather than abnormally larger ones, as is frequently seen in Fragile X 
syndrome (de Vries et al, 1993).   
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One group of clinicians criticized the use of ‘Prader-Willi-like’ by de Vries et al 
(1993), arguing that obesity and intellectual disability are common in many disorders, 
and that their association with Prader-Willi syndrome would only confuse its clinical 
diagnosis (Gillessen-Kaesbach and Horsthemke, 1994).  De Vries and Niermeijer (1994) 
however, responded to this criticism by noting that this special sub-category of patients 
showed many features common to Prader-Willi syndrome, but not Fragile X patients, like 
a round face and small testicles.  Since two of their Fragile X patients had previously 
been misdiagnosed with Prader-Willi syndrome, these clinicians felt broader clinical 
knowledge of this sub-type of Fragile X syndrome would improve diagnosis, rather than 
confuse it (de Vries and Niermeijer, 1994).  
An additional report of a patient diagnosed with Fragile X syndrome, but 
demonstrating Prader-Willi-like symptoms came, once again from the Fryns group, in 
1994.  The patient showed fragile X site expression, early onset childhood obesity, and 
small genitals, but no 15q11-13 deletion.  Hormonal studies on this patient did not 
suggest any abnormalities that could explain his obesity (Schrander-Stumpel et al, 1994).  
Another more recent report has also identified 13 additional cases of this Prader-Willi 
phenotype of Fragile X Syndrome.  Nowicki et al (2007) noted overeating, leading to 
obesity, and more severe behavioral problems than what is seen in most Fragile X 
patients.  These researchers also pointed to a gene, CYFIP1, in the 15q11-13 region, 
which appeared to interact with the FMR-1 protein, as a possible molecular explanation 
for this overlapping clinical phenotype.  Indeed, it has been found that patients with 
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‘Prader-Willi-like’ Fragile X syndrome often show lower than normal expression of 
CYFIP1 (Nowicki, 2007; Hagerman et al, 2010).   
 While interesting to this dissertation in a coincidental sense, the Prader-Willi 
phenotype of Fragile X syndrome also offers a valuable opportunity to reflect on how 
researchers and clinicians name genetic diseases and clinical categories.  The name 
Fragile X syndrome comes from its chromosomal marker, whereas the term Prader-Willi 
syndrome seems to evoke a particular clinical expression.  Is classifying certain patients 
with Fragile X syndrome as being ‘Prader-Willi-like’ clarifying or confusing for other 
clinicians?  Those who opposed the designation felt that it would mislead physicians, and 
add to an existing over diagnosis problem (Gillessen-Kaesbach and Horsthemke, 1994).  
On the other hand, the term reminded clinicians that individuals with Fragile X syndrome 
could ‘look’ as much like Prader-Willi patients as they did Fragile X patients, meaning 
that clinical expression in these individuals often included significant Prader-Willi 
features like obesity and very small genitalia, while excluding macro-orchidism and 
facial characteristics common to Fragile X syndrome.  Indeed, it is important to keep in 
mind that what clinicians call a disorder may be as much about defining how it should be 
classified: ‘Prader-Willi-like’ Fragile X syndrome, as how it should not: Prader-Willi 
syndrome.  
 
Conclusion 
This chapter examines the history of Prader-Willi syndrome, and its unanticipated 
genomic and clinical overlaps with Angelman, as well as Fragile X syndromes.  As I 
have described, during the early-1980s, Prader-Willi syndrome came to exemplify the 
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promises of a new ‘genomic’ nomenclature in postwar biomedicine.  The association of 
Prader-Willi syndrome with a visible deletion at the chromosomally defined genomic 
location 15q11-13, even if the aberration was not seen in all patients, offered a 
representative example of how chromosomal analysis could aid human and medical 
geneticists in their attempts to better to delineate, diagnose, understand, prevent, and treat 
human diseases.  Indeed, Prader-Willi syndrome was pointed to as an important example 
of biomedicine’s growing knowledge of the ‘morbid anatomy’ of the human genome, and 
its central role in disease. 
With the unanticipated identification of the chromosomally visible 15q11-13 
deletion in patients not expressing the classical clinical features of Prader-Willi 
syndrome, the exemplary status of the disorder was called into question, and ultimately 
reconceived.  The nosological system linking genetic diseases to discrete genomic 
locations had shown great success throughout the 1980s (Hogan, 2013a).  Nonetheless, 
the visual association of both Prader-Willi and Angelman syndrome with the same 
genomic location was not regarded as evidence that they were in fact historically distinct 
forms of the same genetic disorder.  Indeed, clinical expression unequivocally trumped 
genomic localization as far as classification was concerned. 
The genomic overlap between Prader-Willi and Angelman syndromes posed 
complications for its accurate diagnosis and understanding in the clinic.   As I 
demonstrate throughout this dissertation however, findings such as this one effectively 
turned human chromosomal analysis into unexpectedly productive experimental system.  
Hans-Jorg Rheinberger’s description of experimental practices in biomedicine highlights 
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the concept that the most productive experimental systems are those that continuously 
produce unanticipated outcomes (Rheinberger, 1997).  Such a situation, while of great 
value in basic laboratory research, is seemingly at odds with the goals of clinical analysis, 
which seeks to provide consistent and reliable results.  In the long-term however, 
unanticipated findings like the one described in this chapter may improve the clinical 
diagnosis and understanding of disease.  Central to the resolution of how Prader-Willi 
and Angelman syndrome could be caused by the same genomic deletion, was the 
application of knowledge about genomic functionality in mice to research on human 
disease.  This intersection, I suggest, was facilitated in part by the late-20th century 
‘genomic’ conception of human disease, which placed disease analysis within the realm 
of both basic biological and clinically targeted research.  Indeed, during this era, the 
human genome became a location where the conventions, questions, and interests of 
clinical and basic genetics intersect and intermingle.   
What does the chromosomal relationship between Prader-Willi and Angelman 
syndrome mean for the researchers who study them and the families who are affected by 
them?  Pedagogically and genomically these two disorders likely will always be linked.  
Indeed, clinicians still need to know about their common genetic deletion and differential 
clinical outcomes, lest they should be misdiagnosed.  Also, as the papers of Judith Hall 
demonstrate, Prader-Willi and Angelman syndrome are an important teaching point more 
generally, both as an example of the role of uniparental disomy and methylation in 
human disease, and well as of the complex functionality of the genome more broadly.  
Institutionally however, these two disorders remain quite distinct.  As Charles Williams 
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noted, “Years ago we thought about, should we have a joint meeting [between the Prader-
Willi and Angelman syndrome foundations] . . . really it never quite had a dynamic, it 
just didn’t make sense” (Interview with Charles Williams, March 16, 2012).  Though 
these two disorders are linked chromosomally and genomically, for those affected by 
them they are remain distinct.  Indeed, while genomic overlaps like the one described in 
this chapter are interesting and valuable findings in both the laboratory and the clinic, 
they do not necessarily change the day-to-day experience of living with a genetic 
disorder.  
In the next chapter, I explore another instance of genomic overlap in the recent 
history of human and medical genetics.  While the two genetic syndromes examined were 
clinically and historically distinct for more than a decade, the finding that they were 
associated with the same chromosomal deletion was pointed to, in this instance, as 
evidence that they were in fact two versions of the same genetic disorder.  As in this 
chapter, I will examine the implications of this finding for the naming, diagnosis, 
understanding, and institutional organization of these two disorders in the years after they 
became genomically associated.  The contrasts between these two stories are meant in 
part to highlight the ongoing power and influence of both laboratory and clinical 
observation in the thinking and practices of postwar biomedicine.   
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CHAPTER 4 
A Single ‘Elephant’ in the Room: How DiGeorge and Velo-Cardio-Facial 
Syndromes Become One Genomic Disorder 
 
 In this chapter, I focus on another instance of genomic overlap, though in this 
case, one with a very different outcome.  Just like Prader-Willi and Angelman 
syndromes, DiGeorge and Velo-cardio-facial (VCF) syndromes were each initially 
identified and historically diagnosed independently based upon clinical observations 
alone.  In the early-1990s however, it was demonstrated that many patients clinically 
affected by DiGeorge and VCF syndromes possessed the same deletion in the 
chromosomal band 22q11.  This finding was not quite as surprising for clinicians as the 
overlap between Prader-Willi and Angelman syndromes had been a few years earlier.  
Indeed, going back to the mid-1980s, some clinicians had noted similarities between 
DiGeorge and VCF syndrome patients.  However, despite these commonalities, the 
natural and clinical histories of these two disorders did not frequently overlap.  
 The established ‘look’ of a disease may be significantly impacted by its clinical 
severity.  If a disorder is generally lethal during early infancy, conceptions of clinical 
appearance will tend to focus on its most visually obvious characteristics: like structural 
birth defects or highly deadly attributes.  In cases where patients are not so severely or 
noticeably impacted at birth, and are expected to live for years or decades after diagnosis, 
more subtle characteristics of the disease become relevant to its diagnosis and treatment, 
as well as to the experiences of patients and their families.  Into the 1980s, the differing 
‘looks’ of DiGeorge and VCF syndrome were closely related to the age of patients when 
first diagnosed.  DiGeorge syndrome was diagnosed at birth and almost always proved 
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deadly by age two.  VCF syndrome, on the other hand, was generally only identified in 
school-aged children based on non-life threatening symptoms.   
 In this chapter, I trace the various visual signs that were used to independently 
identify DiGeorge and VCF syndrome, and which over time brought them together as one 
clinical entity.  The convergent histories of these two disorders highlight the problem of 
‘ascertainment bias’ in genetics research.  As many scholars have previously noted, there 
is nothing certain or obvious when it comes to identifying disease categories.  Indeed, 
nosological categories in medicine are affected by the variable expression of disorders as 
well as the institutional and professional infrastructures that divide clinical specialties and 
assumptions.  Thus, in analyzing clinical nosology, we must focus the collective ways in 
which clinicians and researchers learn and agree to see, name, and standardize their 
objects of study (Fleck, 1979; Daston, 2008).   
Throughout this dissertation, I explore how the introduction of visual genetic 
evidence has impacted the clinical categorization of diseases.  As I show in this chapter, 
while a common genetic marker has the power, in some cases, to make two diseases one 
from etiological and ontological perspectives, the existing names and institutional 
affiliations associated with the disorders will not always immediately follow suit.  In fact, 
to this day, a common name has not been universally accepted for describing DiGeorge 
and VCF syndromes.  It has not been the bodily presentation of disease that has gotten in 
the way in this case, but rather the importance of maintaining certain disease 
classifications, which expand beyond medical textbooks and diagnostic interactions to the 
identity of research grants, foundations, institutions, and careers. 
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 The association of DiGeorge syndrome with a particular genomic location 
occurred, as with Prader-Willi syndrome, through observational chromosomal analysis.  
Translocations, and small deletions, involving the long arm of chromosome 22 eventually 
came to be understood as an additional genomic and anatomical markers for DiGeorge 
syndrome, as well as key pieces of genetic evidence linking the disorder to VCF 
syndrome.  Indeed, over time, a deletion in the chromosomal region 22q11 came to be 
understood as the most significant and reliable indicator of the presence of this genetic 
disease, now widely referred to as ‘22q11 deletion syndrome’.  Unlike DiGeorge 
syndrome, which was historically associated with severe birth defects and early infant 
death, 22q11 deletion syndrome is now traced in family pedigrees, with parents being 
retroactively identified as having a mild case of the disorder after their children are 
clinically diagnosed.  The natural history of DiGeorge, reconceived as 22q11 deletion 
syndrome, now spans entire lifetimes, rather than being primary seen in infants and 
young children.  Indeed, the ‘look’ of 22q11 deletion syndrome is broader, and in some 
cases may be quite distinct from, the severe clinical attributes initially associated with 
DiGeorge syndrome.  
This chapter traces the intersecting clinical and laboratory histories of DiGeorge 
and VCF syndrome.  As I have suggested throughout this dissertation, during the postwar 
period, clinicians and geneticists increasingly looked to the human genome, at the 
microscopically visible level of chromosomes, for new anatomical markers of disease.  In 
previous chapters, I have examined the use of genomic markers for the nosological 
“splitting” off of unique clinical disorders.  The converging histories of DiGeorge and 
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VCF syndrome instead, offer an equally valuable example of how visible chromosomal 
analysis has facilitated the categorical “lumping” of disorders as well.  Indeed, in postwar 
biomedicine, nosological categories have, in some cases, been broken down, rebuilt, and 
even made more clinically variable, based on the association of existing disorders with 
particular genomic locations (McKusick, 1969).  
 
The Clinical Characterization of DiGeorge Syndrome 
 In 1965, Angelo DiGeorge, an endocrinologist at St. Christopher’s Hospital for 
Children in Philadelphia, commented on a series of three newborns he had recently 
observed who had been born without a thymus.  The thymus is an organ located above 
the heart, which plays an important role in the development of the immune response in 
early infancy.  DiGeorge noted that these children suffered from continuous infections 
due to their lack of a thymus, among other problems, and died within the first two years 
of life (DiGeorge, 1965; 1968).  The infants had initially come to the attention of 
clinicians because they also lacked or had under-developed parathyroid glands, which 
play a key role in calcium regulation in the body.  Absence of the thymus was actually 
only recognized in these three patients upon autopsy.  Indeed, as DiGeorge (1965) points 
out, the finding that infants born with under-developed parathyroid glands also lack a 
thymus is not all that surprising given that these two organs develop from the same 
primordial structures, known as the 3rd and 4th pharyngeal pouches (Kretschmer et al, 
1968). 
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Two years later, DiGeorge and two of his colleagues in Philadelphia reported on a 
similarly affected child.  This child suffered from multiple infections due to an 
inadequate immune response, and died at 17 months.  As DiGeorge anticipated, upon 
autopsy, the child was found to lack a thymus, as well as parathyroid glands.  At the time, 
there was no treatment for this condition.  Indeed, DiGeorge was largely interested in 
these children from a research perspective: they offered a unique opportunity to study the 
nature of the human immune response (Lischner et al, 1967).  The affected children also 
had significant cardiac problems, due to occasional inborn heart defects, and because 
their under-developed parathyroid glands were not able to regulate calcium levels, thus 
disrupting proper heart function (DiGeorge, 1968). 
DiGeorge inferred that these symptoms taken together likely represented a unique 
clinical disorder.  Whether or not this disorder was of genetic origin remained unclear.  A 
similar clinical presentation had previously been seen in mice in which it was inherited in 
a recessive manner.  However, none of the siblings or relatives of affected patients were 
known to have similar clinical outcomes, suggesting that the disease occurred 
sporadically in humans.  By 1968, congenital lack of the thymus, and its clinical effects, 
was already been referred to by some clinicians as ‘DiGeorge syndrome’, following the 
suggestion of immunologist Robert Good.  DiGeorge himself “demurred” though, noting 
that such cases had previously been reported, as early as the first half of the 19th century 
(DiGeorge, 1968; Lammer and Opitz, 1986, 114).  The term DiGeorge syndrome, 
nonetheless, was widely adopted by the clinical community soon thereafter (Kretschmer 
et al, 1968; Dodson et al, 1969; Harvey et al, 1970). 
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Many additional patients who appeared to be affected by DiGeorge syndrome 
were identified in the published medical literature during the late-1960s and early-1970s.  
These individuals showed previously unreported symptoms including seizures, palate 
abnormalities, and developmental delay, as well as heart defects or murmurs (Kretschmer 
et al, 1968; Dodson et al, 1969, Harvey et al, 1970, Freedom et al, 1972).  Among the few 
patients who lived past infancy, mild to moderate intellectual disability was seen (Conley 
et al, 1979).  At the time, clinicians were interested in the potential to treat DiGeorge 
patients by using thymus tissue transplants to restore immune function.   One group 
reported doing so, with apparent success, using human fetal thymus tissue in 1968 
(Cleveland et al, 1968).  Steele et al (1972) also attempted such a transplant, which 
seemed to be somewhat effective in restoring immune response.  The long-term impact of 
this treatment however, remained unknown, because this patient died of pneumonia nine 
days later.   
While thymus tissue transplants offered hope for DiGeorge patients, it was 
becoming increasingly apparent during the 1970s that heart defects were also a common 
cause of infant death in this population.  Finley (1977) reported on seven DiGeorge 
patients, all but one of whom died in the first weeks of life due to cardiac problems.  As 
these authors put it, “diagnosis of DiGeorge syndrome should be possible in the newborn.  
The important features are not, however, related to immune deficiency, but rather to 
severe congenital cardiovascular disease” (Finley, 1977, 637).  While clinicians 
continued to consider an underdeveloped or absent thymus to be the most important 
anatomical marker of DiGeorge syndrome during the 1970s, the majority of DiGeorge 
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patients at this time first came to medical attention, and were most likely to die form, 
congenital cardiac problems (Conley et al, 1979).  Indeed, two prominent, and deadly, 
features defined the morbid anatomy of DiGeorge syndrome in the 1970s.  As I describe 
in the next section, during the 1980s, additional anatomical features came to be 
associated with DiGeorge syndrome.  Perhaps most important among these were visible 
cytogenetic aberrations, often involving chromosome 22.  Based on this chromosomal 
marker, DiGeorge syndrome was associated with a particular chromosomal ‘address’, and 
was listed in the earliest editions of Victor McKusick’s ‘morbid anatomy’ of the human 
genome (McKusick, 1982). 
 
Cytogenetic Analysis of DiGeorge Syndrome 
 Medical geneticist Albert de la Chapelle and his Finnish colleagues reported in 
1981 on an extended family affected by DiGeorge syndrome.  Four children of one 
father, and a cousin of theirs on the same side of the family, had died of DiGeorge 
syndrome as infants.  The adult brother and sister, who were separately the parents of 
these affected children, were both found to possess the same balanced translocation 
involving chromosomes 20 and 22.  The balanced translocation in these siblings was 
passed down in an unbalanced manner, meaning that some genetic material was lost or 
gained among individuals the next generation who were affected by DiGeorge syndrome.  
Each of the children in this family who died of DiGeorge syndrome had a similar 
unbalanced translocation, while healthy family members either had a balanced 
translocation or normal chromosomes.  The chromosomal rearrangement could not be 
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traced back further however, because older family members refused to provide tissue 
samples for this study, citing religious reasons (de la Chapelle et al, 1981). 
 The unbalanced translocation seen in affected family members caused a partial 
trisomy of chromosome 20 and a partial monosomy of chromosome 22.  This included 
the deletion of the entire short arm of chromosome 22, as well as a portion of the long 
arm (de la Chapelle et al, 1981).  The clinical effects of trisomy 20 had previously been 
described by Francke (1977), and did not resemble those of DiGeorge syndrome.  From 
this, it was inferred that the deletion of a portion of chromosome 22 was more likely to 
play a causative role in the disorder.  Existing evidence on such abnormalities was mixed 
however, with a previous report of one patient with monosomy 22 appearing to show 
DiGeorge syndrome features (Rosenthal et al, 1972), while another patient lacking one 
copy of chromosome 22 did not (DeCicco et al, 1973). 
Despite these confusing previous findings, de la Chapelle et al (1981) theorized 
that DiGeorge syndrome in these cases was most likely associated with the deleted 
portion of chromosome 22 in the patients his group had described.  Previous individuals 
who lacked the short arm of chromosome 22 had not shown similar clinical 
characteristics.  Therefore, de la Chapelle and colleagues pointed to the deleted portion 
on the long arm of chromosome 22, noting, “the most likely location of the gene is at 
22q11” (de la Chapelle et al, 1981, 255).  These researchers however, could only account 
for the familial patients that they had studied.  DiGeorge syndrome was known to occur 
both sporadically and in families, but no consistent chromosomal anomalies had 
previously been reported (Steele et al, 1972; Raatikka et al, 1981).   
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Summing up their report, the authors admitted, “As of yet we have no clue to the 
nature of the postulated gene.  Another point that remains to be clarified is the part played 
by the remaining gene on the structurally normal chromosome 22 in our cases” (de la 
Chapelle et al, 1981, 255).  Indeed, the idea that the loss of one copy of one particular 
gene played an etiological role in DiGeorge syndrome was purely hypothetical at this 
time.  These clinicians could only see that their DiGeorge patients were missing a rather 
large portion of chromosome 22.  How this visible anatomical aberration impacted the 
genome was a point of speculation.     
 The next year, clinical geneticists in Philadelphia identified an additional 
DiGeorge patient with chromosome 22 abnormalities.  As Beverly Emanuel, a Ph.D. 
geneticist at the Children’s Hospital of Philadelphia and University of Pennsylvania, 
described it to me,   
 
In that family [described by de la Chapelle], the children who wound up 
missing the proximal part of chromosome 22 all had DiGeorge syndrome, 
and it was almost like an ‘ah ha ‘ moment.  We have a child here [in 
Philadelphia] missing part of 22, who has DiGeorge, and they have a 
family, with three affected, missing part of 22, who have DiGeorge 
(Interview with Beverly Emanuel, November 9, 2011).  
 
Clinicians at the Children’s Hospital of Philadelphia immediately contacted DiGeorge 
and cytogenetist Hope Punnett across town at St. Christopher’s Hospital to ask if they 
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had seen any similar chromosomal abnormalities in their own DiGeorge patients.  As 
Children’s Hospital of Philadelphia clinical geneticist Elaine Zackai described it, “We 
went back to DiGeorge [and asked], ‘do you have any others that have chromosome 
abnormalities?’ ‘Yes’ [he said].  Sure enough, it was the 22” (Interview with Elaine 
Zackai, November 10, 2011).   
The case identified at the Children’s Hospital of Philadelphia, along with two 
described by DiGeorge himself, were published in the Journal of Pediatrics in August 
1982.  These three unrelated DiGeorge patients were each found to have lost the all of the 
short arm of chromosome 22, as well as the 22q11 region on the long arm, due to 
translocations involving 22 and another chromosome (3, 10, and 20).  Based on their own 
results, these authors agreed with de la Chapelle et al (1981) that the deletion of 22q11 
was most likely involved in the clinical onset of DiGeorge syndrome (which the 
Philadelphia researchers referred to as ‘DiGeorge anomalad’, a difference in naming that 
I take up in the next section).  Referring to the identification of a chromosomal deletion 
associated with Prader-Willi syndrome a year earlier (discussed in chapter 3), the 
researchers noted the possibility that DiGeorge syndrome may also be caused by a small 
deletion that could be made visible using high-resolution cytogenetics.  Of more 
immediate importance, in two of the cases reported, the unbalanced translocation in 
affected children seemed to result from a balanced translocation in one of the parents. 
This suggested that there was a significant recurrence risk for DiGeorge syndrome in 
these families (Kelley et al, 1982).   
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An addendum to the Kelley et al (1982) report identified an additional family 
impacted by DiGeorge syndrome due to translocations involving chromosomes 22 and 4.  
A full report on this family was submitted the next year, and subsequently published in 
1984.  A sibling of this affected patient had previously died in infancy due to congenital 
heart problems, and was later found to lack a thymus as well.  Chromosomal studies 
however, had not been performed.  The authors even inferred that the mother likely had a 
mild form of DiGeorge syndrome herself, as her immune cell count was low, and because 
she showed the same unbalanced translocation as her affected son.  Indeed, it was 
becoming clear that the same visible abnormality of chromosome 22 could lead to a wide 
range of clinical outcomes (Greenberg et al, 1984). 
The extent and specifics of this potential causative link between chromosome 22 
aberrations and DiGeorge syndrome remained unclear throughout the 1980s.  Multiple 
cases where reported during this time in which, among family members who all appeared 
to have the same visible chromosome 22 translocation, only some were clinically affected 
with DiGeorge syndrome (Augusseau et al, 1986; Bowen et al, 1986).  In addition, 
DiGeorge-like symptoms were also identified in a few patients with other visible 
abnormalities, such as deletions on chromosomes 10 and 18 (Greenberg et al, 1988).  As 
Children’s Hospital of Philadelphia genetic counselor Donna McDonald-McGinn 
summed it up to me, “They did chromosomes [on DiGeorge patients] and in 25% they 
could see a visible piece [of chromosome 22] missing.  But from 1982 to 1992, they 
didn’t know what to do with the other 75%” (Interview with Donna McDonald-McGinn, 
November 10, 2011).  Indeed, like with the history of Prader-Willi syndrome described in 
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chapter 3, similar chromosomal abnormalities appeared frequently enough in DiGeorge 
patients to suggest a genomic location for the disorder.  However, their visual presence or 
absence alone could not be relied upon diagnostically.  
 
Searching for the ‘DiGeorge Gene(s)’ 
How were chromosome 22 abnormalities mechanistically linked to DiGeorge 
syndrome?  As Emanuel explained it to me, “At the time, and this is kind of interesting, 
the thinking in the field was, somewhere on 22 there’s a DiGeorge gene, and probably the 
patients with the translocation were just putting us into the right region.  The idea was 
they all involve 22.  So, missing the ‘DiGeorge gene’, on chromosome 22 was going to 
give you the syndrome” (Interview with Beverley Emanuel, November 9, 2011).  How 
the DiGeorge gene was actually disrupted in patients with chromosome 22 translocations, 
and why this led to such a range of clinical outcomes remained unclear.  Nonetheless, the 
chromosomal band 22q11 had been widely adopted as the genomic address where the 
cause of DiGeorge syndrome resided. 
In 1984, researcher Frank Greenberg and colleagues suggested that, “some cases 
of DiGeorge syndrome might have an interstitial deletion of 22q11, a situation analogous 
to that of Prader-Willi syndrome, and interstitial deletions of 15q11-12” (Greenberg et al, 
1984, 318).  Indeed, the 15q deletion associated with Prader-Willi syndrome identified by 
Ledbetter et al (1981) was seen as a potential model for other genetic disorders that were 
associated with chromosomal translocations, and thereby might be caused by small 
deletions.  The authors however, admitted that even if an interstitial 22q11 deletion did 
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exist in many or all DiGeorge patients, it might well be too small to identify 
microscopically on banded chromosomes, even with the use of new high-resolution 
cytogenetic techniques.  To this point, Greenberg and colleagues (including David 
Ledbetter) had never seen such an interstitial deletion in DiGeorge patients (Greenberg et 
al, 1984), nor had any other DiGeorge researchers (Rohn et al, 1984). 
Clinical geneticist Roy Schmickel, of the University of Pennsylvania, included 
DiGeorge and Prader-Willi syndrome among what he called ‘contiguous gene 
syndromes’ in a 1986 publication in the Journal of Pediatrics.  Contiguous gene 
syndromes are associated with a broad and variant array of clinical outcomes.  Schmickel 
suggested that this might be the result of multiple adjacent genes being deleted in one 
genomic region.  The size of the deletion in this region, and thereby the number of genes 
lost, suggested Schmickel, might be the basis for clinical variation.  As Schmickel notes 
in his discussion, “these genes many be quite independent and no more related than 
apples and Appalachian Mountains; the loss of an encyclopedia page could remove both 
entries.  The organization of genes may be as arbitrary as that of words” (Schmickel, 
1986, 236).  As a result, the loss of multiple genes in a genomic deletion may have wide 
ranging effects on the body, and thereby cause a diverse array of clinical outcomes.  
Schmickel was a mentor of Emanuel at the University of Pennsylvania, and 
encouraged her to study the chromosomal basis of DiGeorge syndrome, “Roy Schmikel 
said, ‘Bev, you know, you ought to study DiGeorge syndrome, I think there’s something 
there’ . . .  And I said, ‘but the reality is, so many of these kids with DiGeorge die in the 
neonatal period, how are we going to study them?’  and he said, ‘I think you’re just going 
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to find out that it is really interesting’ (Interview with Beverly Emanuel, November 9, 
2011).  As Emanuel noted, the natural history of DiGeorge syndrome remained difficult 
to define in the 1980s, since few affected individuals older than childhood were known.  
Indeed, only recently had surgical interventions for heart defects succeeded in allowing 
most patients to survive infancy.  As Schmickel and Emanuel clearly recognized 
however, DiGeorge syndrome offered a unique opportunity to study the genomic impact 
of multiple genes being lost due to a deletion.  
As Schmikel wrote his 1986 piece on contiguous gene syndromes however, the 
prevalence of 22q deletions in DiGeorge patients remained unclear.  In 1988 Greenberg 
reported on the use of high-resolution chromosomal analysis in 27 DiGeorge patients.  
Chromosomal abnormalities were identified in five, including a visible 22q11 interstitial 
deletion in one.  This was the first report of a visible cytogenetic deletion in a DiGeorge 
patient, which was seen without a chromosomal translocation.  The parents of this 
individual showed no such deletion, suggesting that it occurred spontaneously during the 
reproductive process, on the maternally inherited copy of chromosome 22 (Greenberg et 
al, 1988).  A second report of a microscopically visible 22q11 deletion in a DiGeorge 
patient came the next year (Mascarello et al, 1989).  
The lack of visibly identifiable 22q11 deletions in DiGeorge patients suggested 
that most of these aberrations, if they existed, were likely too small to see, even using 
high-resolution cytogenetic techniques.  During the late-1980s, molecular techniques 
began to be applied to the identification of such deletions.  In a 1987 abstract conference 
abstract printed in the American Journal of Human Genetics, Emanuel and her colleague 
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Wendy Fibison, identified a molecular DNA probe specific to the 22q11 region that did 
not bind one copy of chromosome 22 in DiGeorge patients, but bound to both copies in 
normal individuals.  This finding suggested that the molecular probe was specific to the 
DiGeorge deleted region (Fibison and Emanuel, 1987).   
From here, additional molecular studies conducted over next five years helped to 
better define the size and prevalence of the 22q11 deletion in DiGeorge patients.  The 
impacts of molecular analysis will be further discussed later in this chapter.  Before 
returning to this narrative however, the next section explores broader discussions about 
the clinical nature and categorization of this disorder, which was named after DiGeorge 
and associated with chromosome 22 abnormalities.  In addition, I describe the parallel 
clinical history of VCF syndrome, during the years before it was genetically linked to 
DiGeorge ‘syndrome’.   
 
DiGeorge ‘Syndrome’? 
 Throughout the 1980s, clinicians and researchers raised various questions about 
the disorder named after DiGeorge.  Was it a syndrome, or something else?  Definitions 
of what defines a syndrome vary.  Medical geneticist John M. Opitz and colleagues 
lamented in a 1979 account of the history of the term ‘syndrome’ that, “Through 
indiscriminate use, lately also by sociologists and political commentators, the word 
‘syndrome’ has become so debased that few know how to use it correctly anymore” 
(Opitz et al, 1979, 98).  Clinician and geneticist Kurt Hirschhorn has suggested to me that 
identifying syndromes is sometimes, “Tricky business,” noting that, “The conception of a 
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syndrome is simply that, once it’s described, you have the possibility of recognizing it 
and accepting the fact that the same syndrome can have manifestations that are absent or 
present” (Interview with Kurt Hirschhorn, January 26, 2012).  Indeed, as Opitz et al 
(1979) note, ontological thinking is central to how clinicians conceive syndromes: the 
expression of syndromes may be variable within individuals, but nonetheless a syndrome 
is a real world entity, that can be delineated and diagnosed.  
In a letter to the editor of the Journal of Pediatrics, medical geneticist John Carey 
called into question the designation of DiGeorge as a ‘syndrome’ (Carey, 1980).   Noting 
that the disorder was regarded instead as an ‘anomalad’ in the 1976 edition of Smith’s 
Recognizable Patterns of Human Malformation (Smith, 1976, 374), Carey suggested that 
its associated clinical features may represent a discrete developmental defect, rather than 
a syndrome.  Carey offered the term ‘DiGeorge malformation complex’, to describe a set 
of related embryological defects that may be features of many different syndromes.  He 
went on to note that, if additional expressions, such as abnormal facial features, were 
seen along the with heart and immune system defects associated with the DiGeorge 
‘malformation complex’, then these visual characteristics taken together may constitute a 
DiGeorge ‘syndrome’.  In fact, the 2006 edition of Smith’s Recognizable Patterns of 
Human Malformation has separate entries for the DiGeorge ‘sequence’ or ‘malformation 
pattern’, and what some call DiGeorge ‘syndrome’ (Jones, 2006, 298, 714). 
During the 1980s, some clinicians and researchers used the terms DiGeorge 
‘malformation complex’ and the DiGeorge ‘anomalad’ in their published papers (Kelley 
et al, 1982; Keppen et al, 1988).  Goldberg et al (1985), perhaps in following with the 
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1982 edition of Smith’s Recognizable Patters of Human Malformation (Smith, 1982, 
470), referred to the disorder as ‘DiGeorge sequence’, as did Swiss medical geneticist 
Albert Schinzel in a 1988 paper on chromosomal syndromes.  As Schinzel put it, “The 
DiGeorge sequence is a localised defect of development and therefore not a syndrome.  It 
can occur as an isolated defect or as a component of a variety of syndromes” (Schinzel, 
1988, 458).   
A sequence is defined as a chain of physiological abnormalities resulting from 
one primary defect, which leads to a number of secondary and tertiary effects.  In the case 
of DiGeorge syndrome the primary defect occurs during the embryonic development of 
the 3rd and 4th pharyngeal pouches and the 4th branchial arch, which develop into the 
parathyroid, thymus, and heart.  On the other hand, a syndrome involves a number of 
symptoms that occur together, and usually have a common etiology, but are not the result 
of a chain reaction of events (Cohen, 1982).  As a result, sequences are localized 
disorders (Schinzel, 1988), while syndromes more universally affect the body. 
In a 1986 paper, Developmental specialist Edward J. Lammer, writing with Opitz, 
referred to this disorder as the ‘DiGeorge anomaly’ saying, “without detracting in the 
slightest from [Angelo] DiGeorge’s discovery, a change in our conception of the 
condition is necessary because this so-called syndrome is not an etiologically unique 
‘syndrome’ at all, but rather a causally non-specific and heterogeneous complex 
polytropic developmental field defect” (Lammer and Opitz, 1986, 115).  By calling the 
disorder a ‘developmental field defect’ the authors implied that DiGeorge is associated 
with “a group of embryonic cells and primordial that share some morphogenic property 
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that causes them to develop abnormally together” (Lammer and Opitz, 1986, 116).  The 
DiGeorge ‘anomaly’ is caused by an embryonic abnormality, Lammer and Opitz note, 
which may have various etiologies.  Indeed, the disorder was associated with aberrations 
on chromosomes 1, 8, 10, and 22, and also linked to fetal alcohol exposure. 
During the 1980s then, while many clinicians were seeking to associate DiGeorge 
syndrome with a specific chromosomal abnormality, multiple others doubted its status as 
a ‘true’ syndrome (Opitz et al, 1979) with a clear etiological cause.  While translocations 
involving the long arm of chromosome 22, and even a small interstitial deletion at 22q11 
(Greenberg et al, 1988; Mascarello et al, 1989) were considered to be relevant genomic 
markers associated with this disorder, in the majority of cases no chromosomal aberration 
was seen.  The cause of DiGeorge syndrome remained unclear, as did its nosological 
status as a clinical syndrome.  During the 1990s, the identification of a genetic link 
between DiGeorge and a previously distinct clinical disorder, VCF syndrome, would both 
further clarify and confuse its diagnosis and classification. 
 
The Clinical Identification of Velo-cardio-facial Syndrome 
 In 1978, Robert Shprintzen and colleagues at the Center for Cranio-Facial 
Disorders of Montefiore Hospital in New York City reported on what they believed to be 
a newly identified clinical syndrome.  Ten school-age children and two newborns had 
been referred to the center due to various palate problems, and showed “very similar 
patterns of symptoms” (Shprintzen et al, 1978, 56).  Elaborating on these similarities, the 
authors noted, “Perhaps the most striking feature of these patients was the similar facies 
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of all twelve” (Shprintzen et al, 1978, 57).  The children all had large, wide noses, 
flattened cheeks, narrow eyes, and a long face, among other features.  Nine of the twelve 
patients had heart defects, some had been surgically corrected, eleven showed learning 
disabilities (the twelfth was an infant with developmental delay).  IQ scores suggested 
borderline to mild intellectual disability (Shprintzen et al, 1978).    
The most noticeable similarities among these patients were oral and nasal 
(velopharyngeal) abnormalities, heart defects, and distinct facial characteristics, which 
led to the name Velo-cardio-facial (VCF) syndrome for this disorder.  Another syndrome 
had previously been called Cardio-facial syndrome (Yurchak and Fallon, 1976), 
characterized by ‘elfin’ facial features, heart defects, and intellectual disabilities.  
However, the authors of this paper suggest that the mouth and nasal features as well as 
the facial characteristics of patients with VCF syndrome were distinct from those with 
Cadrio-facial syndrome (Shprintzen et al, 1978).   
The cause of VCF syndrome remained unclear at this time.  There did not seem to 
be an environmental or genetic common denominator among all twelve patients.  Among 
them however, there was one instance of familial transmission, with the mother and 
sibling of a patient showing similar clinical effects (Shprintzen et al, 1978).  A 1981 
follow-up report accounted for 39 patients with VCF syndrome.  Most had been referred 
to clinicians because of their hypernasal speech, which is associated with palate clefting.  
Among these patients, four instances of familial transmission of VCF syndrome were 
noted.  This suggested that the syndrome might be inherited in a Mendelian dominant 
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manner.  Chromosomal analysis performed on these familial patients however, showed 
no visible abnormalities (Shprintzen et al, 1981). 
In 1985, a conference abstract published in the journal Clinical Genetics by the 
Shprintzen group noted a phenotypic overlap between the DiGeorge ‘sequence’ and VCF 
syndrome.  A patient diagnosed as having VCF syndrome suffered multiple infections, 
and was found to have the type of immune dysfunction common in DiGeorge patients.  
Upon review of other VCF syndrome patients, it was found that many were judged by 
their parents to have frequent infections, while others were shown to have specific 
immune dysfunction.  In addition, clinically diagnosed DiGeorge patients were seen to 
share the ‘look’ of facial features similar to those affected by VCF syndrome.  The 
disorders were also associated with the same developmental defect of the third and fourth 
branchial arches (Goldberg et al, 1985, A54).   
Based on four instances of familial transmission, among 39 patients reported in 
early-1981, VCF syndrome was regarded by Shprintzen and colleagues as likely 
following an autosomal dominant inheritance pattern (Shprintzen et al, 1981).  The 1982 
edition of Smith’s Recognizable Patterns of Human Malformation, lists this disorder as 
Shprintzen syndrome, and notes that it is a “Probable autosomal dominant” (Smith, 1982, 
194).  Familial transmission of DiGeorge syndrome had been noted previous in a number 
of cases, though the inheritance pattern remained unclear in the early-1980s (de la 
Chapelle et al, 1981; Raatikka et al, 1981).  A 1984 paper, published in the Journal of 
Pediatrics, by researchers from Norfolk, Virginia and Philadelphia, reported on a family 
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that showed an autosomal dominant inheritance pattern for DiGeorge syndrome, with no 
visible chromosomal abnormalities (Rohn et al, 1984).   
Among other similarities, this genetic inheritance pattern further strengthened 
suspicions that DiGeorge and VCF syndromes were related.  As the Shprintzen group 
noted in their 1985 conference abstract, “VCF should be considered in any familial 
instance of DGS [DiGeorge sequence]” (Goldberg et al, 1985, A54).  While the genomic 
cause of inherited DiGeorge in VCF syndromes remained unclear at this time, the 
presence of abnormalities in the chromosomal band 22q11, identified in a number of 
DiGeorge patients using observational cytogenetic analysis, suggested a viable starting 
place for molecular studies seeking to identify a genetic etiology. 
 
Molecular Analysis of DiGeorge Syndrome Patients 
 In 1991, Peter Scambler, and colleagues in London and Stockholm, began to use 
molecular probes to examine DiGeorge patients whose chromosomes appeared normal 
under the microscope.  A report of this research, published in the journal Genomics in 
1991, noted that five of six individuals examined had submicroscopic deletions in the 
22q11 region.  Among these patients however, there was a wide variety of clinical 
outcomes, from mild to severe cases of DiGeorge syndrome.  There did not seem to be a 
correlation between the size of the 22q11 deletion and the severity of the clinical 
outcome.  The researchers therefore hypothesized that DiGeorge syndrome was likely 
caused by the loss of just one gene, common to all of the deletions found (Scambler et al, 
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1991), instead of being a ‘contiguous gene syndrome’, associated with the disruptions of 
multiple genes in the 22q11 region (Schmickel, 1986). 
 The next year, Deborah Driscoll and colleagues at the University of Pennsylvania, 
identified a 22q11 deletion in each of 14 DiGeorge patients tested using molecular 
probes.  Five of these patients had microscopically visible 22q11 deletions as well.  The 
deletions were determined to be both maternally and paternally inherited, ruling out 
instances of imprinting, as had been identified in the cases of Prader-Willi and Angelman 
syndromes.  These findings provided further evidence that a 22q11 deletion was the 
etiological cause of DiGeorge syndrome in most clinical cases.  The genomic deletions 
identified all involved the loss of at least 500,000 DNA base pairs (a large deletion on the 
molecular level, but much too small to be seen microscopically), suggesting that multiple 
genes were impacted (Driscoll et al, 1992).  
 Familiar with previous reports about the clinical overlaps between DiGeorge and 
VCF syndromes, Driscoll and Emanuel were interested in using their molecular probes to 
scan for the 22q11 deletion in patients diagnosed with the latter syndrome as well.  As 
Emanuel recounted to me, “We were very eager to figure out whether there was a 
connection, because we thought there probably was, and we talked to people in our own 
cleft clinic here and at CHOP [Children’s Hospital of Philadelphia] and asked, ‘have you 
ever seen any of those patients here with VCFS?’ . . . We made an arrangement to go into 
the cleft clinic to see if we could detect any of these, VCFS patients, and sure enough 
they were there” (Interview with Beverly Emanuel, November 9, 2011).  Similarly, 
Driscoll told me that, once they were able to identify patients in the cleft clinic who were 
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likely affected with VCF syndrome, and test them for the 22q11 deletion, the link to 
DiGeorge syndrome became obvious, “We found that it is really essentially one and the 
same: it is the same disorder” (Interview with Deborah Driscoll, November 29, 2011).   
Based on this additional research, near the end of their report, Driscoll and 
colleagues note, “Our observation of deletion of loci from within the DGCR [DiGeorge 
Critical Region] in several patients with velo-cardio-facial (Shprintzen) syndrome 
(authors’ unpublished results) may explain the overlapping phenotypic features observed 
in DGS [DiGeorge syndrome] and velo-cardio-facial syndrome” (Driscoll et al, 1992, 
931).  This was the first time that VCF syndrome had been associated with a specific 
chromosomal abnormality or genomic location.  Clearly, this genetic link expanded the 
awareness of DiGeorge and VCF syndrome among cleft palate clinics, while also 
creating the opportunity to improve laboratory diagnosis.  Beyond this, Driscoll and 
colleagues hypothesized that further work might reveal the basis of the differential 
clinical outcomes associated with these historically distinct syndromes (Driscoll et al, 
1992).   
 Peter Scambler and David Kelly in London reported similar findings in a Lancet 
article also published in 1992: deletions in the 22q11 region were found in five additional 
VCF syndrome patients.  These authors interpreted their findings as evidence that 
DiGeorge and VCF syndromes were indeed etiologically related (Scambler and Kelly, 
1992).  A larger follow-up the next year by Driscoll and colleagues analyzed 76 patients 
diagnosed with either DiGeorge or VCF syndrome.  Including their previous results, 
Driscoll et al (1993) reported that the 22q11 deletion could be identified molecularly in 
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88% of DiGeorge patients and 76% of VCF patients.  Many of these individuals were 
referred by outside clinicians, suggesting that diagnoses may not have been consistent: 
some of these patients may not have been affected by DiGeorge or VCF syndrome.  In 
this latter study, the Driscoll and colleagues used a new laboratory technique: 
fluorescence in situ hybridization (FISH).  FISH uses fluorescently labeled DNA probes 
instead of radioactive ones, which allow for easier, quicker, and safer laboratory analysis.  
 Also in 1993, another paper from Scambler and Kelly, this time with Shprintzen 
and Rosalie Goldberg as co-authors, reported on 12 additional VCF syndrome patients 
who each possessed the 22q11 deletion.  These clinicians noted that the deletions 
molecularly identified in both DiGeorge and VCF syndrome patients were very closely 
linked to one another, and indeed might be identical.  It seemed as if the physical 
genomic deletion itself was not directly responsible for the somewhat different clinical 
manifestations associated with these two disorders.  Rather the two syndromes, “Could be 
part of a spectrum of abnormalities which many be caused by monosomy [the deletion of 
one genomic copy of] 22q11.  Chance events during morphogenesis could be responsible 
for much of the difference in phenotypes [clinical outcomes]” (Kelly et al, 1993, 311).  
Indeed, the molecular analysis of increasing numbers of patients suggested that DiGeorge 
and VCF syndrome were each associated with the exact same, or at least closely 
overlapping, genomic abnormality on chromosome 22.  
 In a retrospective look at the diagnosis of these two disorders, Greenberg said of 
the common deletion found in many DiGeorge and VCF syndrome patients, “This 
suggests that the two disorders represent a spectrum of the same gene defect . . . patients 
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with suspected or confirmed DGA [DiGeorge anomaly] should be evaluated for features 
of VCFS” (Greenberg, 1993, 806).  Indeed, with the identification of 22q11 deletions in 
patients diagnosed with each disorder, clinicians had identified yet another visible bodily 
marker shared by DiGeorge and VCF syndromes.  And, since this was a chromosomal 
marker, it was understood to have potential etiological and diagnostic implications.  By 
the mid-1990s, based on their common genomic location and aberration, DiGeorge and 
VCF syndromes were increasingly understood as being two historically distinct forms of 
one genetic syndrome. 
 
Bringing Together DiGeorge and VCF Syndrome 
 As noted at the beginning of this chapter, the association of DiGeorge and VCF 
syndrome with the same genomic location, designated by the chromosome band 22q11, is 
in many ways similar to the overlap between Prader-Willi and Angelman syndromes 
described in chapter three and elsewhere (Hogan, 2013).  In the historical case of Prader-
Willi and Angelman syndromes, clinicians immediately discounted the hypothesis that 
the two disorders were one and the same.  As I have described so far in this chapter, the 
historical trajectory of DiGeorge and VCF syndromes was quite the opposite.  Indeed, 
clinicians took the common 22q11 deletion as definitive evidence that the two disorders 
were in fact historically distinct forms of one clinical syndrome.  However, while the 
etiological sameness of these two disorders was widely accepted in the mid-1990s, 
discussions and disagreements were ongoing (and continue, as Navon and Shwed (2012) 
have recently described) concerning what to name this, now joint, disorder. 
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 One early designation came from Wilson et al (1993), who suggested the acronym 
CATCH-22 syndrome.  The name was meant to remind clinicians of the main features of 
DiGeorge and VCF syndromes: Cardiac defects, Abnormal facial features, lack of or an 
underdeveloped Thymus, Cleft palate, and Hypocalcemia (low calcium levels due to 
underdeveloped parathyroids), all associated with chromosome 22 abnormalities.  The 
authors of this paper went on to note, “We think that these conditions are all part of one 
clinical spectrum and the diagnostic label depends upon the age of presentation and the 
predominant clinical manifestation” (Wilson et al, 1993, 865).  Indeed, DiGeorge 
syndrome tended to be diagnosed primarily in infants with heart defects and immune 
deficiency, whereas VCF syndrome was most often identified in school age children with 
distinct speech anomalies and learning disabilities.  The goal of the term CATCH-22 was 
not to replace these two historical designations, but to bring them together under one 
clinical and diagnostic heading (Wilson et al, 1993).   
 Clinician Judith Hall commented at this time that the designation CATCH-22 
would prove helpful for remembering what symptoms tend to occur together with the 
22q11 deletion.  She also suggested, “CATCH 22 is a wonderful model for what is to 
come over the next 10 years of human genome work” (Hall, 1993, 802).  Indeed, Hall 
recognized that this complicated situation, in which multiple clinically defined disorders 
were found to be associated with the same genomic location and aberration, was likely to 
become increasingly common in the coming years.  Such situations would force clinical 
researchers to consider more complex explanations for why and how the same genomic 
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defect can produce a range of clinical outcomes.  This would include various gene 
interactions, environmental inputs, and epigenetic effects (Hall, 1993). 
 A collaboration of clinical geneticists from the US and Australia, including 
Driscoll and Emanuel, responded to the suggestion of CATCH-22 in a letter to the editor 
of the Journal of Medical Genetics.  These researchers pointed out that the designation 
CATCH-22 could be misleading for families, since those impacted by the 22q11 deletion 
often did not show all of the clinical features captured by the acronym.  This was 
particularly relevant in familial cases where the diagnosis of a child with a mild form of 
the disorder also served as an indicator that future siblings could be more severely 
affected.  If such a diagnosis was missed, that warning would be lost as well (Lipson et 
al, 1994).  Indeed, this problem is central to why syndrome delineation and diagnosis is 
such, “Tricky business” (Interview with Kurt Hirschhorn, January 26, 2011).  While a 
syndrome in general may be associated with a large set of outcomes, and an affected 
individual may only be impacted by some symptoms, and thus overlooked. 
Julie Leana-Cox and colleagues at the University of Maryland also opposed the 
use of ‘CATCH-22’, but for a different reason.  These clinicians saw the term as having 
negative connotations due to its association with the 1962 Joseph Heller book of the same 
name.  Similar to the instance of ‘Happy Puppet syndrome’ (described in chapter 3), 
CATCH-22 was seen as, “inappropriate for use when counseling family members” 
(Leana-Cox et al, 1996, 315).  Rather than CATCH-22 syndrome, Leana-Cox and 
colleagues supported simply combining the disorder’s two historically distinct 
designations: DiGeorge/VCF syndrome, “It calls attention to the phenotypic spectrum 
 
 
186 
using historically familiar names” (Leana-Cox et al, 1996, 315).  Still other clinicians 
during the mid-1990s suggested naming the syndrome after its common, and newly 
defining, genomic feature: the (sometimes microscopically visible) 22q11 deletion 
(McDonald-McGinn, 1997).  For their part, the Leana-Cox group liked that the name 
‘22q11 deletion syndrome’ was neutral, when compared to the pejorative ‘CATCH-22 
syndrome’.  Nonetheless, they opposed the designation because it failed to communicate 
any of the common the clinical features of the disorder (Leana-Cox et al, 1996; 
Wulfsberg et al, 1996).      
  
Just One Elephant in the Room? 
 In a second 1996 paper, also published in the American Journal of Medical 
Genetics, Leana-Cox, writing with Eric Wulfsberg and an Italian colleague, once again 
addressed the issue of naming, this time making reference to the parable of the blind men 
and elephant.  The parable, it turns out, comes up relatively often in the medical literature 
when clinicians make the argument to their colleagues that two previously distinct 
disorders should instead be thought of as one (Hirschhorn, 1975; Kassirer, 1986; Tobin; 
1987).  In this classic story, multiple blind men are asked to describe the characteristics 
of an elephant, based on touching it alone.  Each man focuses on just one portion of the 
elephant, leading one to claim that an elephant is like a wall, and another to compare it to 
a fan, and a third to think of an elephant as tree-like.  Being blind, none of the men can 
see the elephant for what it truly is, as one continuous whole.  Instead, they continuously 
argue about the elephant’s defining features, based on their own limited experience.   
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Using this parable, Leana-Cox and Wulfsberg suggested that a similar situation 
had played out over the clinical history of DiGeorge and VCF syndromes.  Due to their 
own specialties and patient populations, clinicians had defined and diagnosed the same 
syndrome in different ways, and had failed to see that each of these designations was part 
of a greater whole.  With the identification of the common 22q11 deletion in the early-
1990s however, it became clear to clinicians that DiGeorge and VCF syndromes were 
indeed two historically distinct forms of just one genetic syndrome (Wulfsberg et al, 
1996).  Driscoll later put it to me this way,  
 
I think what we realized, is that so much of genetics is based on your 
ascertainment bias [what population of patients you see] . . . you can’t 
always define syndromes based on phenotype.  We came to appreciate that 
they are so highly variable.  When we thought about DiGeorge syndrome, 
we thought immune deficiency, hypocalcaemia, and heart defects: that’s it.  
Many of these were so severe they never survived.  Whereas here [in 
patients initially diagnosed with VCF syndrome] we have this much 
milder phenotype, with mostly learning difficulties and cleft palate, and 
those were how those children were ascertained.  Maybe they had a heart 
defect.  What we realized is really they were all one and the same, and it 
was kind of an ‘a-ha’ moment that you have (Interview with Deborah 
Driscoll, November 29, 2011). 
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Indeed, this ‘a-ha’ moment was akin to a number of formerly blinded clinicians suddenly 
being made to see: the common presence of the 22q11 deletion had brought them all 
together. 
 McDonald-McGinn and colleagues at the Children’s Hospital of Philadelphia 
made a similar argument in an editorial response to the Wulfsberg and Leana-Cox paper.  
The researchers even provided their own drawn image of ‘the blind men and the 
elephant’ to make their point (Figure 9).  The depiction shows multiple clinicians, all 
focused on different portions of the same elephant, and failing to appreciate its singular 
presence.  The elephant in their drawing is also shown wearing a banner with the number 
22 on it, designating the common genomic location and aberration that ties DiGeorge and 
VCF syndromes together.  Indeed, just as Wulfsberg and Leana-Cox had argued, the 
presence of 22q11 chromosomal deletions in patients with both of these syndromes 
represented convincing evidence for clinicians that there had been just one ‘elephant’ in 
the room all along.  
  
Velo-cardio-facial as the One True Syndrome 
While clinicians widely agreed in the mid-1990s that DiGeorge and VCF 
syndrome were two historically distinct forms of one clinical syndrome, they continue, to 
the present day in fact, to disagree about what it should be called (Navon and Shwed, 
2012).  As Shprintzen (1998, 5) suggested, paraphrasing Cohen (1982, 158), “Geneticists 
would rather share their toothbrushes than their terminology.”  Indeed, Shprintzen 
remains one of the primary holdouts in the effort to agree on a common name for these 
two syndromes.  One grouping of clinicians have agreed upon 22q11 deletion syndrome, 
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while Shprintzen and others maintain that VCF syndrome, a name that Shprintzen and his 
colleagues coined in their 1978 paper, represents the most descriptive and accurate name 
for this disorder. 
 
 
Figure 9  Drawing referencing the relevance of the parable of the blind men and the 
elephant to the case of DiGeorge and VCF syndromes (McDonald-McGinn et al, 1997).  
Reprinted with permission from John Wiley & Sons, Inc. 
 
 
In a 1994 letter to the editor of the Journal of Medical Genetics, Shprintzen also 
pointed to the parable blind men and the elephant, noting that previously DiGeorge was 
primarily diagnosed in patients initially presenting with heart defects, and VCF syndrome 
in individuals with facial and palate abnormalities.  In line with other clinicians and 
researchers (Carey, 1980; Lammer and Opitz, 1986; Schinzel, 1988, Shprintzen (1994, 
1998) did not consider DiGeorge to be itself a syndrome, and instead acknowledged only 
the existence of the DiGeorge ‘sequence’.  He went on to suggest that VCF syndrome had 
 
 
190 
been associated with over 40 clinical features, and among them were those attributed to 
the DiGeorge sequence.   
As a result, according to Shprintzen (1994), DiGeorge sequence should be 
thought of as a possible outcome of VCF syndrome.  Its etiology however, was 
heterogeneous: the DiGeorge sequence had been associated with multiple chromosomal 
abnormalities.  In response to the finding of Driscoll et al (1993) that the 22q11 deletion 
was only seen in 76% of VCF syndrome cases, Shprintzen argued that any patient 
thought to have VCF syndrome, who did not have the 22q11 deletion, was clinically 
misdiagnosed.  He also noted that Scambler and colleagues identified a 22q11 deletion in 
all of the VCF syndrome patients they tested (Kelly et al, 1993).  As opposed to 
DiGeorge sequence argues Shprintzen, “There is simply no valid evidence to suggest that 
velocardiofacial syndrome is aetiologically heterogeneous” (Shprintzen, 1994, 424).  As 
Shprintzen saw it, while the DiGeorge sequence had multiple causes, VCF was the one 
‘true’ syndrome because it was always associated with the 22q11 chromosomal deletion.  
Pointing to a singular genetic etiology helped to establish the ontological status of VCF 
as a ‘syndrome’. 
In a 1998 paper titled “The Name Game,” Shprintzen further explicates his 
position, distinguishing between the meaning and medical implications of sequences and 
syndromes, and providing arguments for why ‘VCF syndrome’ remained most 
appropriate for naming the clinical disorder associated with 22q11 deletions.  First, 
Shprintzen noted that he an his colleagues, in their 1978 paper, were the first to suggest 
that VCF represented a newly delineated clinical syndrome, an argument that Angelo 
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DiGeorge had never made in his own publications during the late-1960s.  Second, no 
earlier studies of syndromes with similar features as VCF syndrome fully addressed all of 
its clinical manifestations.  Third, while the DiGeorge sequence had been found to be of 
heterogeneous origin, no other cause of VCF syndrome besides 22q11 deletions had ever 
been identified (Shprintzen, 1998).  Taken together, argued Shprintzen, the term VCF 
syndrome had priority of in terms of timing, clinical scope, and etiological clarity. 
Shprintzen has since presented still more arguments for the designation VCF 
syndrome.  In a 2008 history of VCF syndrome, he noted that his chosen name is, 
“descriptive, geographically nonspecific, free of eponyms, and much easier to write and 
say than 22q11.2 deletion syndrome” (Shprintzen and Golding-Kushner, 2008, 16).36  
Shprintzen also notes in the same paragraph that most other syndromes associated with 
such genomic abnormalities are not named after their chromosomal designations.  In a 
second 2008 publication, Shprintzen noted, “VCFS is simply easier to say and write and 
communicate than any other labels and its use should therefore be encouraged” 
(Shprintzen, 2008, 4).  Shprintzen’s arguments for his chosen name therefore extend 
beyond issues of priority, to a consideration of communicative simplicity. 
Clearly the name VCF syndrome is important to Shprintzen in a way that 
DiGeorge syndrome never was to the clinician after whom it was named.  While 
Shprintzen has dedicated his career to VCF syndrome research, Angelo DiGeorge rather 
quickly moved on to other interests.  Shprintzen has published regularly on VCF 
syndrome, especially after it became associated with 22q11 in the early-1990s.  
                                                 
36 22q11.2 represents an additional level of cytogenetic specificity made possible by 
high-resolution analysis. 
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DiGeorge, on the other hand, who died in 2008, did not publish on DiGeorge syndrome 
again after 1969, though he did remain interested in keeping up with ongoing research 
concerning the disorder (Interview with Beverly Emanuel, November 9, 2011).  Indeed, 
Shprintzen’s professional identity is much more closely tied to VCF syndrome, the 
disorder he named in 1979, than DiGeorge’s ever was in the disorder named after him.      
Perhaps as a result, to this day, VCF syndrome advocates maintain their own 
website, hold separate annual research conferences, and have a specific research institute, 
the Velo-Cardio-Facial International Center located at the State University of New 
York’s Upstate Medical University in Syracuse.  At the same time, the 22q11.2 Deletion 
Syndrome Foundation also has its own website, annual conferences, and institutions, such 
as the 22q Center located in the Children’s Hospital of Philadelphia.  The 22q foundation 
has an ongoing “Same Name Campaign” aimed at bringing together patients, families, 
advocates, and clinicians impacted by or interested these historically distinct syndromes, 
under one name (Interview with Donna McDonald-McGinn, November 10, 2011).   
I have no interest in taking a side in this debate.  However, I do think that this 
ongoing difference of opinion over naming demonstrates that the identification of a 
common genomic location, in some cases, does not provide sufficient force to meld 
together the existing social networks and institutions built around two historically distinct 
syndromes.  For the remainder of this chapter, I will refer to this disorder as 
DiGeorge/VCF syndrome, a name that captures its historical duality, but one that 
proponents from both the Velo-Cardio-Facial International Center and 22q11.2 Deletion 
Syndrome Foundation would likely oppose. 
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A Gene for DiGeorge/VCF Syndrome? 
Just like most cases of Prader-Willi and Angelman syndrome, DiGeorge/VCF 
syndrome is associated with the deletion of genetic material, specifically from 
chromosome 22.  Since humans have two copies of chromosome 22, the genes deleted in 
the 22q11 region among DiGeorge/VCF patients continue to exist on the non-deleted 
copy of the chromosome.  Unlike Prader-Willi and Angelman syndromes however, the 
deleted region of 22q11 is not affected by genetic imprinting in any way: all genes in this 
region are believed to be functional on the remaining single copy present in 
DiGeorge/VCF syndrome patients with the deletion (Driscoll et al, 1992).  Over 35 genes 
are present within the genomic area that is most frequently deleted in DiGeorge/VCF 
patients (Kobrynski and Sullivan, 2007).  One of more of these genes may play a role in 
the clinical expression of the disorder when a copy of it is lost due to a 22q11 deletion.  
During the late 1990s, a number of ‘candidate genes’ were identified in the 22q11 
region, which could be associated with the DiGeorge/VCF syndrome etiology (Budarf 
and Emanuel, 1997; Lindsay and Baldini, 1998).  Based on studies in mice, in which 
targeted segments of the 22q11 region were deleted, Elizabeth Lindsay of the Baylor 
College of Medicine, along with American and British colleagues, highlighted the gene 
Tbx1 in 2001 (Lindsay et al, 2001).  Researchers from Columbia University in New York 
also published on Tbx1 the same month (Jerome et al, 2001).  The loss of Tbx1 in mice 
seemed to cause heart abnormalities, suggesting that it might also play a significant role 
in the clinical outcomes of DiGeorge/VCF patients.  Researchers continued to believe 
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however, that Tbx1 alone probably is not entirely responsible for the wide-ranging 
clinical expression of this disorder (Kobrynski and Sullivan, 2007).   
Others have similarly suggested that the clinical expression of DiGeorge/VCF 
syndrome is too variable for it to be explained by one gene mutation alone (Schinke and 
Izumo, 2001).  In 2003, Hisato Yagi and colleagues in Japan reported in the Lancet on 
five patients diagnosed with DiGeorge/VCF syndrome who did not have a 22q11 
deletion, but did have a mutation specific to the Tbx1 gene.  The clinical expression of 
these patients remained variable, but most showed the major features of this disorder, 
including distinctive heart, thymus, parathyroid, palate, and facial abnormalities.  These 
patients however, did not show the mild intellectual disability normally associated with 
the disorder.  The authors of this paper also proposed that the variability of expression 
among the five patients they studied suggested that additional environmental and 
developmental factors likely influence clinical outcomes (Yagi et al, 2003).  
Indeed, going back to the mid-1990s, clinicians and geneticists have been aware 
that individuals with the same exact 22q11 deletion can have quite variant clinical 
outcomes.  This has been made particularly apparent by the identification of identical 
twins with widely variable expression of DiGeorge/VCF syndrome.  For instance, in 
1995 Goodship, Scambler, and colleagues reported on twins who had the same 22q11 
deletion, and showed some similar features of this disorder.  However, only one twin had 
the heart defect characteristics of DiGeorge/VCF syndrome (Goodship et al, 1995).  In 
1998, Yamagishi and colleagues in Japan reported a similar case.  In this instance, the 
identical twins both had the same 22q11 deletion, and each showed the distinct facial 
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features of the DiGeorge/VCF syndrome, but only one twin expressed other clinical 
indicators of the disorder, including a heart defect (Yamagishi et al, 1998).  As clinical 
geneticist Eli Hatchwell noted in a letter to the editor responding the report by Goodship 
et al (1995), a number of genetic mechanisms might lead to such an outcome.  For 
instance, the deletion of 22q11 from one chromosome may uncover recessive mutations 
present on the other copy of 22q11.  It is also possible that a second abnormality, 
somewhere else in the genome, may represent a ‘second hit’ facilitating certain clinical 
outcomes (Hatchwell, 1996).   
 As Emanuel has described to me, there are a number of factors, such as the 
genomic background and chance events embryonic during development that may impact 
clinical outcomes.  In addition, she noted that, “We don’t know for example, and we’re 
trying to pick away at it: what about the non-deleted allele?  There are some 40 genes 
there.  Are there particular forms of those genes that affect whether you do or you don’t 
develop a heart defect or neuropsychiatric behavior differences, etc” (Interview with 
Beverly Emanuel, November 9, 2011).  Emanuel is pointing here to the same issue that 
Hatchwell did previously: when an individual only has one copy of a particular gene 
because of a deletion, there is always the possibility that a mutation may be uncovered on 
the remaining chromosomal copy that will influence clinical outcomes.  This also ties 
back in with the ongoing discussion over the extent to which DiGeorge/VCF syndrome is 
a ‘contiguous gene syndrome’: one in which a variety of impacted genes in one particular 
genomic region, 22q11, contribute to clinical expression.   
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While Tbx1 appears to play an important role in causing this disorder, it seems 
likely that other genes in this region are significant in at least some cases.  Researchers 
generally agree that the size of the 22q11 deletion does not correlate with the severity of 
clinical outcomes (Carlson et al, 1990), but this does not discount the possibility that 
larger deletions at least increase the probability that other mutant gene effects could arise.  
Indeed, despite its association with the 22q11 deletion, DiGeorge/VCF syndrome 
continues to pose significant challenges when it comes to clinical, and in particular 
prenatal, diagnosis.  In at least 10-15% of cases, children inherit the 22q11 deletion from 
one of their parents (in most cases the deletion occurs de novo during the reproductive 
process).  Most of the parents passing down the mutation have had such mild effects that 
they were never diagnosed themselves, and did not need any clinical interventions.  If 
they possess the deletion, a parent has a 50% chance of passing it on to each additional 
child they have.  The severity of its clinical impact however, remains impossible to 
predict (Driscoll, 2001).   
Indeed, there is no way to know another fetus found prenatally to have the 22q11 
deletion will be more severely affected than their existing sibling, have an almost entirely 
normal life like their previously undiagnosed parent, or fall somewhere in between.  This 
continued uncertainty greatly complicates the diagnostic process.  As Emanuel put it to 
me,  
 
We have a lot to learn.  The good news is that we understand a fair amount 
of the syndrome, i.e. we know it’s due to the deletion.  But the good news 
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from the scientific perspective is that there are still many, many questions 
to ask in answer.   And you can look at it from the reverse, the bad news is 
that we don’t know the answer, but the good news is that someone is 
interested in finding the answers (Interview with Beverly Emanuel, 
November 9, 2011).   
 
Indeed, while clinicians face many challenges when it comes to offering reliable and 
reproducible diagnoses, this uncertainty continues to offer researchers with interesting 
and potentially valuable questions and opportunities.  Variations of the 22q11 deletion 
and genomic region found in patients diagnosed with DiGeorge/VCF syndrome, or not, 
offer additional opportunities to identify new genomic mutations and interactions that 
play a central role in the clinical expression of this disorder, as well as in human disease 
and biology more broadly. 
 
Conclusion 
 In this chapter, I explore the clinical and laboratory history of two previously 
distinct disorders that have since come to be understood as one.  As I demonstrate here, 
the ‘look’ of a particular clinical disease may be impacted by a variety of genetic, social, 
and institutional factors.  Historical distinctions between DiGeorge and VCF syndrome 
seem to have resulted from the different medical specializations, and related patient 
populations, of those who first described the disorder.  Angelo DiGeorge identified the 
syndrome, later named after him, based on his experience with severely impacted 
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newborns at a children’s hospital, while Robert Shprintzen primarily saw school-aged 
patients who were brought to his clinic due to their speech and palate abnormalities.  
Indeed, before the two disorders were linked, the natural history of DiGeorge syndrome 
was widely assumed to end by age two, and that of VCF syndrome largely seemed to go 
unnoticed until age four or five. 
 Though the identification of the 22q11 deletion in both subsets of patients 
represented an important turning point in the history of DiGeorge/VCF syndrome, it was 
certainly not the first indication that these disorders were somehow linked.  The openness 
to identifying a wide array of potential symptoms associated with VCF syndrome led the 
Shprintzen group to notice the impact of immune system abnormalities in their patients, 
and link this to existing accounts of DiGeorge patients.  Based on this recognition, when 
a genomic deletion was found in most individuals diagnosed with DiGeorge syndrome in 
1992, it seemed an obvious next step to also look for it in patients who showed signs of 
VCF syndrome, even if they were not previously diagnosed with this disorder.  
Ultimately, the 22q11 deletion was pointed to, by way of the parable of the blind men and 
the elephant, as proof that when it came to differentially diagnosing DiGeorge and VCF 
syndromes, there had always in fact been just one ‘elephant’ in the room.  
 The nosological status of the clinical disorder Angelo DiGeorge first identified – 
‘syndrome’ or ‘sequence’ – has remained a point of contention.  However, following the 
introduction of laboratory testing for the 22q11, it has been clearly established that 
individuals who have the ‘look’ described by DiGeorge, as well as this genomic 
aberration, are affected by a distinct syndrome.  Indeed, while the clinical attributes of 
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DiGeorge/VCF syndrome in an individual, or their child, remains the primary indication 
for genetic testing, the genomic deletion itself has become so central to the diagnosis of 
this disease that its absence would almost certainly overturn a clinical diagnosis.   
As Shprintzen has argued, if the 22q11 deletion is not present in a patient, then 
the clinical diagnosis of VCF syndrome was almost certainly incorrect (Shprintzen, 1994, 
1998).  And similarly, as McDonald-McGinn has told me, “It’s the 22q, the only thing 
that everyone has in common is that deletion.  Even if it’s a smaller deletion it’s the same 
thing” (Interview with Donna McDonald-McGinn, November 10, 2011).  The move 
towards a more universal use of ‘22q11 deletion syndrome’ instead of DiGeorge and 
VCF, only further re-enforces the clinical boundaries of this category.  At least in terms 
of diagnosis, this genomic finding, of a 22q11 deletion, now seems to be privileged in the 
clinic over bodily expression. 
   This said, while clinicians and researchers have agreed for 15 years now that 
DiGeorge and VCF syndrome are the same clinical disorder, a universally agreed about 
upon name for this disease has not been reached.  In this chapter, I have noted the various 
institutional and professional reasons why a common name is so difficult to establish.  
Organizations have been created, research dollars spent, and careers built around the 
historical names of these clinical disorders.  The identification of a common genomic 
abnormality may have quickly impacted how individuals are diagnosed with this 
disorder, but it has failed to so rapidly alter how the clinicians, researchers, patients, and 
families interested in and affected by DiGeorge/VCF syndrome identify themselves and 
promote their causes.  Indeed, in merely attempting to refer to this syndrome in my own 
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scholarly analysis of it, I cannot help but make myself subject to the politics that swirl 
around it.  
 The outcome of the instance of genomic overlap discussed in this chapter may 
appear on its surface to have been more easily and simply resolved than in the case of 
Prader-Willi and Angelman syndromes.  My goal in this chapter however, has been to 
demonstrate the various complications that remain when two disorders become one.  
Beyond just institutional and professional debates, the association of DiGeorge and VCF 
syndromes with the 22q11 deletion has also done little to explain or predict the great 
clinical variability of this disorder.  While it is easy to diagnose DiGeorge/VCF syndrome 
prenatally, or during early childhood, it is impossible to predict how the disorder will 
ultimately be expressed. 
 During the 1980s, many hoped that the association of DiGeorge syndrome with 
aberrations at the genomic address 22q11 would lead to the identification of a single 
mutant gene for this disorder.  However, as recognition of the clinical variability of this 
syndrome increased, particularly following its genomic link with VCF syndrome, many 
researchers began to assume that one gene alone could not explain the complicated ‘look’ 
of this disorder in the clinic.  A number of theories since have been applied to explaining 
the variable expression of DiGeorge/VCF syndrome, including the idea that it is a 
‘contiguous gene syndrome’, and the related concept that the 22q11 deletion unmasks 
mutant genes in some patients.   
 While clinical diagnosis would certainly benefit from the resolution of some of 
these uncertainties, their genomic implications do continue to drive valuable research in 
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human and medical genetics.  The concept that this disorder could be explained by one-
to-one correlations between gene mutations and clinical outcomes has now been largely 
overshadowed by the recognition of multiple-dimensional genomic functionality in this 
and other disorders.  However, we should not discount the continued importance of the 
chromosomally defined genomic region 22q11 over the past 30 years, and in the present 
day understanding of DiGeorge/VCF syndrome.  While the mechanism of this disease is 
complex and unclear, the 22q11 deletion remains an important visual genomic, and 
anatomical, marker of this disorder, which has undoubtedly improved the diagnosis, 
understanding, and significance of it in the laboratory and the clinic. 
 Indeed, the ‘look’ of this disorder is very much rooted in the types of visual 
evidence that clinicians and researchers choose to highlight and give epistemic priority.  
These standards are established and reinforced by the collective ways in which these 
biomedical professionals learn and agree to see their objects of study.  These research 
objects have taken various forms in postwar biomedicine, including the clinically 
presented body, and microscopically visible human chromosome set.  As this chapter 
described, the established ‘look’ of a disease may vary among different institutions, 
medical specializations, and over time as new evidence is introduced and re-conceived as 
being increasingly important and reliable.  
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CHAPTER 5 
The Lasting Impacts of Chromosome Level Thinking and Analysis 
 
 
In 2011, during the early days of my dissertation research, I interviewed Beverly 
Emanuel, a medical genetics researcher at the University of Pennsylvania and Children’s 
Hospital of Pennsylvania.  As our conversation was drawing to a close (and after I had 
already turned off my tape recorder), Emanuel was reflecting on her career, which has 
largely been defined by her research focus on a particular sub-region on the long arm of 
chromosome 22.  As Emanuel mused, she held her thumb and 1st finger about a 
centimeter apart and spoke of how amazing it was that something so small could be the 
focus of an entire (quite productive and rewarding) career.  Now, she knew as well as I 
did that the genomic region she works on is much smaller than the space between her 
fingers; in fact, it is almost imperceptibly small.  That bit of space between her fingers 
however, was real to her in terms of how she understood chromosome 22 in her head.  
Visualized as an ideogram, the chromosome was a tangible entity, maybe a few inches in 
length.  Small portions of this chromosome have been the focus of many a life’s work. 
Most of the genomic entities and processes that Emanuel and thousands of other 
postwar medical geneticists dedicated their lives to studying were too small to ever be 
directly seen.  However, as this dissertation has sought to demonstrate, the work objects 
of these researchers were far from invisible to them.  In line with generations of 
biomedical researchers before then, these individuals relied on painstaking observation, 
and standardized ways of seeing and communicating, in practicing their trade.  Nicholas 
Rose (2007, p. 12) and others (Clarke et al, 2010) have suggested that a new “style of 
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thought” (Fleck, 1979), the “molecular gaze” has “supplemented, if not supplanted” the 
longstanding centrality of the ‘clinical gaze’ in biomedicine.  In this dissertation however, 
I demonstrate that an increasing focus on the ‘genomic basis’ of disease has not undercut 
the centrality of observational approaches in genetics in biomedicine.  Rather, I suggest 
that the postwar period is perhaps best defined by the rise of a ‘genomic gaze’, which 
integrates molecular understandings of disease with visible and tangible genomic markers 
and conventions. 
What is the point of retaining chromosome level conceptions and depictions of the 
human genome in an era when clinicians and researchers have a complete DNA reference 
sequence at their fingertips?  Why has an ‘antique’ nomenclature developed in the 1970s 
for the visual description of chromosomes remained a prominent set of landmarks in the 
post-Human Genome Era?  The answers to these questions are particularly perplexing 
when one considers that chromosomal banding nomenclature and genomic sequence data 
are incommensurable languages: banding boundaries can, at best, be located within a 
100,000 DNA base pair range (Interview with David Haussler, February 29, 2012).  In 
this chapter, I examine the forces and considerations that have helped to maintain the 
importance of chromosome level thinking and nomenclature, and reflect on why older 
languages of description based on chromosomal analysis remain intact in the face of 
newer, more exacting options.  Following this, I offer a series of broader conclusions that 
tie together the various case studies examined in this disseration.  
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From Sequencing to Browsing 
The official announcement of the completion of a rough draft of the human 
genome took place on June 26th 2000 at the White House.  The draft DNA sequence itself 
however, was not made publically available until over a week later on July 7th, when the 
genome was for the first time posted on the Internet by the University of Santa Cruz 
Genome Bioinformatics Group.  As David Haussler put it to me, “that was the day that 
the world got the first glimpse of the human genome”.  On that day however, the draft 
was little more than 2.7 billion letters, “It was nothing more than a waterfall of As, Ts, 
Cs, and Gs.  So you had people counting how many times GATTACA appeared in it, or 
looking for secret biblical messages . . . it was something you could use for wallpaper” 
(Interview with David Haussler, February 29, 2012).       
In order to make the human genome sequence more accessible to the thousands of 
clinicians and geneticists who expected to be begin using it for diagnosis and research, 
multiple genome ‘browsers’ were built during the second half of 2000.  This included the 
Map Viewer, created by the National Center for Biotechnology Information (NCBI) at 
the NIH campus, the Ensembl Genome Browser, sponsored by the Wellcome Trust 
Sanger Institute and the European Molecular Biology Laboratory (EMBL), and the 
University of California, Santa Cruz (UCSC) Genome Browser (Wolfsberg et al, 2002).  
These browsers served as portals to the raw human genome sequence data, and provided 
the online software and annotations necessary to make the information useful to those 
who accessed it.  As Haussler put it, in reference to the online release of the initial human 
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genome draft in July 2000, “In terms of usefulness it wasn’t until this browser was built 
that people could actually use it” ((Interview with David Haussler, February 29, 2012). 
The UCSC Genome Browser and others, made analyzing the human genome a lot 
like browsing a bookshelf.  These data portals offered a top down view of the genome, 
with the human chromosome set as the primary unit of analysis.  One can jump straight to 
a particular gene or genome region, or begin with a specific chromosome and zoom-in 
from there.  When I began my interview with Haussler at UCSC, he immediately asked 
me for my favorite gene, so that he could search for it in the Genome Browser.  I picked 
SNRPN, a gene associated with Prader-Willi syndrome.  Haussler typed this into the 
search mechanism, and the browser immediately brought us to a region near the 
centromere on the long arm of chromosome 15.   
The UCSC genome browser has a horizontal orientation, with a series of 
customizable data tracks appearing on the screen.  In its default mode, one is shown the 
nucleotide number of the region in question (the DNA nucleotides on each chromosome 
are numbered from 1 into the hundreds of millions, beginning at the farthest point from 
the centromere on the short arm).  Below this, the expanse of the gene and its coding 
regions are shown, and continuing downward a number of additional data tacks are 
shown, including the sequence homologies with a number of other organisms.  Above all 
of this information, featured prominently at the top of the page is a banded ideogram of 
the chromosome being explored: in the case of SNRPN this was chromosome 15.  A red 
box (or line depending on how zoomed in the tracks are) shows the location and extent of 
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chromosome 15 being viewed.  SNRPN falls into the chromosomal band 15q11.2, and 
appears to be quite close to the boundary with the next visible band, 15q12 (Figure 10). 
 
   
Figure 10  Output impage from the UCSC Genome Browser, showing the prominient 
position of a chromosome 15 ideogram above all other genetic tracks.  "The UCSC 
Genome Browser, http://genome.ucsc.edu", Human genome assembly Feb. 2009. 
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Chromosomal ideograms have a similarly prominent position in the other major 
genome browsers.  In Ensembl, one begins with a vertically oriented view of all 24 
human chromosomes, the “whole genome”, and from here can click on a particular band, 
or drag the cursor and select a larger region of one chromosome.  From here, Ensembl 
offers a similar experience as the UCSC Browser, with a horizontal ideogram of the 
chromosome being examined above and a series of data tracks below.  The NCBI Map 
Viewer also has a number of common experiential features.  For instance, one begins by 
choosing a chromosome from a vertical depiction of 24 unbanded chromosomes.  The 
interface is noticeably different at the chromosome level however, because it is vertically 
oriented, with a chromosomal ideogram on the far left, and a series of data tracks to the 
right.  The NCBI depiction of chromosomes is more in line with early genomic 
representations, which depict chromosomes vertically with their short arm on top.  In the 
era of widescreen computers however, horizontal depictions of ideograms may become 
more standard. 
Initially, UCSC and NCBI provided their own, slightly different assemblies of the 
human genome.  However, it was quickly decided that for clarity, there should be one 
reference genome sequence shared by all browsers, for which the NCBI assembly was 
chosen (Wolfsberg et al, 2002).  Each browser continues to have its own annotational and 
organizational strengths.  The Ensembl browser specializes in highlighting protein 
structure and function, while the UCSC Browser is more focused on the genetic code 
itself.  Human geneticists therefore often go to the USCS browser first, and then jump 
into the Ensembl browser for protein analysis (Interview with David Haussler, February 
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29, 2012).  The NCBI Map Viewer is particularly closely integrated with OMIM, and 
tends to highlight genes and their chromosomal positions.   
The official publication of the draft genome sequence came in issues of Science 
and Nature in February 2001.  By agreement, papers concerning the results from the 
publically funded Human Genome Project appeared in Nature, and those from Craig 
Venter’s competing private venture, which also finished its draft in June 2000, were 
published in Science.  The primary collaborative paper from the public project in Nature 
highlighted the newly constructed UCSC and Ensembl genome browsers (Lander et al, 
2001).  Published along side a series of related papers on different aspects of the genome 
project and its preliminary results, was a foldout map depicting the genome at the level of 
chromosomes.  A vertical, microscopic image of each chromosome was placed next to a 
series of horizontal data tracks.  Similar to the genome browsers, these tracks broke down 
each chromosome into cytogenetic banding units and nucleotide base pair distances.  
Known genes were also listed along each chromosome. 
When I walked into his office at UCSC, Haussler had the Nature foldout 
displayed prominently on his wall.  I asked why the contributors to the Human Genome 
Project’s primary publication decided to plot the large mass of information that they had 
sequenced and compiled in this very visibly oriented format.  Haussler responded,  
 
People needed to have something tangible, they wanted a fold out.  It was 
a monumental achievement, so you wanted something you could 
physically touch and look at to get an idea of the scope of the work.  
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Previously you would publish a paper in Nature based on five years work 
of locating one of those genes, and Figure 1 would be the chromosomal 
ideogram and your location of your gene.  And that was an incredible 
achievement, and I think this made a statement of, wow, look at the scale, 
all at once, all those genes (Interview with David Haussler, February 29, 
2012).  
 
Having spent a decade sequencing and assembling the entire human genome, it remained 
the case that the best way to capture and make apparent the broad implications of this 
great accomplishment was to visually depict it a much lower level of resolution.  Even on 
this poster sized, foldout figure, each linear inch represented 10 million DNA base pairs.  
In this sense, the figure certainly conveyed the immensity of the data set that had been 
obtained.   
 This foldout published along with the initial Human Genome Project publications 
in early-2001 is representative of continuity of conceptions about the genome before and 
after the completion of a draft sequence.  Clinician and research understandings of the 
genome as a visible, tangible entity did not immediately fade away or become irrelevant.  
Rather, they remained central to the thinking and practices of post-HGP era genetics and 
biomedicine.  In the next section, I trace this continuity more extensively through my 
interviews with geneticists. 
 
Cytogenetic Thinking and Analysis in the Era of Whole Genome Sequencing 
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 One of the publications found in Nature along side the initial paper on the 
completed human genome draft sequence, reported on a large project to integrate 
cytogenetic landmarks into the genomic DNA sequence (Cheung et al, 2001).  7600 
probes had been utilized in an attempt to correlate the chromosomal banding 
nomenclature with the draft sequence of the human genome.  Each probe was 
fluorescently tagged, and under the microscope, which chromosome and band it annealed 
with noted, along with the relative ordering of each probe.  The probes were associated 
with specific genomic fragments, and so their location in the draft sequence was also 
known.  The goal of all this was to correlate two existing physical maps of the genome: 
one based on observational analysis of the human chromosome set going back to the 
1970s, and the newly completed draft DNA sequence.   
To improve the accuracy of the genome browsers, researchers wanted to know 
where boundary lines should be drawn between each consecutive chromosomal band 
within the genome sequence.  Realistically, these data sets are incommensurable.  Asked 
how closely the banding boundaries could be associated with the reference sequence, 
Haussler told me that the estimations were within, “100,000 bases at best, and that’s 
assuming fairly dense mapping, in the optimum conditions.  In sparse places, it is a 
million bases” (Interview with David Haussler, February 29, 2012).  Indeed, where one 
chromosomally visible band ends and another begins primarily has to do with the 
physical compaction of chromosomes, a process that is only indirectly related to the DNA 
codes itself (areas with fewer genes tend to be less compacted and appear as lighter G-
bands). 
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Knowing the approximate correlation between chromosomally visible bands and 
the genomic code is of value in part for research purposes.  As Cheung et al (2001, p. 
954) put it in their 2001 report, “To proceed from cytogenetic observation to gene 
discovery and mechanistic explanation, scientists will need access to a resource of 
experimental reagents that effectively integrates the cytogenetic and sequence maps of 
the human genome”.  Often times, as is described throughout this dissertation, the first 
indicator of the genomic location of a disease etiology comes from the identification of a 
chromosomal abnormality in a number of similarly affected individuals.  A better 
correlation between chromosomal band and genomic sequence location can help to target 
the search for genes in that region, potentially involved in the disorder.  In a similar study 
reported in 2003, and based on 9000 probes, UCSC postdoctoral researcher Terrence 
Furey made a similar argument about the importance of linking the chromosomal banding 
and genomic sequence maps, “The integration of the cytogenetic map with this draft 
sequence provides cytogeneticists with the necessary link to this molecular-based 
resource.  Given a chromosomal abnormality in a diseased cell where the affected region 
has been cytogenetically mapped, the corresponding area in the draft sequence can be 
easily determined, and then investigated for potential disease genes” (Furey and Haussler, 
2003, p. 1037).   
In practice however, correlating the cytogenetic banding map to the draft human 
genome sequence was about more than helping to target the molecular search for new 
disease genes.  From a conceptual perspective, the chromosomal banding map offer 
clinicians and researchers a way to find themselves in the genome, and to communicate 
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genomic locations to their patients and colleagues.  As medical geneticist David 
Ledbetter has put it to me, “It’s hard to talk about a gene using genome sequence 
coordinates, because how do you visualize that, how do you wrap your brain around 
genome sequence coordinates?” (Interview with David Ledbetter, March 21, 2012).  Here 
Ledbetter is referring to the system by which each nucleotide in the human genome 
reference sequence is numbered on each chromosome from 1 into the hundreds of 
millions.  So, for instance, one can refer the gene SNRPN as being located on 
chromosome 15 between the nucleotide coordinates 25,217,650 and 25,224,945, or as 
being with the visible band labelled 15q11.2.  The first method is more exacting 
quantitatively, but it does not give one a sense of where they are in the genome or on 
chromosome 15.  
Many other clinicians and geneticists have offered similar accounts of how their 
conceptions of the genome remain grounded in the human chromosome set.  As medical 
geneticist Beverly Emanuel put it, 
 
If you go to any of the sequence websites, like the [UCSC] Genome 
Browser, and you focus in, there is an ideogram that is still there . . . 
because for so long we have used that information in that way, and it does 
help to put that in a perspective, as opposed to a long string of numbers.  A 
long string of numbers, from 17 to 20 million, doesn’t necessarily put you 
into a visual of where in the genome it is (Interview with Beverly 
Emanuel, November 9, 2011). 
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Chromosome bands offer a better sense of location and nucleotide numbers do.  In 
addition, banding nomenclature locations also help to historicize a disorder and its 
genomic association.  Medical geneticist Kurt Hirschhorn described the important of 
chromosomal context to me in this way, once again referencing the UCSC Genome 
Browser, “Some of this is historical, a number of difficulties have been described by 
virtue of a chromosome and a position in a chromosome.  So, if you want to understand 
what the background of the whole thing is, you really need to see the chromosome.  And 
I think they have done a very good job of that at Santa Cruz” (Interview with Kurt 
Hirschhorn, January 26, 2012).     
 Chromosomal locations are also more useful than genomic coordinates when 
communicating with patients.  As medical geneticist Uta Francke noted to me, “It’s hard 
to visualize just DNA . . . if you talk to parents, or people who are affected with a 
chromosomal imbalance, it helps a lot to show them a picture of a chromosome, and say 
look, this is the piece that is now translocated.  It gives them some coordinate numbers” 
(Interview with Uta Francke, February 27, 2012).  Indeed, it is much easier to offer 
patients a visual representation of a genomic abnormality than a sequence level, 
quantitative account.  Deborah Driscoll offered a similar narrative of how she uses 
chromosome level explanations to counsel patients, 
 
We have come a long way [with molecular genetics], and I think it has 
really changed the way we can counsel families, but visually you still 
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think of a chromosome.  It is kind of where the DNA lives, the genes live, 
so that’s how I think of it.  When I talk to patients, I talk about 
chromosomes, and then what I try to do is explain to them what is a gene 
(Interview with Deborah Driscoll, November 29, 2011). 
    
Along similar lines, many of the clinicians and geneticists I interviewed told me 
that those who work with the human genome have a communal sense of its geography 
based on the chromosomal banding nomenclature initially developed in the 1970s.  
Indeed, one cannot know the entire genome at the level of resolution that the DNA 
reference sequence provides.  But geneticists are quite used to visualizing the genome 
under the microscope as a karyotype.  Referring to Victor McKusick’s ‘morbid anatomy’ 
of the human genome, Reed Pyertiz suggested to me, “I think if you had psychoanalyzed 
people back then and tried to get them to express what image flashed in their mind when 
they thought of the genome that [McKusick’s chromosome level gene and disease maps] 
would be it . . . I still have tucked away the notion of the karyotype . . . but now I think of 
a cloud, it’s just a mass of data” (Interview with Reed Pyeritz, April 18, 2012).  Indeed, 
even in the era of whole genome sequencing, it is difficult for geneticists to conceive of 
the human genome without referring back to the chromosomes.  
 While the human genome reference sequence is an impossibly large and repetitive 
data set, chromosomal nomenclature offers researchers and clinicians with a satisfying 
sense of place.  Medical geneticist Dorothy Warburton has suggested to me that she 
thinks of the genome as a familiar neighborhood, full of landmarks that make navigating 
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it easy and intuitive.  To remove these landmarks, and replace them only with 
consecutive numbering she told me, is to take away the native elements that make a 
neighborhood recognizable Interview with Dorothy Warburton, May 11, 2011).  
Ledbetter expressed a similar feeling that chromosomal locations offer him a sense of 
place and context,  
 
If I am in a seminar or talking with somebody and they start talking about 
a gene, the first question I ask is, what chromosome is it on, where does it 
live?  And, it is sort of like saying, where are you from?  Just the 
geography of where somebody lives or comes from just helps you . . . If a 
gene is on chromosome 18 or it is on chromosome 16, I’m not really 
asking because I want to know what the individual gene neighbors are.  I 
just can’t imagine a gene without thinking where it is in the genome 
(Interview with David Ledbetter, March 21, 2012).  
 
As Ledbetter went on to explain, there really is not an explicit functional purpose for 
knowing on which chromosome a gene is located.  Indeed, genomic proximity does not 
suggest that there is a functional relationship or interaction among gene functions or 
products.   
 Knowing where a gene is located in the human genome however, may offer 
context more generally about what other genetic entities or regulatory elements are in the 
area, which could be relevant in cases involving chromosomal aberration or genomic 
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imprinting (as in the instance of Prader-Willi and Angelman syndrome).  In this sense, 
chromosomal banding offers a set of signposts that may help to guide one through the 
genome.  As Robert Nicholls put it in our interview, “for me the chromosome correlation 
is a guidepost as to the underlying genes or regulatory sequences” (Phone Interview with 
Robert Nicholls, April 5, 2012).  Driscoll similarly referred to cytogenetic banding 
nomenclature as “the signposts along the genome” (Interview with Deborah Driscoll, 
November 29, 2011).  In fact, the genome offers many useful signposts (expressed 
sequence tags, ESTs, and restriction enzyme sites have been used in this way).  However, 
chromosomal ideograms offer a broadly shared, visual language for describing the human 
genome, which is known to geneticists worldwide, thereby making it highly useful for 
positional communication. 
 Indeed, while the human genome may in many ways be an expansive cloud of 
data, as Pyeritz described it to me, in the post-HGP era, clinicians and geneticists 
continue to rely on familiar landmarks and low-resolution chromosomal representations 
of the human genome as they communicate about and interact with it.  Chromosomal 
ideograms offer a tangible landscape within which clinicians and geneticists situate and 
contextualize their research, and offer a useful visual referent as they counsel patients on 
the genomic basis of a particular disorder.  While genetic analysis now regularly takes 
place at the level of DNA sequence analysis, chromosomal level thinking and 
representation continue to be an important starting point for conversation.     
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Concluding Remarks 
 This dissertation is a contribution to the ongoing observational turn in the history 
of postwar genetics and biomedicine.  In recent years, scholars have made significant 
contributions to our understandings of the visual practices of human and medical 
geneticists since the 1950s (Martin, 2004; Lindee, 2005; de Chadarevian, 2010; 
Santesmases, 2010).  As part of this, historians of science have sought to better 
understand how the human genetic complement and chromosome set have been seen and 
standardized as a scientific object by genetics researchers.  To this body of literature, I 
add a historical analysis of evolving conceptions and depictions of the human genome 
since the 1960s, an entity that has become increasingly central to the thinking, practices, 
and promotion of biomedical research over the past 30 years. 
 Each of the case studies presented in this dissertation seek to capture the 
development of a new nosolgical and diagnostic system in postwar biomedicine, in which 
clinical disorders have come to be understood as having a genomic basis.  As I describe, 
the visible chromosomal markers associated with each of these disorders played a central 
role during the 1970s, 80s, and 90s in shaping their clinical delineation, diagnosis, 
understanding, and treatment.  These visible genomic markers, specifically the fragile X 
site, 15q11-13, and 22q11 deletions, have served as an influential basis for delineating 
and naming a new disorder, identifying a relationship between two diseases that were 
otherwise clinically distinct, and ontologically (though not institutionally) unifying two 
previously separate syndromes into one.   
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 As these case studies are meant to demonstrate, the ideal of one-to-one 
correlations between genetic mutations and diseases was often complicated during the 
postwar period by the unanticipated and confusing behavior of visible chromosomal 
markers.  While a source of frustration for many clinicians and patients, such ambiguous 
findings attracted the attention of many more basic genetics researchers.  Indeed, 
chromosomal analysis proved to be a very productive experimental system for human 
geneticists throughout the postwar period.  As I describe, sustained observational analysis 
of chromosomes in patients impacted by various genetic disorders led to new, more 
complex, understandings of genomic functionality in the decades before the completion 
of the Human Genome Project.  Far from a one-dimensional dataset, chromosomal 
analysis offered a window into the multi-level functionality of the genome. 
 Many of the disorders examined in this dissertation represented important (and 
sometimes short-lived) exemplars of particular forms of genomic disease in the postwar 
period.  For example, Fragile X and Prader-Willi syndrome have long been, and remain, 
important teaching cases in human genetics and biomedicine.  The deletion of the 
chromosomal region 15q11-13 was pointed to throughout the early-1980s as 
representative of how the loss of specific genomic information could cause a discrete 
clinical outcome, and since 1990 with the demonstration of genomic imprinting, has been 
used as a means for demonstrating the multi-dimensional functionality of the human 
genome.  Likewise, the fragile X site similarly represented in the early-1980s a visible 
chromosomal feature that could be used to delineate a particular form of intellectual 
disability, which it in the 1990s was presented to clinicians and geneticists as the basis of 
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a new genomic mechanism, trinucleotide repeat expansions, which turned out to explain 
the unusual inheritance pattern of multiple genetic disorders.   
 As Angela Creager has suggested, exemplars are much more than fixed textbook 
renderings of established scientific theory.  In fact, existing exemplars are constantly 
being renegotiated within productive experimental models (Creager, 2002).  The case 
studies presented in this dissertation demonstrate that throughout the 1980s, 
chromosomal analysis remained an important and productive experimental system for 
human and medical geneticists, which brought about new exemplary understandings of 
the structure and function of the human genome and its role in disease.  While during the 
1980s, clinicians and geneticists had high expectations for the value of new molecular 
approaches to doing genetics, and for the potential of DNA sequence level mapping of 
the human genome, this did not undercut their willingness to take advantage of existing 
cytogenetic tools.   
 Particularly in the clinic where the treatment of individual patients could not be 
put on hold pending new techniques or understandings, researchers developed new 
approaches for better understanding genetic diseases through a process of bricolage.  
Using whatever tools were currently had available they built what was at once a 
technological and experimental system.  As I have described throughout this dissertation, 
the questions and findings of the clinic often shaped more basic genetics research, and 
vice versa.  The trading zone of problems, interests, and information between the 
laboratory and clinic, I argue, was greatly facilitated during the 1970s and 1980s by 
adoption of common conventions for describing the genomic basis of disease among 
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basic and clinical geneticists.  These conventions were perhaps best embodied by the 
standardized chromosomal ideograms discussed throughout this dissertation.  
 Chromosomal ideograms offered idealized representations of what chromosomes 
looked like under the microscope, and at the same time tangible entities within which 
known cartographic and anatomical features of the human genome could be 
systematically represented.  In this sense, following the distinction first made by Charles 
Pierce (1982), these ideograms were both iconic and indexical representations.  Iconic 
images are those that capture the likeness of an object, such as a photograph of someone, 
whereas indexical representations point to something unseen within them, such as dark 
clouds suggesting an impending rainstorm.37  Along these lines, ideograms roughly 
approximated what chromosomes looked like under the microscope, and at the same time 
have been used to represent the basic landscape and anatomy of the unseen DNA 
sequence of the human genome, which is compacted within them.     
 As I describe throughout this dissertation, the combined iconic and indexical 
status of chromosomal ideograms in postwar genetics and biomedicine was central to 
evolving notions of the human genome as a standardized object of research and analysis 
in the laboratory and the clinic.  As iconic representations, ideograms helped clinicians 
and geneticists to distinguish and communicate about chromosomes and their visible 
anomalies.  During the 1970s and 1980s, these ideograms also increasingly took on an 
indexical role as the framework upon which the genetic and disease related components 
                                                 
37 For me on this distinction: 
http://www.cs.indiana.edu/~port/teach/103/sign.symbol.short.html.  See also, Lukas 
Rieppel’s (2012) recent paper on the museum exhibition of fossilized dinosaurs.  
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of the human genome were mapped.  Over this period, these ideograms evolved both 
visually and conceptually, coming at once to represent the human chromosome set 
iconically and the human genome indexically.   
 Chromosomal characteristics that could be seen under the microscope and were 
represented on ideograms, such as dark and light bands, fragile sites, and deletions, were 
used as a basis for understanding unseen genomic structures and functionality.  Light 
bands on ideograms suggested areas of the human genome with a much higher density of 
genes, while bands that were absent in patients diagnosed with particular disorders were 
assumed to contain the etiological basis for certain clinical outcomes.  In this way, 
ideograms were used to represent knowledge about both the normal and pathological 
human genome.   
 Keating and Cambrosio (2003) have argued that central to postwar biomedicine 
has been a material and institutional realignment of the normal and the pathological, in 
the form of what they call biomedical platforms.  In this dissertation, I suggest that 
McKusick’s ‘morbid anatomy’ of the human genome captures a similar conceptual 
realignment, through its iconic use of normal chromosomal ideograms to point, 
indexically, to the genomic basis of hundreds of genetic disorders.  Indeed, as the case 
studies presented here demonstrate, when diseases come to be understood as having a 
genomic basis, they may draw the attention of more basic genetics researchers, who are 
not interested in a particular disorder, so much as what it might reveal more broadly 
about the structure and function of the human genome.  This continuity of in the 
questions and interests of basic biological and applied clinical researchers, I argue, has 
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been facilitated in part by shared conventions for mapping the human genome using the 
standardized banding patterns provided by chromosomal ideograms.     
 Chromosome level depictions of the human genome embody particular modes of 
thinking and sets of approaches that have been central to the development of 
contemporary biomedicine.  Indeed, understandings of the human genome as visual, 
tangible, and anatomical have helped to facilitate a broad communication, exchange of 
interests, and sense of common relevance among the diverse array of individuals who are 
involved in biomedical research.  Each day, in meetings, clinics, and laboratories, 
biomedical professionals look to chromosomal depictions of the human genome, and see 
in them iconic and indexical representations of what has been accomplished so far, and 
what territory remains to be explored.  Mindful of this, as historians of science and 
medicine continue to probe the material and conceptual underpinnings of postwar 
biomedicine, I hope that they will keep an eye open to its visual cultures, which have 
been integral to the postwar success of genetic medicine – scientifically, clincally, and 
socially. 
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